Table of Contents
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-K
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
SECURITIES EXCHANGE ACT OF 1934
For the Fiscal Year Ended December 31, 2006
Commission File Number 1-5620
Safeguard Scientifics, Inc.
(Exact name of Registrant as specified in its charter)
| Pennsylvania (State or other jurisdiction of incorporation or organization) |
23-1609753 (I.R.S. Employer ID No.) |
|
| 435 Devon Park Drive Building 800 Wayne, PA (Address of principal executive offices) |
19087 (Zip Code) |
(610) 293-0600
(Registrant’s telephone number, including area code)
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
| Title of Each Class | Name of each exchange on which registered | |
| Common Stock ($.10 par value) | New York Stock Exchange |
Securities registered pursuant to Section 12(g) of the Act:
None
None
Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in
Rule 405 of the Securities Act.
Yes o No þ
Indicate by check mark if the Registrant is not required to file reports pursuant to Section
13 or Section 15(d) of the Exchange Act.
Yes o No þ
Indicate by check mark whether the Registrant (1) has filed all reports required to be filed
by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or
for such shorter period that the Registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days.
Yes þ No o
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation
S-K is not contained herein, and will not be contained, to the best of Registrant’s knowledge, in
definitive proxy or information statements incorporated by reference in Part III of this Form 10-K
or any amendment to this Form 10-K. þ
Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated
filer, or a non-accelerated filer. See definition of “accelerated filer and large accelerated
filer” in Rule 12b-2 of the Exchange Act.
Large accelerated filer o Accelerated filer þ Non-accelerated filer o
Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of
the Exchange Act).
Yes o No þ
As of June 30, 2006, the aggregate market value of the Registrant’s common stock held by
non-affiliates of the registrant was $257,629,375 based on the closing sale price as reported on
the New York Stock Exchange.
The
number of shares outstanding of the Registrant’s Common Stock,
as of March 22, 2007 was
120,771,313.
DOCUMENTS INCORPORATED BY REFERENCE
Portions of the definitive proxy statement (the “Definitive Proxy Statement”) to be filed
with the Securities and Exchange Commission for the Company’s 2007 Annual Meeting of Shareholders
are incorporated by reference into Part III of this report.
SAFEGUARD SCIENTIFICS, INC.
FORM 10-K
DECEMBER 31, 2006
FORM 10-K
DECEMBER 31, 2006
2
Table of Contents
PART I
Cautionary Note concerning Forward-Looking Statements
This Annual Report on Form 10-K contains forward-looking statements that are based on current
expectations, estimates, forecasts and projections about Safeguard Scientifics, Inc. (“Safeguard”
or “we”), the industries in which we operate and other matters, as well as management’s beliefs and
assumptions and other statements regarding matters that are not historical facts. These statements
include, in particular, statements about our plans, strategies and prospects. For example, when we
use words such as “projects,” “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,”
“estimates,” “should,” “would,” “could,” “will,” “opportunity,” “potential” or “may,” variations of
such words or other words that convey uncertainty of future events or outcomes, we are making
forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. Our forward-looking statements are subject to
risks and uncertainties. Factors that could cause actual results to differ materially, include,
among others, managing rapidly changing technologies, limited access to capital, competition, the
ability to attract and retain qualified employees, the ability to execute our strategy, the
uncertainty of the future performance of our partner companies, acquisitions and dispositions of
companies, the inability to manage growth, compliance with government regulation and legal
liabilities, additional financing requirements, labor disputes and the effect of economic
conditions in the business sectors in which our partner companies operate, all of which are
discussed in Item 1A. “Risk Factors.” Many of these factors are beyond our ability to predict or
control. In addition, as a result of these and other factors, our past financial performance
should not be relied on as an indication of future performance. All forward-looking statements
attributable to us, or to persons acting on our behalf, are expressly qualified in their entirety
by this cautionary statement. We undertake no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information, future events or otherwise,
except as required by law. In light of these risks and uncertainties, the forward-looking events
and circumstances discussed in this report might not occur.
Item 1. Business
Business Overview
Safeguard’s charter is to build value in growth-stage technology and life sciences businesses.
We provide growth capital as well as a range of strategic, operational and management resources to
our partner companies. Safeguard participates in expansion financings, carve-outs, management
buy-outs, recapitalizations, industry consolidations and early-stage financings. Our vision is to
be the preferred catalyst for creating great technology and life sciences companies.
We strive to create long-term value for our shareholders through building value in our partner
companies. We help our partner companies in their efforts to increase market penetration, grow
revenue and improve cash flow in order to create long-term value. We concentrate on companies that
operate in two categories:
Technology — including
companies focused on providing software as a service (SaaS),
technology-enabled services and vertical software solutions for analytics, enterprise application,
infrastructure, security and communication; and
Life Sciences — including companies focused on medical devices, molecular diagnostics, drug
delivery and specialty pharmaceuticals.
In 2006, our management team set forth five strategic objectives:
| • | Reposition Safeguard from an operating company to a holding company; | ||
| • | Time the acquisition and disposition of partner companies to achieve maximum risk-adjusted value; | ||
| • | Ignite our deal machinery process, from sourcing partner company candidates through completing transactions; | ||
| • | Augment our organization, both internally and externally, so that we can achieve our goals; and | ||
| • | Execute these objectives boldly, with focused effort. |
3
Table of Contents
As a result of achieving our goals in 2006, our management team has shifted focus to four
strategic objectives for 2007:
| • | Deploy capital in companies within our strategic focus; | ||
| • | Build value in our partner companies with strong management teams using organic and acquisitive growth to position our partner companies for liquidity at premium valuations; | ||
| • | Realize the value of select partner companies through selective, well-timed exits to maximize risk-adjusted value; and | ||
| • | Provide the tools needed for investors to fully recognize the shareholder value that has been created by our efforts. |
To meet these strategic objectives during 2007, Safeguard will focus on:
| • | finding opportunities to deploy our capital in additional partner company holdings; | ||
| • | helping to achieve additional market penetration, revenue growth, cash flow improvement and growth in the long-term value of our current partner companies: |
Acsis, Inc.
|
NuPathe, Inc. | |
Advantedge Healthcare Solutions, Inc.
|
Pacific Title & Art Studio, Inc. | |
Alliance Consulting Group Associates, Inc.
|
Portico Systems, Inc. | |
Clarient, Inc.
|
PROMODEL Corporation | |
Laureate Pharma, Inc.
|
Rubicor Medical, Inc. | |
Neuronyx, Inc.
|
Ventaira Pharmaceuticals, Inc. | |
NexTone Communications, Inc. |
| • | realizing value in our partner companies if and when we believe doing so will maximize value for our shareholders. |
We incorporated in the Commonwealth of Pennsylvania in 1953. Our corporate headquarters is
located at 435 Devon Park Drive, Building 800, Wayne, Pennsylvania 19087.
Significant 2006 Highlights
We are proud of our key accomplishments in 2006:
Realizing Value:
| • | We sold our interest in Mantas, Inc. to i-flex solutions, ltd., an affiliate of Oracle Corporation, for $112.8 million, for which we recognized a pre-tax gain of approximately $83.9 million. The sale price reflected a 3.9x premium over our carrying value of Mantas, and represented a significant premium over recent valuations of firms in Mantas’ line of business based upon multiples of revenue and earnings. | ||
| • | We provided strategic and operational guidance and resources to Alliance Consulting Group Associates, Inc. in the sale of its southwestern U.S. operations for $4.5 million to Logicalis, Inc. Alliance Consulting booked a gain of $1.6 million from this sale. | ||
| • | We sold our interest in Traffic.com, Inc. for $3.2 million, recognizing a gain of $0.4 million, and in Garage.com, Inc. for $1.2 million, all of which was recognized as a gain. |
Deploying Capital:
| • | We acquired 12% of Authentium, Inc. for $5.5 million, enabling this leading provider of security software to internet service providers to expand its growth strategies. |
4
Table of Contents
| • | We provided $6.0 million of equity capital to Acsis, Inc. to fund its growth strategies and expand its business increasing our ownership to 96%. | ||
| • | We provided Clarient, Inc. $3 million of equity capital to support its purchase of the assets of Trestle Holdings, Inc. | ||
| • | We provided strategic guidance and operational support for Alliance Consulting’s acquisition of the assets of Fusion Technologies, Inc. for $5.6 million, enabling Alliance Consulting to leverage its Indian technology center resources for clients throughout the world. | ||
| • | We purchased 36% of Rubicor Medical, Inc. for $20 million, allowing this medical device company to work toward the launch of its innovative products for breast cancer biopsy and removal. | ||
| • | We purchased 47% of Portico Systems, Inc. for $6.0 million, allowing Portico to pursue product and service development for its health plan business process software platform. | ||
| • | We acquired 21% of NuPathe, Inc. for $3.0 million as part of a $15.0 million financing that positions NuPathe to advance clinical development of novel transdermal delivery technology for treatment of migraines and central nervous system disorders. | ||
| • | We acquired 32% of Advantedge Healthcare Solutions, Inc. for $5.8 million as part of an up to $20.0 million financing to accelerate its organic growth and make future acquisitions. | ||
| • | Over the course of 2006, we purchased $21.0 million in face value of our 2.625% Convertible Senior Debentures due 2024 for an aggregate of $16.4 million, including accrued interest, resulting in a net gain of $4.3 million. |
Augmenting and Building Value:
| • | We added George D. McClelland and Michael J. Cody to our Board of Directors. Mr. McClelland has served in executive management capacities in information technology, life sciences and private equity businesses. Mr. Cody brings to the Board extensive experience in strategic acquisitions and investments, and currently serves as vice president of corporate development for EMC Corp. | ||
| • | We made key hires and promotions in our Life Sciences and Technology Groups, as well as for our investor relations, marketing and support functions. | ||
| • | We formed Technology and Life Sciences Advisory Boards, comprised of prominent industry leaders with specialized knowledge and expertise in their respective sectors. The Advisory Boards augment our internal resources and provide expert guidance and strategic direction to Safeguard and its partner companies, as well as identifying and evaluating deal opportunities. | ||
| • | In July, our common stock was added to the Russell 2000® Index, a leading benchmark of small-cap stocks compiled by the Russell Investment Group. |
Our Strategy
We focus on companies that address the strategic challenges facing businesses today, and the
opportunities they present. We believe these challenges have five general themes:
| • | Maturity—existing technologies, solutions and therapies are reaching the end of their designed life or patent protection; the population of the U.S. is aging; businesses based on once-novel technologies are now facing consolidation and other competitive pressures. | ||
| • | Migration—technology platforms are migrating to newer technologies and facing changing cost structures; medical treatments are moving toward earlier stage intervention; and business models are migrating toward different revenue-generation models integrating technologies and services. | ||
| • | Convergence—technology and life sciences are intersecting, in fields like medical devices and targeted diagnostics for targeted therapies. | ||
| • | Compliance—business spending is being driven by new or increased regulation in both technology and life sciences. |
5
Table of Contents
| • | Cost containment—both technology and life sciences are facing increasing pressure for cheaper, yet better solutions. |
These themes tend to attract entrepreneurs who need capital support and strategic guidance.
Safeguard deploys growth capital along with management expertise, process excellence and
marketplace insight designed to provide tangible benefits to growth companies.
Our corporate staff (31 employees at December 31, 2006) is dedicated to creating long-term
value for our shareholders by helping our partner companies build value and by finding additional
acquisition opportunities.
Identifying Opportunities
Safeguard’s marketing and sourcing activities are designed to generate a large volume of
high-quality opportunities. Our primary focus is on acquiring majority or minority stakes in
growth-stage companies within the technology and life sciences industries with attractive growth
prospects. Generally, we prefer candidates:
| • | operating in large or growing markets; | ||
| • | with barriers to entry by competitors, such as proprietary technology and intellectual property, or other competitive advantages; | ||
| • | with capital requirements between $5 million and $50 million; and | ||
| • | with a compelling strategy for achieving growth. |
We target our sourcing efforts on the Northeast/Mid-Atlantic region of the U.S. — although we
evaluate candidate companies opportunistically throughout the U.S. and southern Canada.
Our Technology Group currently targets companies with the following business models in these
technology segments and vertical markets:
6
Table of Contents
Our Life Sciences Group currently targets companies with the following business models in
these segments and vertical markets:
We believe there are many opportunities within these segments and vertical markets, and our
sourcing activities are focused on finding candidate companies and evaluating how well they align
with our criteria. However, we recognize we may have difficulty identifying candidate companies
and completing transactions on terms we believe appropriate. As a result, we cannot be certain how
frequently we will complete acquisitions.
Competition. We face intense competition from other companies that acquire, or provide
capital to, technology and life sciences businesses. Competitors include venture capital and
private equity investors, as well as companies seeking to make strategic acquisitions. Many
providers of growth capital also offer strategic guidance, networking access for recruiting and
general advice. Nonetheless, we believe we are a preferable capital provider to growth-stage
companies because our strategy and capabilities offer:
| • | responsive operational assistance, including strategy design and execution, business development, corporate development, sales, marketing, finance, facilities, human resources and legal support; | ||
| • | the flexibility to structure minority or majority transactions with equity and debt; | ||
| • | liquidity opportunities for founders and investors; | ||
| • | a focus on maximizing risk-adjusted value growth, rather than absolute value growth within a narrow or predetermined time frame; | ||
| • | interim c-level management support, as needed; | ||
| • | opportunities to leverage Safeguard’s balance sheet for borrowing and stability; and | ||
| • | a record of building revenue growth in our partner companies. |
Helping Our Partner Companies Build Value
We offer operational and management support to each of our partner companies through
experienced professionals. Our employees have expertise in the areas of business and technology
strategy, sales and marketing, operations, finance, legal and transactional support. We provide
hands-on assistance to the management of our partner companies to support their growth. We believe
our strengths include:
7
Table of Contents
| • | applying our expertise to support the company’s introduction of new products and services; | ||
| • | leveraging our market knowledge to generate additional growth opportunities; | ||
| • | leveraging our business contacts and relationships; and | ||
| • | identifying and evaluating potential acquisitions and providing capital to pursue potential acquisitions to accelerate growth. |
Strategic Support. By helping our partner companies’ management teams remain focused on critical
objectives through provision of human, financial and strategic resources, we believe we are able to
accelerate their development and success. We play an active role in determining the strategic
direction of our partner companies, including:
| • | defining short- and long-term strategic goals; | ||
| • | identifying and planning for the critical success factors to reach these goals; | ||
| • | identifying and addressing the challenges and operational improvements required to achieve the critical success factors and, ultimately, the strategic goals; | ||
| • | identifying and implementing the business measurements that we and others will apply to measure the company’s success; and | ||
| • | providing capital to drive growth. |
Management and Operational Support. We provide management and operational support to our
partner companies in order to accelerate their growth. We engage in ongoing planning and
assessment of the development of our partner companies and their management teams. Our executives
and our Advisory Boards provide mentoring, advice and guidance to develop the management of our
partner companies. Our executives generally serve as directors of our partner companies and work
with them to develop and implement strategic and operating plans. We measure and monitor
achievement of these plans through regular operational and financial performance measurements. We
believe these services provide our partner companies with significant competitive advantages within
their respective markets.
Realizing Value
In general, we will hold our stake in a partner company as long as we believe the
risk-adjusted value of that stake is maximized by our continued ownership and effort. From time to
time, we engage in discussions with other companies interested in our partner companies, either in
response to inquiries or as part of a process we initiate. To the extent we believe that a partner
company’s further growth and development can best be supported by a different ownership structure
or if we otherwise believe it is in our shareholders’ best interests, we may sell some or all of
our stake in the partner company. These sales may take the form of privately negotiated sales of
securities or assets, public offerings of the partner company’s securities and, in the case of our
publicly traded partner companies, sales of their securities in the open market. We have in the
past taken partner companies public through rights offerings and direct share subscription
programs, and we will continue to consider these (or similar) programs to maximize shareholder
value. We expect to use the proceeds from these sales (and sales of other assets) primarily to
pursue other candidate company opportunities or for other working capital purposes.
8
Table of Contents
Our Partner Companies
An understanding of our partner companies is important to understanding Safeguard and its
value-building strategy. Following are more detailed descriptions of our majority-owned partner
companies. The ownership percentage is presented as of December 31, 2006 and reflects the
percentage of the vote we are entitled to cast based on issued and outstanding voting securities,
excluding the effect of options, warrants and convertible debt. From time to time we may seek to
opportunistically increase our position or sell some or all of our interests in these companies.
| Acsis, Inc. | (Safeguard Ownership: 96%) |
Safeguard Opportunity. We acquired Acsis in December 2005 because we believe Acsis is and
will be integral to the migration of mature supply-chain management systems to include newer
technologies, such as radio-frequency identification (RFID) in a heterogeneous environment that
will integrate the manufacture and distribution floors into Enterprise Resource Planning (ERP)
systems. Many Fortune 1000 clients already leverage Acsis’ solutions to obtain labor efficiencies
and supply chain visibility. We believe that powerful industry trends—business process
automation, RFID compliance mandates, and compliance with regulations mandating tracking of food
and drug products—provide a large market and growth opportunity for Acsis. Spending on enterprise
data collection software and services has been growing significantly, and Acsis believes it
currently exceeds $1 billion annually. Recent mandates from major national retailers as well as
government agencies have prompted manufacturers to upgrade their existing data collection
infrastructure with RFID technology.
General. Acsis (www.acsisinc.com) is a leading provider of software and service solutions
that assist manufacturing companies in improving efficiencies throughout the entire supply-chain.
Its solutions enable manufacturers to automate plant floor/warehouse operations and take advantage
of emerging automated-ID technologies, including RFID and barcode. Acsis’ solutions provide the
critical data links between activities or material movements that take place on the shop floor and
ERP systems. They improve visibility of goods throughout supply-chains, ultimately resulting in
increased revenues, improved customer service and reduced costs. Founded in 1996, Acsis offered
one of the first solutions to facilitate the control and integration of plant floor and warehouse
devices with SAP’s ERP software.
Strategy. Acsis’ strategy is to leverage its wide and deep experience in a variety of
vertical industries, such as chemical, pharmaceutical and consumer packaged goods, to craft
real-time supply-chain solutions for SAP™ R/3® as well as other enterprise systems.
Acsis’ knowledge of the business processes and typical transactions in these industries allows it
to deliver tailored solutions. Acsis couples this with broad expertise in SAP R/3 implementations,
automated data-collection and integration solutions, and a proven track record. Acsis also has
strategic partnerships with leading technology providers and consultants. As an example, Acsis was
the first to successfully complete the integration testing between its xDDi software and SAP’s
Auto-ID Infrastructure component of the SAP NetWeaver™ open integration and application platform.
Manufacturers are upgrading and enhancing their existing infrastructure to improve
efficiencies and integrate new technologies like RFID. Manufacturers are making these investments
not only in response to governmental and retailer mandates, but also to maximize the benefits of
just-in-time inventory practices. Acsis believes its solutions provide them with better ways to:
| • | constantly view and manage every link in their supply-chain in real time; | ||
| • | communicate and control changes in their supply-chain; | ||
| • | automate the collection and integration of critical data from any source; and | ||
| • | protect their processes from interruption. |
Solutions. Acsis draws from a variety of technologies and service offerings to create a
solution that matches the client’s business, budget and IT environment. Solutions range from
value-added services for implementing SAPConsole to the advanced shop floor process automation and
data collection using the xDDi as a shop floor platform. If requested, Acsis will also procure all
necessary hardware and software to deliver a turnkey data-collection system.
9
Table of Contents
Acsis’ key internally-developed software solution components featured in the Acsis Lean
Enterprise Suite (“ALES”)—a bundled set of applications that connects people, devices and supply
chain events with client ERP systems. ALES is comprised of the following components:
| • | xDDi (xApp for Device and Data Integration) Software |
| • | enterprise software solution enabling data collection from any device in the supply-chain (such as scales, optical eyes printers bar code scanners and RFID tags) and aggregate filter and translate it for integration with ERP systems | ||
| • | converts SAP process and workflows into manageable shop floor events, directs employee task lists (via handheld devices or vehicle mounted units) and integrates the resulting data back to SAP |
| • | Enterprise Label Management Software |
| • | enterprise software solution enabling users to design and generate customer-specific label formats directly from SAP ERP data and manage them from a central location | ||
| • | enables users to manage label formats across your enterprise to reduce time and costs, and insures compliance to reduce shipment rejections, incorrect shipments and mislabeling |
| • | Line Manager Appliances |
| • | intelligent appliances to support RFID- and barcode-based product tracking for warehouse, manufacturing, packing and shipping operations | ||
| • | automates manufacturing, packing, labeling and shipping operations, and manages events and alerts to proactively notify users of significant process events in order to improve quality and prevent production delays |
| • | Plant Manager Software |
| • | enterprise software solution helping users efficiently execute manufacturing and warehouse operations |
| • | allows operations to be monitored from receiving to manufacturing and through distribution, and management of key performance indicators for real-time visibility of work orders throughout all manufacturing and warehouse facilities |
| • | RFID Analytics |
| • | helps users gain product visibility and intelligence throughout your supply chain by analyzing key metrics |
Acsis works with its clients to develop manufacturing, warehousing, RFID and mobile solutions
tailored to the client’s needs and budget. Acsis also maintains a highly-experienced and trained
professional services group to provide consulting and technical services. Typical professional
service engagements include:
| • | problem analysis and business case development; | ||
| • | enterprise systems design; | ||
| • | data modeling; | ||
| • | process evaluations and recommendations; | ||
| • | hardware and software evaluation; | ||
| • | help desk; | ||
| • | application maintenance and enhancements; and | ||
| • | communications and connectivity. |
Offices and Employees. Acsis employs approximately 109 people at its headquarters in Marlton,
New Jersey, and in Munich, Germany.
Sales and Marketing; Customers. Acsis has a track record including more than 650
implementations in 28 countries. Acsis’ typical customers are large manufacturing, pharmaceutical
or consumer packaged goods businesses with more than $1 billion in revenue and substantial
international operations. In 2006, two customers each represented more than 10% of Acsis’s
revenue.
10
Table of Contents
Sales are typically made in warehouse, logistics, fulfillment or other operations units of its
clients with a customary sales cycle of three to six months. At the end of a sales cycle, Acsis
provides consulting, blueprinting and implementation services, go-live support and ongoing help
desk support. Acsis then works with customers on a regular and ongoing basis to support their
operations and provide further benefits with additional solutions or by implementing solutions at
additional sites. Approximately half of Acsis’ customer base utilizes multiple solutions provided
by Acsis, and many customers are using Acsis’ solutions in multiple sites across the world.
Competition. Acsis’ competition generally comes from large, diversified consulting businesses
or niche providers with a variety of individual solutions for barcode, RFID or other data
collection systems. Acsis seeks to differentiate itself by proving a single, integrated platform
which can be used across the enterprise to increase efficiencies and reduce operational costs.
| Alliance Consulting Group Associates, Inc. | (Safeguard Ownership: 99%) |
Safeguard Opportunity. We acquired Alliance Consulting in December 2002 because we saw a
growing and highly fragmented market in which we believed Alliance Consulting could achieve
profitable growth. Capitalizing on its deep domain expertise in the pharmaceutical, healthcare,
financial services, manufacturing and high tech distribution industries, its extensive staff
resources and strong customer relationships, we believe that Alliance Consulting can continue to
grow its profitability.
General. Alliance Consulting (www.alliance-consulting.com) is a leading national business
intelligence solutions consultancy providing services to primarily Fortune 2000 clients in the
pharmaceutical, financial services, manufacturing and high tech industries. Alliance Consulting
specializes in two practice areas:
| • | Information Management, which is comprised of a full range of business intelligence solutions from data acquisition and warehousing to master data management, analytics and reporting; and | ||
| • | Application Services, which includes software development, integration, testing and application support, delivered through a high quality and cost effective hybrid global delivery model. |
Strategy. Alliance Consulting has developed a strategy focused on enabling business
intelligence through the application of domain experience and custom-tailored project teams to
deliver software solutions and consulting services. Alliance Consulting believes that its growth
opportunities benefit from the following industry trends:
| • | The volume of data being processed by businesses is increasing at an exponential rate, making businesses dependent upon the effective and efficient processing of this data and requiring significant and ongoing investment in technology infrastructure and resources, but with continuing decreases in the cost of computing power, storage and communication systems. |
| • | The complexity of this data is increasing, with multiple and diverse inflow sources containing a wide variety of structured and unstructured information. |
| • | The value to the business of this data is increasing, driven in part by regulatory and compliance requirements and strategic and competitive pressures, yet businesses are facing continuing budget constraints, prompting the need to maximize cost-effective solutions. |
Services. Through an integrated network of local branch offices in North America, and its
offshore development centers located in Hyderabad and Bangalore, India, Alliance Consulting
provides a flexible engagement approach to its clients, using fixed bid or time and materials
pricing models; teams or individual consultants; on-site, off-site or offshore delivery; and short-
or long-term support.
Alliance Consulting’s services are targeted to:
| • | Business intelligence and data management — using data warehousing technologies to develop complete business intelligence infrastructures, applications and processes to enhance the competitiveness of clients. |
11
Table of Contents
| • | Corporate performance management — using enterprise-wide reporting and analysis, forecasting and budgeting and other tools to provide real-time information, enabling corporate managers to better monitor critical operating performance metrics and implement rapid, targeted adjustments to increase effectiveness, efficiency and profitability. | ||
| • | Application development — using assessment tools, architecture design and implementation of advanced, scalable and flexible, customized software solutions to leverage existing software assets through the integration of state-of-the-art web-based technologies. | ||
| • | Outsourcing — working with clients to understand the IT support needs of the business, costs and internal/external service capabilities and then implementing outsourcing solutions for data center operations, applications development and maintenance, distributed and desktop processing, voice and data networks, Internet and web hosting and help/service desk functions. |
Alliance Consulting maintains a full-time core staff complemented by a flexible combination of
hourly employees and independent contractors, providing clients with specialized engagement teams
tailored to their specific business requirements. This approach enables Alliance Consulting to
offer a precise combination of technical, industry, and process knowledge to support each
engagement while maximizing utilization of its staff and contracting consultants. Alliance
Consulting’s employee and independent contractor resources are supported on an ongoing basis
through internal and external recruiting targeted at high-quality, experienced professionals with
significant product and industry expertise.
Offices and Employees. Alliance Consulting is headquartered in Conshohocken, Pennsylvania,
and it operates five other regional offices and three satellite locations throughout the United
States and two primary locations in India. Alliance Consulting supplements its full-time employees
by utilizing subcontractors. At December 31, 2006, Alliance Consulting had 697 full-time employees
and approximately 205 subcontractors. Alliance Consulting believes its relationship with its
employees and subcontractors is good. Alliance Consulting believes its growth and success are
dependent on the caliber of its people and will continue to dedicate significant resources to
hiring, training and development, and career advancement programs.
During 2006, Alliance Consulting sold its non-core southwest regional operation with offices
in Phoenix, Los Angeles and Dallas, along with associated client activity and consultants, to
Logicalis, Inc. The Company used the proceeds of the sale to acquire Fusion Technologies, an
application outsourcing provider with significant operations in Hyderabad and Bangalore, India.
This acquisition more than doubled Alliance Consulting’s capacity for application outsourcing work
in India, and added several strong reference clients in financial services and high tech in the
United States.
Sales and Marketing; Customers. Alliance Consulting uses a customer relationship-based
approach to generating new clients and new engagements with existing clients. Some of Alliance
Consulting’s clients include JP Morgan Chase, Wyeth Pharmaceuticals, Pfizer Pharmaceuticals,
Johnson & Johnson and EMC. Alliance Consulting markets its services through a direct sales force,
which is based in regional and satellite offices. Account executives are assigned to a limited
number of accounts so they can develop an in-depth understanding of each client’s individual needs
and form strong client relationships. In 2006, two customers each represented more than 10% of
Alliance Consulting’s revenue. In 2005, the same two customers each represented more than 10% of
Alliance Consulting’s revenue.
Following common industry practice, many of Alliance Consulting’s orders are terminable by
either the client or Alliance Consulting on short notice. Because many clients can cancel or
reduce the scope of their engagements on short notice, Alliance Consulting does not believe that
backlog is a reliable indication of future business.
Competition. Alliance Consulting’s revenue potential is largely dependent upon target
customers’ spending for IT services and its ability to compete with local, national and offshore
providers of consulting services. Many of these competitors (such as major IT consulting firms)
have greater financial and human resources than Alliance Consulting. Alliance Consulting believes
that the basis for competition in its industry includes the ability to create an integrated
solution that best meets the needs of an individual customer, provide competitive cost pricing
models,
12
Table of Contents
develop strong client relationships, provide high-quality consultants with industry and
process specific technical expertise, and offer flexible client-service delivery options.
| Clarient, Inc. | (Safeguard Ownership: 60%) |
Safeguard Opportunity. Safeguard first took an ownership interest in Clarient in 1996, and we
have increased our ownership position over time. Shares of Clarient’s common stock trade on the
Nasdaq Capital Market under the symbol “CLRT.”
We believe that increasingly specific targeted cancer therapies will need more specialized and
complex diagnostic tests in order to improve cancer therapy outcomes. The continued aging of the
U.S. and European populations, coupled with the higher incidence of cancer among seniors, support
an expanding market for Clarient’s services. Clarient is now leveraging its technical expertise,
access to proprietary technology and capital investment to provide its diagnostic services to a
larger customer base.
General. Clarient (www.clarientinc.com) is a comprehensive cancer diagnostics company
providing cellular assessment and cancer characterization to
community pathologists.
Clarient’s goal is to be positioned to capture a substantially greater portion of the cancer
diagnostics market by serving the needs of the market from drug discovery through clinical practice
through a technology-empowered laboratory, deploying the best available testing platforms and
leveraging the Internet to deliver this information to the community pathologist.
Strategy. Clarient’s mission is to be the leader in cancer diagnostics by building
collaborative relationships with the health care community in order to translate cancer discovery
and information into better patient care. To accomplish this, Clarient focuses on identifying
high-quality opportunities to increase profitability and differentiate its service offerings in its
highly-competitive market. An important aspect of Clarient’s strategy is to combine its medical
expertise with proprietary technologies to develop novel diagnostic tests and analytical
capabilities. In particular, Clarient is seeking to deploy novel markers, or biomarkers, which are
characteristics of an individual’s tumor or disease that, once identified and qualified, allow for
more accurate prognosis, diagnosis and treatment. Broader discovery and use of novel markers is
hoped to clarify and simplify decisions for healthcare providers and the biopharmaceutical
industry. The growing demand for personalized medicine has generated a need for these novel
diagnostics.
Services. Clarient provides a wide variety of cancer diagnostics and consultative services,
ranging from technical laboratory services to professional interpretation. By combining core
competencies in image analysis and data quantification with its knowledge of virtual environments,
Clarient has created valuable service offerings for pathologists in practice and research.
Clarient believes that the growing need for precise diagnosis combined with the ability to put
comprehensive information into a single, coherent computer-accessible platform for clinicians
presents development opportunities for new directed diagnostic services using the image analysis
platform. Clarient offers a broad menu of specialized technologies such as image analysis,
fluorescent in situ hybridization (FISH), flow cytometry, cytogenetics and molecular diagnostics.
Within anatomic pathology, Clarient focuses on the top four solid tumors (breast, prostate, lung and
colon), which represent 61% of all new cases.
Clarient also provides hematopathology testing for leukemia and lymphoma, and expects to
expand service offerings as new assays emerge. For biopharmaceutical companies and other research
organizations, Clarient offers a complete compliment of commercial services to assist their
efforts, ranging from drug discovery to the development of directed diagnostics through clinical
trials.
13
Table of Contents
Sale of Technology Group. On March 8, 2007, Clarient sold its technology group business
(which developed, manufactured and marketed the ACIS® Automated Image Analysis System) and related
intellectual property to Zeiss MicroImaging, Inc. (the “ACIS Sale”) for an aggregate purchase price
of $12.5 million (including $1.5 million in contingent purchase price). As part of the ACIS
Sale, Clarient entered into a license agreement with Zeiss pursuant to which Zeiss granted the
Company a non-exclusive, perpetual and royalty-free license to
certain of the transferred intellectual property
for use in connection with imaging applications and the Company’s laboratory services business.
Clarient and Zeiss also committed to pursue a strategic joint development arrangement to develop
novel markers and new menu applications for the ACIS product line.
Sales and Marketing. Most of Clarient’s sales resources are dedicated to the growing
diagnostic services business. Targeting community pathology practices and hospitals, the sales
process is designed to understand the customer’s needs and develop
appropriate solutions from its range of laboratory service options. Clarient’s sales approach
focuses on expanding organic sales within its current customer base as well as potential customers.
Marketing efforts focus on establishing a strong and distinctive brand identity for Clarient’s
diagnostic services within the targeted segment of community pathologists. Clarient uses its
CONTINUUM™ national and regional seminar and webinar programs designed to provide a one-on-one
collaborative environment for its advisory board and medical staff to interact directly with
potential customers.
Patents and Proprietary Technology. Clarient seeks to broaden the scope of its intellectual
property portfolio for laboratory services methodologies, using automated cellular instrumentation,
rare event identification, and proteomic mathematic capabilities. As part of the ACIS Sale,
Clarient transferred its patent portfolio and related intellectual property to Zeiss. However,
Clarient retained a license to use certain of that intellectual
property, which Clarient plans to use in the development of new tests, applications, unique analytical capabilities and other service
offerings, including novel markers. Clarient also relies on trade secrets and proprietary know-how
that it seeks to protect, in part, through confidentiality agreements with employees and
consultants. If Clarient is unable to protect its patents and proprietary rights, its reputation
and competitiveness in the marketplace could be materially damaged.
Competition. The clinical laboratory business is highly competitive and dominated by several
national laboratories, as well as many smaller niche and regional organizations. Clarient’s
primary competitors include large independent laboratories that offer a wide test and product menu
on a national scale. These large national independent laboratories have significantly greater
financial, sales and logistical resources than Clarient and may be able to achieve greater
economies of scale, or establish contracts with payor groups on more favorable terms. Clarient
also competes with smaller niche laboratories that address a narrow segment of the esoteric market
by offering very specific assay menus. Finally, institutions that are affiliated with large
medical centers or universities compete with Clarient on the limited basis of perceived quality of
service.
Companies within the diagnostic testing industry are also responding to new technologies, products and services. We
believe some of Clarient’s current competitors — as well as other currently non-competitive companies — are actively
conducting research in areas where Clarient is also conducting development activities. The products and services these
companies develop may directly compete with Clarient’s current or potential services, or may address other areas of
diagnostic evaluation, making those companies compete more effectively against Clarient. Furthermore, because the
diagnostic testing market is sensitive to the timing of product and service availability, quickly developing and achieving
clinical study and regulatory success may provide an advantage.
Research
& Development. With the ACIS Sale complete, Clarient’s
research and development efforts are now primarily focused on developing new assays and novel cancer markers to commercialize for its laboratory services
business. Quality and regulatory staff assure that every developed test and application meets
stringent regulatory guidelines. Research and development spending by
Clarient (which had been primarily focused on improving the ACIS technology) was approximately
$4.5 million, $3.7 million and $4.1 million in 2006,
2005, and 2004, respectively. As a result of the ACIS Sale, we expect
Clarient’s research and development expenses to decline substantially in 2007.
Governmental Regulation. Because Clarient operates a clinical laboratory, many aspects of its business are subject to the complex federal, state and
local regulations applicable to laboratory operations. In particular, the federal Clinical Laboratory Improvement
Amendments (CLIA) specify the quality standards for proficiency testing, patient test management, quality control,
personnel qualifications and quality assurance for Clarient’s
laboratory. Clarient received its CLIA certification in late 2004. In addition, Clarient’s
facilities have been issued licenses to provide laboratory diagnostic services in California. The
State of California could prohibit provision of laboratory services if Clarient
14
Table of Contents
fails to maintain or renew these licenses. Additionally, requirements of states where
laboratory services may be provided have various application and provisional requirements that must
be satisfied. Laws and regulations pertaining to the services provided by Clarient are subject to
change and depend heavily on administrative interpretations by federal and state agencies.
Facilities. In 2006, Clarient moved all of its operations into a new 78,000 square foot
facility in Aliso Viejo, California to expand its capacity and allow for the ongoing growth.
Clarient currently occupies approximately 43,000 square feet of that facility, and has subleased an
additional 34,000 square feet.
Employees. As of December 31, 2006, Clarient had 204 employees. As a result of the ACIS
Sale, at March 9, 2007, Clarient had 171 employees: 119 in laboratory diagnostics positions
(including product development); 23 in finance, executive and administrative positions; and 29 in
sales and marketing positions. Clarient believes that its relationship with its employees is good.
| Laureate Pharma, Inc. | (Safeguard Ownership: 100%) |
Safeguard Opportunity. We acquired the business and assets operated by Laureate Pharma in
December 2004. We made this acquisition because we recognized that the substantial growth in sales
of biotechnology products has spurred a significant investment by large pharmaceutical companies
and smaller biotechnology companies in the development of new biotechnology products for human
therapeutics. Few of these companies, particularly biotechnology companies have the resources or
expertise to manufacture the quantities of drug product needed to conduct clinical trials and
commercialize approved products. Laureate Pharma provides its customers with a cost-effective,
lower-risk alternative, which also improves the quality of their products and processes and reduces
time-to-market.
General. Laureate Pharma (www.laureatepharma.com) is a full-service contract manufacturing
organization (CMO) providing critical development and current Good Manufacturing Practices (cGMP)
manufacturing services. Laureate Pharma manufactures small- and medium-scale quantities of
biopharmaceutical products in its FDA-registered facility. Laureate Pharma’s clients use these
supplies (depending on their regulatory status) for preclinical studies, clinical trials or
commercial sales. Laureate Pharma seeks to become a leader in this segment of the
biopharmaceutical industry by delivering superior development and manufacturing services to its
customers. Laureate Pharma’s headquarters and manufacturing facility is located in Princeton, New
Jersey.
Strategy. Laureate Pharma’s strategy is to build on its strong customer relationships and
generate new customers, to increase its new services and products, and to maintain its reputation
for high quality in the use of state-of-the-art technology to deliver products and services that
meet applicable regulatory, environmental and safety requirements, including cGMPs.
Laureate Pharma believes its growth opportunities are driven by the following industry trends:
| • | Substantial growth in the development of biotechnology products for human therapeutics, representing an increasing percentage of the total pharma pipeline. | ||
| • | Demand for manufacturing capacity, along with the significant capital required to build capacity, creating increased opportunities for outsourced services. | ||
| • | Need for product development support, equipment and facilities by biotechnology companies without existing capabilities. |
We believe Laureate Pharma’s broad range of services and deep development expertise position
it to benefit from these trends.
Services. Laureate Pharma’s services include:
15
Table of Contents
| • | Bioprocessing, which focuses on clinical stage and small-to medium-sale commercial biopharmaceutical products and comprises the essential steps to support the development and commercialization of customers’ products, including: |
| • | Cell Line Development and Optimization — to improve and maximize protein productivity of production cell lines in optimal growth media; the cell lines in turn produce the product protein. | ||
| • | Process Development — to bring the product from clinical laboratory scale to pilot production and on to clinical- and commercial-scale production; essential to make sufficient product to support clinical trials and small-scale commercial production. | ||
| • | Purification Development — to design and validate procedures for removal of impurities and purification of products that comply with regulatory requirements. | ||
| • | Bioreactor Production — using stirred-tank, disposable bag and hollow-fiber mammalian cell culture bioreactors ranging from 20 to 2,500 liters to produce biopharmaceutical protein products. | ||
| • | Downstream Processing — to develop and operate robust purification processes for cGMP manufacture of client’s products; Laureate Pharma also performs process validation studies as may be required for client products. | ||
| • | Aseptic Filling — aseptic vial filling of biopharmaceutical and drug products in batch sizes up to 10,000 vials or 200 liters of bulk volume. |
| • | Quality Control, which includes analytical and microbiology testing of raw materials, in-process and finished products. | ||
| • | Quality Assurance, which includes preparation, control and review of documentation, including standard operating procedures (SOPs), master batch records, test procedures, and specifications. Laureate Pharma reviews and releases all controlled materials, including raw materials, intermediates and products. |
Research and Development. Laureate Pharma’s research and development efforts are focused on
improving its technology and developing processes for the manufacture of new products to meet
customer requirements. The primary goals are to improve manufacturing processes to reduce costs,
improve quality and increase capacity.
Intellectual Property. Laureate Pharma relies primarily on know-how in its manufacturing
processes and techniques not generally known to other life sciences companies to develop and
maintain its market position. Laureate Pharma requires employees to sign confidentiality and other
protective agreements where appropriate.
Sales and Marketing; Customers. Laureate Pharma provides process development and
manufacturing services on a contract basis to biopharmaceutical companies. Laureate Pharma’s
customers generally include small to mid-sized biotechnology and pharmaceutical companies seeking
outsourced bioprocessing manufacturing and development services. Laureate Pharma’s customers are
often dependent on the availability of funding to pursue drugs that are in early stages of clinical
trials, and thus have high failure rates. The loss of one or more customers can result in
significant swings in profitability from quarter to quarter and year to year. Although there has
been a trend among biopharmaceutical companies to outsource drug production functions, this trend
may not continue. Although clients tend to maintain one manufacturer through clinical trial phases
and even early commercial production, many of Laureate Pharma’s contracts are of short duration.
As a result, Laureate Pharma seeks new contracts to sustain its revenue. In 2006, four customers
each represented more than 10% of Laureate Pharma’s revenues; in 2005, two customers each
represented more than 10% of Laureate Pharma’s revenue from continuing operations.
Competition. Our primary competitors focus on supplying clinical scale contract
biopharmaceutical development and manufacturing services to biotechnology companies. Generally,
the larger of these competitors focus on larger quantities and scale of manufacturing capacity.
Laureate Pharma focuses on process development and manufacturing services for clinical and small-
and medium-scale commercial production, and maintains a reputation for regulatory compliance, a
commitment to quality and excellent early process development services. Laureate Pharma believes
that customers in its target markets display loyalty to their initial services provider.
16
Table of Contents
Therefore, it may be difficult to generate sales to potential customers who have purchased
development and manufacturing services from competitors. To the extent Laureate Pharma is unable
to be the first to develop and supply new biopharmaceutical products for its clients, its
competitive position may suffer.
Employees. At December 31, 2006, Laureate Pharma had 92 full-time employees and believes its
employee relations are good.
| Pacific Title & Art Studio, Inc. | (Safeguard Ownership: 100%) |
Safeguard Opportunity. We acquired an interest in Pacific Title in 1997 and increased our
ownership position over time. Technology has driven fundamental changes in the production and
post-production of motion picture and television content, with increased emphasis on special
effects, digital color correction, 3D animation and many other sophisticated elements. As a
pioneer since 1919 in the development and introduction of new methods, services and technologies,
we believe Pacific Title is uniquely positioned to lead the continued expansion of digital
technologies. Leveraging state-of-the-art equipment and significant domain expertise, Pacific
Title can handle the enormous volume and complex programming needed to meet the often changing and
rush delivery needs of its clients.
General. Pacific Title (www.pactitle.com) is a leading provider of a broad range of digital
and photo-chemical services for post-production and archival applications in the Hollywood motion
picture and television industry. Pacific Title provides a complete array of state-of-the-art
digital post-production capabilities both for new releases and restoration of film libraries,
leading the transformation from optical, analog image reproduction and processing to more dynamic,
cost-effective and flexible digital image processing technologies.
Strategy. Pacific Title seeks to meet the high-quality service and technological support
needs of motion picture studios and production companies. Pacific Title believes that its past
growth and future opportunities are being driven by the following industry trends:
| • | A shift in demand for original film entertainment content capture and manipulated in digital formats as opposed to analog format; | ||
| • | The development of new and expanding markets for existing film libraries, including remastering, high resolution scanning, archiving and restoration services. | ||
| • | Increased demand for innovation and technological advances to support creative vision; | ||
| • | Expanding application of digital technologies for content manipulation, as well as the anticipated deployment of digital distribution and display technologies (including emerging digital projection); and | ||
| • | Increasing concern for the preservation, restoration and storage of aging film libraries. |
We believe Pacific Title’s services and industry stature have well positioned the company to
continue its leadership in anticipating and meeting its customers’ needs.
Services. Pacific Title maintains post-production facilities as components of its full range
of integrated services. Pacific Title’s customers may choose one, several or all of these services
based on their needs from project to project.
Sales and Marketing; Customers. Pacific Title markets its services through a combination of
industry referrals, formal advertising, trade show participation, special client events, and its
Internet website. While it relies primarily on its reputation and business contacts within the
industry for the marketing of its services, Pacific Title also maintains a direct sales force to
communicate the capabilities and competitive advantages of its services to potential new customers.
In addition to its traditional sales efforts directed at those individuals responsible for placing
orders, Pacific Title negotiates discounted rates with large volume clients in return for being
promoted within the client’s organization as an established and accepted vendor. Pacific Title
negotiates such agreements periodically with major entertainment studios.
17
Table of Contents
Pacific Title’s clients include Walt Disney Company, 20th Century-Fox, Universal
Studios, Warner Bros., Sony Pictures Entertainment, Dreamworks SKG, Columbia/Tri-Star and Paramount
Pictures, as well as many independent motion picture and television production companies. Pacific
Title generally does not have exclusive service agreements with its clients. Because clients
generally do not make arrangements with Pacific Title until shortly before its facilities and
services are required, Pacific Title usually does not have a significant backlog of service orders.
Pacific Title’s services are generally offered on an hourly or per unit basis based on volume and
client demand. For 2006, three customers each represented more than 10% of Pacific Title’s
revenues. For the year ended December 31, 2005, four customers each represented more than 10% of
Pacific Title’s revenues.
Competition. Pacific Title operates in a competitive, service-oriented industry. Certain
competitors provide many of the services provided by Pacific Title, while others specialize in one
or several of these services. Some of these companies have greater financial, operational and
marketing resources than Pacific Title. Substantially all of Pacific Title’s competitors have a
presence in the Hollywood, California area, which is the largest market for Pacific Title’s
services. Pacific Title believes that it maintains a competitive edge in its market through the
quality and scope of the services it provides and its proven tradition of providing timely delivery
of these services. Pacific Title believes that prices for its services are competitive within its
industry, although some competitors may offer certain of their services at lower rates than Pacific
Title. The principal competitive factors affecting this market are reliability, timeliness,
quality and price. Pacific Title also competes, to a lesser extent, with the in-house operations
of major motion picture studios.
Seasonality. Pacific Title’s business is subject to substantial variations as a result of
seasonality, which the company believes is typical of the film post-production industry. Demand
for Pacific Title’s service also has been adversely impacted on several occasions in recent years
as a result of actual or threatened labor stoppages in its customers’ film production industry.
Employees. At December 31, 2006, Pacific Title had 131 employees. Approximately 38 employees
are represented by the International Alliance of Theatrical and Stage Employees pursuant to a
collective bargaining agreement, which expires in July 2009. Pacific Title has never experienced a
work stoppage and considers its relations with its employees to be good.
Other Partner Companies and Funds
In 2006 we added five new partner companies; these partner companies are not consolidated
based on the level of our voting interests.
| Advantedge Healthcare Solutions, Inc. | (Safeguard Ownership: 32%) |
General. AHS (www.ahsnewyork.com) provides advanced medical billing software and services,
operating both as a business process outsourcer (BPO) and an applications services provider (ASP).
AHS employs proprietary, web-based technology and continuous business process improvement methods
to increase the operating efficiencies of medical billing and to improve results for its physician
customers.
Safeguard Opportunity. The outsourced medical claims billing market is estimated to be
approximately $4 billion and growing. However, despite its size, the market is extremely
fragmented, allowing for numerous consolidation opportunities. We
believe AHS’ proprietary software, coupled
with its management team’s extensive experience in the healthcare, software and medical claims
billing markets, lays the foundation for AHS’ continued growth and acquisitions.
| Authentium, Inc. | (Safeguard Ownership: 12%) |
General. Authentium (www.authentium.com) is a leading developer of security
software as a service (SaaS) technologies and systems. Its Extensible Security Platform (ESP)
allows users to customize security technologies from Authentium and others (such as antivirus,
firewalls, content filtering, and compliance monitoring) into their products and services.
Authentium’s customers—ISPs, cable companies, carriers and other service providers—in turn
distribute these bundled solutions to residential and enterprise customers.
18
Table of Contents
Safeguard Opportunity. As hackers become more sophisticated, the market for IT security
has grown and is expected to reach $10.7 billion by 2009. We
believe Authentium’s recurring revenue model,
coupled with its ability to leverage its customers’ sales efforts, provides a good foundation for
growth in this market.
| NuPathe, Inc. | (Safeguard Ownership: 21%) |
General. NuPathe (www.nupathe.com) is a specialty pharmaceutical company focused on acquiring
and developing innovative therapeutic products for the treatment of neurological or psychiatric
disease. NuPathe’s lead product, NP101, is a transdermal patch
that delivers the drug sumatriptan
for the treatment of migraines. The ability to deliver migraine medication through a fast and
long-acting transdermal patch may provide an alternative for the large percentage of migraine
patients who suffer from nausea, vomiting or migraine recurrence. Two additional products, NP201
and NP202, are in preclinical development as potential therapies to treat Parkinson’s disease and
schizophrenia respectively. The development of drug delivery alternatives designed to make current
therapies safer and more effective is a core focus of NuPathe’s business platform.
Safeguard Opportunity. By combining existing drug delivery technology with a market-accepted
drug, NuPathe is positioned at a compelling market junction. We
believe that NuPathe’s approach presents an opportunity to
compete effectively in the market for migraine treatments, estimated to exceed
$2 billion.
| Portico Systems, Inc. | (Safeguard Ownership: 47%) |
General. Portico (www.porticosys.com) is a leading software solutions provider for regional
and national health plans looking to optimize provider network operations and streamline business
processes. The Portico Provider Platform is a suite of solutions that helps health plans address
challenges such as growing healthcare costs, quality, consumerism, competition and regulatory
changes while creating an agile infrastructure that lays a foundation for efficiency and
flexibility. Portico Provider Platform easily integrates with other plan systems, leading
partners, service consultants and complementary solution providers. The Portico Provider Platform
streamlines provider network processes and accelerates new revenue streams, enhancing employee
effectiveness and optimizing provider relationships.
Safeguard Opportunity. There are increasing pressures on health plans to improve operating
efficiencies, and their current provider data typically does not provide visibility and detailed
analysis. In an effort to address the growing need for data transparency, as well as reduce the
estimated $18 billion in administrative costs from rejected medical claims due to incorrect
provider data, health plans are looking to leverage provider network operations as a strategic
asset. We believe Portico is well-positioned to assist health plans in streamlining business
processes and ensuring timely and accurate information with their innovative software solution,
Portico Provider Platform. We believe Portico has a competitive advantage in the healthcare
enterprise applications and analytics market and has sizable growth opportunities.
| Rubicor Medical, Inc. | (Safeguard Ownership: 36%) |
General. Rubicor (www.rubicor.com) develops and distributes technologically advanced,
disposable, minimally-invasive, breast biopsy and tumor removal
devices. Rubicor’s three device (which have received FDA clearance) represent attractive alternatives to existing procedures and technology for breast lesion biopsy
and removal. This results in a more accurate assessment of the sample including
evaluation of margin and determination of size.
Safeguard Opportunity. The innovative concept and design of Rubicor’s products makes them an
attractive alternative to open surgical biopsy and lesion removal. We estimate the market in which
Rubicor competes could be in excess of $500 million today in the
United States. We believe there is an opportunity for physicians using Rubicor technology to improve patient outcomes and move
many breast surgeries from the operating room to the doctor’s office.
19
Table of Contents
Other Partner Companies and Funds. We hold minority interests in a number of other companies
and funds, some of which do not operate in our currently targeted market segments. Following are
summary descriptions of some of these companies, none of which are consolidated based on the level
of our voting interests.
| % Owned By | ||||||
| Company | Description of Business | Safeguard | ||||
| Neuronyx, Inc. (www.neuronyx.com) |
Development-stage biopharmaceutical company, developing stem-cell based therapeutic products. Neuronyx leverages the ability of adult bone marrow-derived stem cells to repair, regenerate and remodel tissue in acute and chronic disease settings. Neuronyx is currently in phase I clinical trials for the prevention of heart failure post myocardial infarction. | 7 | % | |||
| NexTone Communications, Inc. (www.nextone.com) |
Developer of carrier-grade products that provide scalable session management of voice over IP (VoIP) and other real-time services. | 17 | % | |||
| PROMODEL Corporation (www.promodel.com) |
Combines professional services and innovative technology to deliver business process optimization and decision support solutions to the pharmaceutical, healthcare and manufacturing and logistics industries. | 50 | % | |||
| Ventaira Pharmaceuticals, Inc. (www.ventaira.com) |
Specialty pharmaceutical company using novel aerosolization technology to develop highly differentiated pharmaceutical products. Ventaira Pharmaceuticals combines novel applications of generic drugs with the superior delivery benefits of its MysticTM inhaled drug delivery technology. | 13 | % | |||
We also participate in earlier stage technology and life sciences development through our interests
in several private equity funds. During 2006, we provided a total of $1.7 million in funding of
previously committed capital to these funds. We sold our interests in
many of our private equity funds in 2005, and we may continue to opportunistically sell our remaining private equity fund interests.
FINANCIAL INFORMATION ABOUT OPERATING SEGMENTS
Information on revenues, operating income (loss), net income (loss) from continuing operations
and assets for each operating segment of Safeguard’s business for each of the three years in the
period ended December 31, 2006 is contained in Note 20 to the Consolidated Financial Statements.
OTHER INFORMATION
The operations of Safeguard and its companies are subject to environmental laws and
regulations. Safeguard does not believe that expenditures relating to those laws and regulations
will have a material adverse effect on the business, financial condition or results of operations
of Safeguard.
AVAILABLE INFORMATION
All periodic and current reports, registration statements, and other filings that Safeguard is
required to file with the Securities and Exchange Commission (“SEC”), including our annual report
on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and amendments to those
reports filed or furnished pursuant to Section 13(a) of the Exchange Act, are available free of
charge from the SEC’s website (http://www.sec.gov) or public reference room at 450 Fifth Street
N.W., Washington, DC 20549 (1-800-SEC-0330) or through Safeguard’s Internet website at
http://www.safeguard.com. Such documents are available as soon as reasonably practicable after
electronic filing of the material with the SEC. Copies of these reports (excluding exhibits) may
also be obtained free
20
Table of Contents
of charge, upon written request to: Investor Relations, Safeguard Scientifics, Inc., 435 Devon
Park Drive, Building 800, Wayne, PA 19087.
The internet website addresses for Safeguard and its companies are included in this report for
identification purposes. The information contained therein or connected thereto are not intended
to be incorporated into this Annual Report on Form 10-K.
The following corporate governance documents are available free of charge on Safeguard’s
website: the charters of our Audit, Compensation and Nominating & Corporate Governance Committees, our Corporate
Governance Guidelines and our Code of Business Conduct and Ethics. Copies of these corporate
governance documents also may be obtained by any shareholder, free of charge, upon written request
to: Corporate Secretary, Safeguard Scientifics, Inc., 435 Devon Park Drive, Building 800, Wayne,
Pennsylvania 19087. We also will post on our website any amendments to or waivers of our Code of
Business Conduct and Ethics that relate to our directors and executive officers.
Item 1A. Risk Factors
You should carefully consider the information set forth below before making an investment
decision. If any of the following risks actually occur, our business, financial condition or
results of operations could be materially harmed, and the value of our securities may decline. You
should also refer to other information included or incorporated by reference in this report.
Risks Related to Our Business
Our business depends upon the performance of our partner companies, which is uncertain.
If our partner companies do not succeed, the value of our assets could be significantly
reduced and require substantial impairments or write-offs, and our results of operations and the
price of our common stock could decline. The risks relating to our partner companies include:
| • | most of our partner companies have a history of operating losses or a limited operating history; | ||
| • | intensifying competition affecting the products and services our partner companies offer could adversely affect their businesses, financial condition, results of operations and prospects for growth; | ||
| • | inability to adapt to the rapidly changing marketplaces; | ||
| • | inability to manage growth; | ||
| • | the need for additional capital to fund their operations, which we may not be able to fund or which may not be available from third parties on acceptable terms, if at all; | ||
| • | inability to protect their proprietary rights and infringing on the proprietary rights of others; | ||
| • | certain of our partner companies could face legal liabilities from claims made against their operations, products or work; | ||
| • | the impact of economic downturns on their operations, results and growth prospects; | ||
| • | inability to attract and retain qualified personnel; and | ||
| • | government regulations and legal uncertainties may place financial burdens on the businesses of our partner companies. |
These risks are discussed in greater detail under the caption “— Risks Related to Our Partner
Companies” below.
The identity of our partner companies and the nature of our interests in them could vary widely
from period to period.
As part of our strategy, we continually assess the value to our shareholders of our interests
in our partner companies. We also regularly evaluate alternative uses for our capital resources.
As a result, depending on market conditions, growth prospects and other key factors, we may at any
time:
21
Table of Contents
| • | change the partner companies on which we focus; | ||
| • | sell some or all of our interests in any of our partner companies; | ||
| • | or otherwise change the nature of our interests in our partner companies. Therefore, the nature of our holdings could vary significantly from period to period. |
Our consolidated financial results may also vary significantly based upon the partner
companies that are included in our financial statements. For example:
| • | For the twelve months ended December 31, 2006, we consolidated the results of operations of Acsis, Alliance Consulting, Clarient, Laureate Pharma and Pacific Title. | ||
| • | In October 2006, we completed the sale of Mantas and its results of operations for the periods prior to the sale are presented as discontinued operations in the consolidated financial statements. |
Our partner companies currently provide us with little cash flow from their operations so we rely
on cash on hand, liquidity events and our ability to generate cash from capital raising activities
to finance our operations.
We need capital to acquire new partner companies and to fund the capital needs of our existing
partner companies. We also need cash to service and repay our outstanding debt, finance our
corporate overhead and meet our funding commitments to private equity funds. As a result, we have
substantial cash requirements. Our partner companies currently provide us with little cash flow
from their operations. To the extent our partner companies generate any cash from operations, they
generally retain the funds to develop their own businesses. As a result, we must rely on cash on
hand, liquidity events and new capital raising activities to meet our cash needs. If we are unable
to find ways of monetizing our holdings or to raise additional capital on attractive terms, we may
face liquidity issues that will require us to curtail our new business efforts, constrain our
ability to execute our business strategy and limit our ability to provide financial support to our
existing partner companies.
Fluctuations in the price of the common stock of our publicly-traded holdings may affect the price
of our common stock.
Fluctuations in the market prices of the common stock of our publicly-traded holdings are
likely to affect the price of our common stock. The market prices of our publicly-traded holdings
have been highly volatile and subject to fluctuations unrelated or disproportionate to operating
performance. For example, the aggregate market value of our holdings in Clarient (Nasdaq: CLRT) at
December 31, 2006 was approximately $72.8 million, and at December 31, 2005 was approximately $44.8
million.
Intense competition from other acquirers of interests in companies could result in lower gains or
possibly losses on our partner companies.
We face intense competition from other capital providers as we acquire and develop interests
in our partner companies. Some of our competitors have more experience identifying and acquiring
companies and have greater financial and management resources, brand name recognition or industry
contacts than we have. Despite making most of our acquisitions at a stage when our partner
companies are not publicly traded, we may still pay higher prices for those equity interests
because of higher valuations of similar public companies and competition from other acquirers and
capital providers, which could result in lower gains or possibly losses.
We may be unable to obtain maximum value for our holdings or sell our holdings on a timely basis.
We hold significant positions in our partner companies. Consequently, if we were to divest
all or part of our holdings in a partner company, we may have to sell our interests at a relative
discount to a price which may be received by a seller of a smaller portion. For partner companies
with publicly traded stock, we may be unable to sell our holdings at then-quoted market prices.
The trading volume and public float in the common stock of our publicly-traded partner companies
are small relative to our holdings. As a result, any significant divestiture by us of our holdings
in these partner companies would likely have a material adverse effect on the market price of their
22
Table of Contents
common stock and on our proceeds from such a divestiture. Additionally, we may not be able to
take our partner companies public as a means of monetizing our position or creating shareholder
value.
Registration and other requirements under applicable securities laws may adversely affect our
ability to dispose of our holdings on a timely basis.
Our success is dependent on our executive management.
Our success is dependent on our executive management team’s ability to execute our strategy.
A loss of one or more of the members of our executive management team without adequate replacement
could have a material adverse effect on us.
Our business strategy may not be successful if valuations in the market sectors in which our
partner companies participate decline.
Our strategy involves creating value for our shareholders by helping our partner companies
build value and, if appropriate, accessing the public and private capital markets. Therefore, our
success is dependent on the value of our partner companies as determined by the public and private
capital markets. Many factors, including reduced market interest, may cause the market value of
our publicly traded partner companies to decline. If valuations in the market sectors in which our
partner companies participate decline, their access to the public and private capital markets on
terms acceptable to them may be limited.
Our partner companies could make business decisions that are not in our best interests or with
which we do not agree, which could impair the value of our holdings.
Although we may seek a controlling equity interest and participation in the management of our
partner companies, we may not be able to control the significant business decisions of our partner
companies. We may have shared control or no control over some of our partner companies. In
addition, although we currently own a controlling interest in some of our partner companies, we may
not maintain this controlling interest. Acquisitions of interests in partner companies in which we
share or have no control, and the dilution of our interests in or loss of control of partner
companies, will involve additional risks that could cause the performance of our interests and our
operating results to suffer, including:
| • | the management of a partner company having economic or business interests or objectives that are different than ours; and | ||
| • | partner companies not taking our advice with respect to the financial or operating difficulties they may encounter. |
Our inability to adequately control our partner companies also could prevent us from assisting
them, financially or otherwise, or could prevent us from liquidating our interests in them at a
time or at a price that is favorable to us. Additionally, our partner companies may not act in
ways that are consistent with our business strategy. These factors could hamper our ability to
maximize returns on our interests and cause us to recognize losses on our interests in these
partner companies.
We may have to buy, sell or retain assets when we would otherwise not wish to do so in order to
avoid registration under the Investment Company Act.
The Investment Company Act of 1940 regulates companies which are engaged primarily in the
business of investing, reinvesting, owning, holding or trading in securities. Under the Investment
Company Act, a company may be deemed to be an investment company if it owns investment securities
with a value exceeding 40% of the value of its total assets (excluding government securities and
cash items) on an unconsolidated basis, unless an exemption or safe harbor applies. We refer to
this test as the “40% Test.” Securities issued by companies other than majority-owned subsidiaries
are generally considered “investment securities” for purpose of the Investment Company Act. We are
a company that partners with growth-stage technology and life sciences companies to build value; we
are not engaged primarily in the business of investing, reinvesting or trading in securities. We
are in
23
Table of Contents
compliance with the 40% Test. Consequently, we do not believe that we are an investment
company under the Investment Company Act.
We monitor our compliance with the 40% Test and seek to conduct our business activities to
comply with this test. It is not feasible for us to be regulated as an investment company because
the Investment Company Act rules are inconsistent with our strategy of actively helping our partner
companies in their efforts to build value. In order to continue to comply with the 40% Test, we
may need to take various actions which we would otherwise not pursue. For example, we may need to
retain a majority interest in a partner company that we no longer consider strategic, we may not be
able to acquire an interest in a company unless we are able to obtain majority ownership interest
in the company, or we may be limited in the manner or timing in which we sell our interests in a
partner company. Our ownership levels may also be affected if our partner companies are acquired
by third parties or if our partner companies issue stock which dilutes our majority ownership. The
actions we may need to take to address these issues while maintaining compliance with the 40% Test
could adversely affect our ability to create and realize value at our partner companies.
Risks Related to Our Partner Companies
Most of our partner companies have a history of operating losses or limited operating history and may never be profitable.
Most of our partner companies have a history of operating losses or limited operating history,
have significant historical losses and may never be profitable. Many have incurred substantial
costs to develop and market their products, have incurred net losses and cannot fund their cash
needs from operations. We expect that the operating expenses of certain of our partner companies
will increase substantially in the foreseeable future as they continue to develop products and
services, increase sales and marketing efforts and expand operations.
Our partner companies face intense competition, which could adversely affect their business,
financial condition, results of operations and prospects for growth.
There is intense competition in the technology and life sciences marketplaces, and we expect
competition to intensify in the future. Our business, financial condition, results of operations
and prospects for growth will be materially adversely affected if our partner companies are not
able to compete successfully. Many of the present and potential competitors may have greater
financial, technical, marketing and other resources than those of our partner companies. This may
place our partner companies at a disadvantage in responding to the offerings of their competitors,
technological changes or changes in client requirements. Also, our partner companies may be at a
competitive disadvantage because many of their competitors have greater name recognition, more
extensive client bases and a broader range of product offerings. In addition, our partner
companies may compete against one another.
Our partner companies may fail if they do not adapt to the rapidly changing technology and life
sciences marketplaces.
If our partner companies fail to adapt to rapid changes in technology and customer and
supplier demands, they may not become or remain profitable. There is no assurance that the
products and services of our partner companies will achieve or maintain market penetration or
commercial success, or that the businesses of our partner companies will be successful.
The technology and life sciences marketplaces are characterized by:
| • | rapidly changing technology; | ||
| • | evolving industry standards; | ||
| • | frequent new products and services; | ||
| • | shifting distribution channels; | ||
| • | evolving government regulation; | ||
| • | frequently changing intellectual property landscapes; and |
24
Table of Contents
| • | changing customer demands. |
Our future success will depend on our partner companies’ ability to adapt to this rapidly
evolving marketplace. They may not be able to adequately or economically adapt their products and
services, develop new products and services or establish and maintain effective distribution
channels for their products and services. If our partner companies are unable to offer competitive
products and services or maintain effective distribution channels, they will sell fewer products
and services and forego potential revenue, possibly causing them to lose money. In addition, we
and our partner companies may not be able to respond to the rapid technology changes in an
economically efficient manner, and our partner companies may become or remain unprofitable.
Many of our partner companies may grow rapidly and may be unable to manage their growth.
We expect some of our partner companies to grow rapidly. Rapid growth often places
considerable operational, managerial and financial strain on a business. To successfully manage
rapid growth, our partner companies must, among other things:
| • | rapidly improve, upgrade and expand their business infrastructures; | ||
| • | scale-up production operations; | ||
| • | develop appropriate financial reporting controls; | ||
| • | attract and maintain qualified personnel; and | ||
| • | maintain appropriate levels of liquidity. |
If our partner companies are unable to manage their growth successfully, their ability to
respond effectively to competition and to achieve or maintain profitability will be adversely
affected.
Our partner companies may need to raise additional capital to fund their operations, which we may
not be able to fund or which may not be available from third parties on acceptable terms, if at
all.
Our partner companies may need to raise additional funds in the future and we cannot be
certain that they will be able to obtain additional financing on favorable terms, if at all.
Because our resources and our ability to raise capital are limited, we may not be able to provide
our partner companies with sufficient capital resources to enable them to reach a cash flow
positive position. If our partner companies need to, but are not able to raise capital from other
outside sources, then they may need to cease or scale back operations.
Some of our partner companies may be unable to protect their proprietary rights and may infringe on
the proprietary rights of others.
Our partner companies assert various forms of intellectual property protection. Intellectual
property may constitute an important part of our partner companies’ assets and competitive
strengths. Federal law, most typically, copyright, patent, trademark and trade secret laws,
generally protects intellectual property rights. Although we expect that our partner companies
will take reasonable efforts to protect the rights to their intellectual property, the complexity
of international trade secret, copyright, trademark and patent law, coupled with the limited
resources of these partner companies and the demands of quick delivery of products and services to
market, create a risk that their efforts will prove inadequate to prevent misappropriation of our
partner companies’ technology, or third parties may develop similar technology independently.
Some of our partner companies also license intellectual property from third parties and it is
possible that they could become subject to infringement actions based upon their use of the
intellectual property licensed from those third parties. Our partner companies generally obtain
representations as to the origin and ownership of such licensed intellectual property; however,
this may not adequately protect them. Any claims against our partner companies’ proprietary
rights, with or without merit, could subject our partner companies to costly litigation and the
diversion of their technical and management personnel from other business concerns. If our partner
companies incur costly litigation and their personnel are not effectively deployed, the expenses
and losses incurred by our partner companies will increase and their profits, if any, will
decrease.
25
Table of Contents
Third parties have and may assert infringement or other intellectual property claims against
our partner companies based on their patents or other intellectual property claims. Even though we
believe our partner companies’ products do not infringe any third party’s patents, they may have to
pay substantial damages, possibly including treble damages, if it is ultimately determined that
they do. They may have to obtain a license to sell their products if it is determined that their
products infringe another person’s intellectual property. Our partner companies might be
prohibited from selling their products before they obtain a license, which, if available at all,
may require them to pay substantial royalties. Even if infringement claims against our partner
companies are without merit, defending these types of lawsuits take significant time, may be
expensive and may divert management attention from other business concerns.
Certain of our partner companies could face legal liabilities from claims made against their
operations, products or work.
The manufacture and sale of certain of our partner companies’ products entails an inherent
risk of product liability. Certain of our partner companies maintain product liability insurance.
Although none of our partner companies to date have experienced any material losses, there can be
no assurance that they will be able to maintain or acquire adequate product liability insurance in
the future and any product liability claim could have a material adverse effect on our partner
companies’ revenues and income. In addition, many of the engagements of our partner companies
involve projects that are critical to the operation of their clients’ businesses. If our partner
companies fail to meet their contractual obligations, they could be subject to legal liability,
which could adversely affect their business, operating results and financial condition. The
provisions our partner companies typically include in their contracts, which are designed to limit
their exposure to legal claims relating to their services and the applications they develop, may
not protect our partner companies or may not be enforceable. Also as consultants, some of our
partner companies depend on their relationships with their clients and their reputation for high
quality services and integrity to retain and attract clients. As a result, claims made against our
partner companies’ work may damage their reputation, which in turn, could impact their ability to
compete for new work and negatively impact their revenues and profitability.
Our partner companies’ success depends on their ability to attract and retain qualified personnel.
Our partner companies are dependent upon their ability to attract and retain senior management
and key personnel, including trained technical and marketing personnel. Our partner companies will
also need to continue to hire additional personnel as they expand. Some of our partner companies
have employees represented by labor unions. Although these partner companies have not been the
subject of a work stoppage, any future work stoppage could have a material adverse effect on their
respective operations. A shortage in the availability of the requisite qualified personnel or work
stoppage would limit the ability of our partner companies to grow, to increase sales of their
existing products and services and to launch new products and services.
Government regulations and legal uncertainties may place financial burdens on the businesses of our
partner companies.
Failure to comply with applicable requirements of the FDA or comparable regulation in foreign
countries can result in fines, recall or seizure of products, total or partial suspension of
production, withdrawal of existing product approvals or clearances, refusal to approve or clear new
applications or notices and criminal prosecution. Manufacturers of pharmaceuticals and medical
diagnostic devices and operators of laboratory facilities are subject to strict federal and state
regulation regarding validation and the quality of manufacturing and laboratory facilities.
Failure to comply with these quality regulation systems requirements could result in civil or
criminal penalties or enforcement proceedings, including the recall of a product or a “cease
distribution” order. The enactment of any additional laws or regulations that affect healthcare
insurance policy and reimbursement (including Medicare reimbursement) could negatively affect our
partner companies. If Medicare or private payors change the rates at which our partner companies
or their customers are reimbursed by insurance providers for their products, such changes could
adversely impact our partner companies.
26
Table of Contents
Some of our partner companies are subject to significant environmental, health and safety
regulation.
Some of our partner companies are subject to licensing and regulation under federal, state and
local laws and regulations relating to the protection of the environment and human health and
safety, including laws and regulations relating to the handling, transportation and disposal of
medical specimens, infectious and hazardous waste and radioactive materials as well as to the
safety and health of manufacturing and laboratory employees. In addition, the federal Occupational
Safety and Health Administration has established extensive requirements relating to workplace
safety.
Item 2. Properties
Safeguard’s corporate headquarters and administrative offices in Wayne, Pennsylvania contain
approximately 31,000 square feet of office space in one building. In October 2002, Safeguard sold
this facility along with the office park in which our corporate headquarters and administrative
offices are located. Safeguard leased back its corporate headquarters for a seven-year term with
one five-year renewal option.
Safeguard’s consolidated partner companies lease various facilities throughout the United
States and in certain non-U.S. locations. The physical properties occupied by each of our
consolidated partner companies, under leases expiring between 2007 and 2015, are summarized below:
| Approximate | ||||||||
| Company | Locations | Use | Square Footage | |||||
Acsis |
New Jersey and Germany | Office/Sales/Development | 39,000 | |||||
Alliance Consulting |
Pennsylvania and other locations in the U.S. and India (11 facilities) | Office/Sales/Development | 83,000 | |||||
Clarient |
California | Office/Manufacturing/Laboratory Services | 78,000 | |||||
Pacific Title |
California (two facilities) | Office/Production | 37,000 | |||||
Laureate Pharma |
New Jersey | Office/Manufacturing | 58,000 | |||||
We believe that all of the existing facilities are suitable and adequate to meet the current
needs of our respective partner companies. If new or additional space is needed, we believe each
of our partner companies can readily obtain suitable replacement properties to support their needs
on commercially reasonable terms. However, we note that Clarient’s and Laureate Pharma’s
facilities are operated under and subject to various federal, state and local permits, rules and
regulations. As a result, any extended interruption in the availability of these facilities could
have a material adverse effect on the results of operations of the respective companies.
Item 3. Legal Proceedings
We, as well as our partner companies, are involved in various claims and legal actions arising
in the ordinary course of business. While in the current opinion of management, the ultimate
disposition of these matters will not have a material adverse effect on our consolidated financial
position or results of operations, no assurance can be given as to the outcome of these lawsuits,
and one or more adverse rulings could have a material adverse effect on our consolidated financial
position and results of operations, or that of our partner companies.
Item 4. Submission of Matters to a Vote of Security Holders
No matter was submitted to a vote of security holders, through the solicitation of proxies or
otherwise, during the fourth quarter of 2006.
27
Table of Contents
ANNEX TO PART I — EXECUTIVE OFFICERS OF THE REGISTRANT
| Name | Age | Position | Executive Officer Since | |||||||
Peter J. Boni |
61 | President, Chief Executive Officer and Director | 2005 | |||||||
James A. Datin |
44 | Executive Vice President and Managing Director, Life Sciences | 2005 | |||||||
John A. Loftus |
45 | Executive Vice President and Managing Director, Technology | 2004 | |||||||
Steven J. Feder |
43 | Senior Vice President and General Counsel | 2004 | |||||||
Stephen T. Zarrilli |
45 | Acting Senior Vice President, Acting Chief Administrative Officer and Acting Chief Financial Officer | 2006 | |||||||
Mr. Boni joined Safeguard as President and Chief Executive Officer in August 2005. Prior to
joining Safeguard, Mr. Boni was an Operating Partner for Advent International, a global private
equity firm with $10 billion under management, from April 2004 to August 2005; Chairman and Chief
Executive Officer of Surebridge, Inc., an applications outsourcer serving the mid-market, from
March 2002 to April 2004; Managing Principal of Vested Interest LLC, a management consulting firm,
from January 2001 to March 2002; and President and Chief Executive Officer of Prime Response, Inc.,
an enterprise applications software provider, from February 1999 to January 2001. Mr. Boni is
currently non-executive Chairman of Intralinks, Inc. and a director of Clarient, Inc.
Mr. Datin joined Safeguard as Executive Vice President and Managing Director, Life Sciences in
September 2005. Mr. Datin served as Chief Executive Officer of Touchpoint Solutions, Inc., a
provider of software that enables customers to develop and deploy applications, content and media
on multi-user interactive devices, from December 2004 to June 2005; Group President in 2004, and as
Group President, International, from 2001 to 2003, of Dendrite International, a provider of sales,
marketing, clinical and compliance solutions and services to global pharmaceutical and other life
sciences companies; and Group Director, Corporate Business Strategy and Planning at
GlaxoSmithKline, from 1999 to 2001, where he also was a member of the company’s Predictive Medicine
Board of Directors that evaluated acquisitions and alliances. His prior experience also includes
international assignments with and identifying strategic growth opportunities for E Merck and
Baxter. Mr. Datin is a director of Intralinks, Inc. and Clarient, Inc.
Mr. Loftus joined Safeguard in May 2002, became Senior Vice President and Chief Technology
Officer in December 2003 and Executive Vice President and Managing Director, Technology Group in
September 2005. Mr. Loftus is a founder of Gestalt LLC where he served as Chief Technology Officer
from September 2001 to May 2002. Mr. Loftus served as Senior Vice President, e-Solutions (and in
other executive roles) at Breakaway Solutions from May 1999 until August 2001 (Breakaway Solutions
filed for bankruptcy protection under Chapter 11 of the United States Bankruptcy Code in September
2001); and served as Senior Vice President and Chief Technology Officer of WPL Laboratories from
February 1997 to May 1999. Mr. Loftus spent the first 14 years of his career in a variety of
executive, management, and engineering positions at GE and PECO Energy.
Mr. Feder joined Safeguard in November 2004 as Senior Vice President and General Counsel.
Prior to joining Safeguard, Mr. Feder was a partner with the law firm of Pepper Hamilton LLP in its
Berwyn, Pennsylvania office from May 2000 to November 2004. He was a partner from March 1998 to
May 2000 at the law firm of White and Williams LLP in Philadelphia, Pennsylvania and a senior
associate from July 1995 to March 1998 at the law firm of Ballard Spahr Andrews and Ingersoll in
Philadelphia, Pennsylvania. From 1990 to June 1995, Mr. Feder was corporate counsel for MEDIQ
Incorporated, formerly an AMEX-listed diversified healthcare company. Mr. Feder is a director of
Clarient, Inc.
Mr. Zarrilli entered into a consulting agreement with Safeguard in December 2006 pursuant to
which he commenced service as Acting Senior Vice President, Acting Chief Administrative Officer and
Acting Chief Financial Officer. Mr. Zarrilli is a Managing Partner of the Penn Valley Group, a
middle-market management
28
Table of Contents
advisory and private equity firm which he co-founded in October 2004. Previously, Mr.
Zarrilli served as the Chief Financial Officer from August 2001 to December 2004 of Fiberlink
Communications Corporation, a provider of remote access VPN solutions for large enterprises; as the
Chief Executive Officer from October 2000 to August 2001 of Concellera Software, Inc., a developer
of content management software; as the Chief Executive Officer from January 1999 to September 2000
and Chief Financial Officer from July 1994 to December 1998 of US Interactive, Inc., a provider of
internet strategy consulting, marketing and technology services; and, previously, with Deloitte &
Touche from 1983 to 1994. Mr. Zarrilli is a director and Chairman of the Audit Committee of
NutriSystem, Inc.
29
Table of Contents
PART II.
Item 5. Market for the Registrant’s Common Equity, Related Stockholder Matters and Issuer
Purchases of Equity Securities
Safeguard’s common stock is listed on the New York Stock Exchange (Symbol: SFE). The high and
low sale prices reported within each quarter of 2006 and 2005 are as follows:
| High | Low | |||||||
Fiscal year 2006: |
||||||||
First quarter |
$ | 2.57 | $ | 1.77 | ||||
Second quarter |
2.90 | 1.91 | ||||||
Third quarter |
2.30 | 1.71 | ||||||
Fourth quarter |
2.55 | 1.92 | ||||||
Fiscal year 2005: |
||||||||
First quarter |
$ | 2.17 | $ | 1.36 | ||||
Second quarter |
1.58 | 0.98 | ||||||
Third quarter |
1.85 | 1.21 | ||||||
Fourth quarter |
2.05 | 1.31 | ||||||
The
high and low sale prices reported in the first quarter of 2007
through March 22, 2007 were
$3.15 and $2.31, respectively, and the last sale price reported on
March 22, 2007, was $3.02. No
cash dividends have been declared in any of the years presented, and Safeguard has no present
intention to declare cash dividends.
As
of March 22, 2007, there were approximately 44,000 beneficial holders of Safeguard’s common
stock.
The following graph compares the cumulative total return on $100 invested in our common stock
for the period from December 31, 2001 through December 31, 2006 with the cumulative total return on
$100 invested for the same period in the Russell 2000 Index and the Dow Jones Wilshire 4500 Index.
In light of the diverse nature of Safeguard’s business and based on our assessment of available
published industry or line-of-business indices, we determined that no single industry or
line-of-business index would provide a meaningful comparison to Safeguard. Further, we did not
believe that we could readily identify an appropriate group of industry peer companies for this
comparison. Accordingly, under SEC rules, we selected the Dow Jones Wilshire 4500 Index, a
published market index in which the median market capitalization of the included companies is
similar to our own. Safeguard’s common stock is included as a component of the Russell 2000 and
Dow Jones Wilshire 4500 indices.
Comparison of Cumulative Total Returns
| • | Assumes reinvestment of dividends. We have not distributed cash dividends during this period. | ||
| • | Assumes an investment of $100 on December 31, 2001. |
30
Table of Contents
Item 6. Selected Consolidated Financial Data
The following table sets forth our selected consolidated financial information for the
five-year period ended December 31, 2006. The selected consolidated financial data presented below
should be read in conjunction with Item 7. Management’s Discussion and Analysis of Financial
Condition and Results of Operations and Item 8. Consolidated Financial Statements and Notes thereto
included in this report. The historical results presented herein may not be indicative of future
results. As a result of the sale of Mantas in October 2006, Mantas’ operating results are included
in discontinued operations for all periods presented. Alliance Consulting sold its Southwest
region business in July 2006; as a result the operations of the Southwest region are included in
discontinued operations for all periods presented. As a result of the sale of Laureate Pharma’s
Totowa, New Jersey facility in December 2005, the operating results related to its Totowa facility
are included in discontinued operations in 2005. As a result of the sale of CompuCom on October 1,
2004, the operating results of CompuCom are included in discontinued operations for 2002 through
2004.
| December 31, | ||||||||||||||||||||
| 2006 | 2005 | 2004 | 2003 | 2002 | ||||||||||||||||
| (In thousands) | ||||||||||||||||||||
Consolidated Balance Sheet Data: |
||||||||||||||||||||
Cash and cash equivalents |
$ | 71,251 | $ | 124,916 | $ | 143,398 | $ | 129,676 | $ | 117,326 | ||||||||||
Short-term investments |
94,155 | 31,770 | 33,555 | 7,081 | 9,986 | |||||||||||||||
Restricted cash |
— | 1,098 | 1,069 | 1,019 | 3,634 | |||||||||||||||
Working capital of continuing operations |
136,894 | 145,996 | 172,737 | 133,332 | 121,935 | |||||||||||||||
Cash held in escrow |
19,630 | — | — | — | — | |||||||||||||||
Total assets of continuing operations |
443,381 | 375,344 | 399,616 | 329,696 | 381,565 | |||||||||||||||
Long-term debt, net of current portion |
3,095 | 3,041 | 7,852 | 2,118 | 932 | |||||||||||||||
Capital leases, net of current portion |
1,972 | 2,129 | 1,858 | 409 | 652 | |||||||||||||||
Other long-term liabilities |
10,918 | 14,013 | 11,785 | 13,152 | 14,018 | |||||||||||||||
Convertible subordinated notes |
— | — | — | 200,000 | 200,000 | |||||||||||||||
Convertible senior debentures-non-current |
129,000 | 145,000 | 150,000 | — | — | |||||||||||||||
Total shareholders’ equity |
211,881 | 164,975 | 201,230 | 236,171 | 272,287 | |||||||||||||||
31
Table of Contents
Consolidated Statements of Operations Data
| Year Ended December 31, | ||||||||||||||||||||
| 2006 | 2005 | 2004 | 2003 | 2002 | ||||||||||||||||
| (In thousands except per share amounts) | ||||||||||||||||||||
Revenue: |
||||||||||||||||||||
Product sales |
$ | 10,668 | $ | 5,898 | $ | 2,211 | $ | 9,134 | $ | 19,298 | ||||||||||
Service sales |
187,392 | 137,933 | 107,143 | 122,170 | 86,786 | |||||||||||||||
Total revenue |
198,060 | 143,831 | 109,354 | 131,304 | 106,084 | |||||||||||||||
Operating Expenses: |
||||||||||||||||||||
Cost of sales — product |
7,556 | 1,921 | 2,532 | 10,349 | 7,005 | |||||||||||||||
Cost of sales — service |
134,834 | 103,260 | 74,882 | 72,824 | 40,979 | |||||||||||||||
Selling, general and administrative |
99,962 | 74,178 | 73,053 | 73,197 | 94,976 | |||||||||||||||
Research and development |
6,977 | 3,794 | 4,699 | 6,570 | 11,041 | |||||||||||||||
Purchased in-process research and
development |
— | 2,183 | 89 | 265 | 1,129 | |||||||||||||||
Amortization of intangibles |
3,413 | 2,367 | 2,192 | 1,976 | 1,085 | |||||||||||||||
Goodwill impairment |
— | — | — | 15,968 | 6,575 | |||||||||||||||
Total operating expenses |
252,742 | 187,703 | 157,447 | 181,149 | 162,790 | |||||||||||||||
Operating loss |
(54,682 | ) | (43,872 | ) | (48,093 | ) | (49,845 | ) | (56,706 | ) | ||||||||||
Other income (loss), net |
5,573 | 7,338 | 38,803 | 48,838 | (5,241 | ) | ||||||||||||||
Recovery (impairment) — related party |
360 | 28 | (3,400 | ) | (659 | ) | (11,434 | ) | ||||||||||||
Interest income |
6,914 | 4,984 | 2,612 | 2,165 | 6,313 | |||||||||||||||
Interest expense |
(6,821 | ) | (6,428 | ) | (9,585 | ) | (11,853 | ) | (21,594 | ) | ||||||||||
Equity loss |
(3,267 | ) | (6,597 | ) | (14,534 | ) | (17,179 | ) | (51,004 | ) | ||||||||||
Minority interest |
7,120 | 6,356 | 8,736 | 3,216 | 6,389 | |||||||||||||||
Net loss from continuing operations
before income taxes and change in
accounting principle |
(44,803 | ) | (38,191 | ) | (25,461 | ) | (25,317 | ) | (133,277 | ) | ||||||||||
Income tax benefit (expense) |
1,023 | 83 | 120 | (209 | ) | (46 | ) | |||||||||||||
Net loss from continuing operations
before change in accounting principle |
(43,780 | ) | (38,108 | ) | (25,341 | ) | (25,526 | ) | (133,323 | ) | ||||||||||
Income (loss) from discontinued
operations, net of tax |
89,810 | 6,038 | (29,479 | ) | (7,805 | ) | 4,655 | |||||||||||||
Cumulative effect of change in
accounting principle |
— | — | — | — | (21,815 | ) | ||||||||||||||
Net income (loss) |
$ | 46,030 | $ | (32,070 | ) | $ | (54,820 | ) | $ | (33,331 | ) | $ | (150,483 | ) | ||||||
Basic Income (Loss) Per Share: |
||||||||||||||||||||
Net loss from continuing operations |
$ | (0.36 | ) | $ | (0.32 | ) | $ | (0.21 | ) | $ | (0.22 | ) | $ | (1.13 | ) | |||||
Net income (loss) from discontinued
operations |
0.74 | 0.05 | (0.25 | ) | (0.06 | ) | 0.03 | |||||||||||||
Cumulative effect of change in
accounting principle |
— | — | — | — | (0.18 | ) | ||||||||||||||
Net income (loss) |
$ | 0.38 | $ | (0.27 | ) | $ | (0.46 | ) | $ | (0.28 | ) | $ | (1.28 | ) | ||||||
Diluted Income (Loss) Per Share: |
||||||||||||||||||||
Net loss from continuing operations |
$ | (0.36 | ) | $ | (0.32 | ) | $ | (0.21 | ) | $ | (0.22 | ) | $ | (1.16 | ) | |||||
Net income (loss) from
discontinued operations |
0.74 | 0.05 | (0.25 | ) | (0.08 | ) | 0.04 | |||||||||||||
Cumulative effect of change in
accounting principle |
— | — | — | — | (0.18 | ) | ||||||||||||||
Net income (loss) |
$ | 0.38 | $ | (0.27 | ) | $ | (0.46 | ) | $ | (0.30 | ) | $ | (1.30 | ) | ||||||
Shares used in computing: |
||||||||||||||||||||
Basic and diluted income (loss)
per share |
121,476 | 120,845 | 119,965 | 118,486 | 117,736 | |||||||||||||||
Certain amounts for prior periods in the Consolidated Financial Statements have been
reclassified to conform with current period presentations.
32
Table of Contents
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations
Cautionary Note concerning Forward-Looking Statements
This report contains forward-looking statements that are based on current expectations,
estimates, forecasts and projections about us, the industries in which we operate and other
matters, as well as management’s beliefs and assumptions and other statements regarding matters
that are not historical facts. These statements include, in particular, statements about our
plans, strategies and prospects. For example, when we use words such as “projects,” “expects,”
“anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “should,” “would,” “could,”
“will,” “opportunity,” “potential” or “may,” variations of such words or other words that convey
uncertainty of future events or outcomes, we are making forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act
of 1934. Our forward-looking statements are subject to risks and uncertainties. Factors that could
cause actual results to differ materially, include, among others, managing rapidly changing
technologies, limited access to capital, competition, the ability to attract and retain qualified
employees, the ability to execute our strategy, the uncertainty of the future performance of our
partner companies, acquisitions and dispositions of interests in partner companies, the inability
to manage growth, compliance with government regulation and legal liabilities, additional financing
requirements and the effect of economic conditions in the business sectors in which our partner
companies operate, all of which are discussed in Item 1A. Business under the caption “Risk
Factors.” Many of these factors are beyond our ability to predict or control. In light of these
risks and uncertainties, the forward-looking events and circumstances discussed in this report
might not occur. In addition, as a result of these and other factors, our past financial
performance should not be relied on as an indication of future performance.
All forward-looking statements attributable to us, or to persons acting on our behalf, are
expressly qualified in their entirety by this cautionary statement. We undertake no obligation to
publicly update or revise any forward-looking statements, whether as a result of new information,
future events or otherwise, except as required by law.
Overview
Safeguard’s charter is to build value in growth-stage technology and life sciences businesses.
We provide growth capital as well as a range of strategic, operational and management resources to
our partner companies. Safeguard participates in expansion financings, carve-outs, management
buy-outs, recapitalizations, industry consolidations and early-stage financings. Our vision is to
be the preferred catalyst for creating great technology and life sciences companies.
We strive to create long-term value for our shareholders through building value in our partner
companies. We help our partner companies in their efforts to increase market penetration, grow
revenue and improve cash flow in order to create long-term value. We concentrate on companies that
operate in two categories:
Technology — including
companies focused on providing software as a service (SaaS),
technology-enabled services and vertical software solutions for analytics, enterprise application,
infrastructure, security and communication; and
Life Sciences — including companies focused on medical devices, molecular diagnostics, drug
delivery and specialty pharmaceuticals.
Principles of Accounting for Ownership Interests in Partner Companies
The various interests that we acquire in our partner companies and private equity funds are
accounted for under three methods: consolidation, equity or cost. The applicable accounting method
is generally determined based on our influence over the entity, primarily determined based on our
voting interest in the entity.
Consolidation Method. Partner companies in which we directly or indirectly own more than 50%
of the outstanding voting securities are accounted for under the consolidation method of
accounting. Participation of other partner company shareholders in the income or losses of our
consolidated partner companies is reflected as Minority Interest in the Consolidated Statements of
Operations. Minority interest adjusts our consolidated operating results to
33
Table of Contents
reflect only our share of the earnings or losses of the consolidated partner company. If
there is no minority interest balance remaining on the Consolidated Balance Sheets related to the
respective partner company, we record 100% of the consolidated partner company’s losses; we record
100% of subsequent earnings of the partner company to the extent of such previously recognized
losses in excess of our proportionate share.
Equity Method. The partner companies whose results are not consolidated, but over whom we
exercise significant influence, are accounted for under the equity method of accounting. We also
account for our interests in some private equity funds under the equity method of accounting, based
on our respective general and limited partner interests. Under the equity method of accounting, our
share of the income or loss of the company is reflected in Equity Loss in the Consolidated
Statements of Operations. We report our share of the income or loss of the equity method partner
companies on a one quarter lag.
When the carrying value of our holding in an equity method partner company is reduced to zero,
no further losses are recorded in our Consolidated Statements of Operations unless we have
outstanding guarantee obligations or have committed additional funding to the equity method
company. When the equity method partner company subsequently reports income, we will not record our
share of such income until it equals the amount of our share of losses not previously recognized.
Cost Method. Partner companies not consolidated or accounted for under the equity method are
accounted for under the cost method of accounting. Under the cost method, our share of the income
or losses of such partner companies is not included in our Consolidated Statements of Operations.
However, the effect of the change in market value of cost method holdings classified as trading
securities is reflected in Other Income (Loss), Net in the Consolidated Statements of Operations.
Critical Accounting Policies and Estimates
Accounting policies, methods and estimates are an integral part of the Consolidated Financial
Statements prepared by management and are based upon management’s current judgments. These
judgments are normally based on knowledge and experience with regard to past and current events and
assumptions about future events. Certain accounting policies, methods and estimates are
particularly important because of their significance to the financial statements and because of the
possibility that future events affecting them may differ from management’s current judgments. While
there are a number of accounting policies, methods and estimates affecting our financial statements
as described in Note 1 to our Consolidated Financial Statements, areas that are particularly
significant include the following:
| • | Revenue recognition; | ||
| • | Recoverability of long-lived assets; | ||
| • | Recoverability of goodwill; | ||
| • | Recoverability of ownership interests in and advances to companies; | ||
| • | Income taxes; | ||
| • | Commitments and contingencies; and | ||
| • | Stock-based compensation. |
Revenue Recognition
During 2006, 2005 and 2004, our revenue from continuing operations was primarily attributable
to Acsis (since December 2005), Alliance Consulting, Clarient, Laureate Pharma (since December
2004) and Pacific Title.
34
Table of Contents
Acsis generates revenue from (i) software fees, which consist of revenue from the licensing of
software, (ii) services revenue, which consist of fees from consulting, implementation and
training services, plus customer support services, and (iii) hardware and reimbursed project
expenses.
Acsis recognizes software fees in accordance with Statement of Position No. 97-2, “Software
Revenue Recognition” (“SOP 97-2”), as amended. Although Acsis follows specific and detailed
guidelines in measuring revenue, the application of those guidelines requires judgment including:
(i) whether a software arrangement includes multiple elements, and if so, whether vendor-specific
objective evidence of fair value exists for those elements; (ii) whether customizations or
modifications of the software are significant; and (iii) whether collection of the software fee is
probable. Additionally, Acsis specifically evaluates any other terms in its license transactions,
including but not limited to, options to purchase additional software at a future date, extended
payment terms and functionality commitments not delivered with the software. Acsis recognizes
software license revenue when the following criteria are met: (1) a signed contract is obtained;
(2) delivery of the products has occurred; (3) the license fee is fixed or determinable; and (4)
collectibility is probable. Acsis generally recognizes license revenue using the “residual method”
when there is vendor-specific objective evidence of the fair values of all undelivered elements in
a multiple-element arrangement that is not accounted for using long-term contract accounting. For
those contracts that contain significant customization or modifications, license revenue is
recognized using the percentage-of-completion method.
Most of Acsis’ software arrangements include professional services. Acsis provides
professional services under service agreements on a time and material-basis or based on a
fixed-price arrangement. The revenues from Acsis’ time and material-based professional consulting
and implementation services are recognized as the work is performed, provided that the customer has
a contractual obligation to pay, the fee is non-refundable and collection is probable. Delays in
project implementation will result in delays in revenue recognition. Acsis recognizes revenues
from professional consulting services under fixed-price arrangements, using the
proportional-performance method based on direct labor costs incurred to date as a percentage of
total estimated labor costs required to complete the project. Revisions to the estimates are
reflected in the period in which changes become known. Project losses are provided for in their
entirety in the period they become known, without regard to the percentage-of-completion. If Acsis
does not accurately estimate the resources required or the scope of work to be performed, or if
Acsis does not manage their projects properly within the planned periods of time, then future
consulting margins on its projects may be negatively affected or losses on existing contracts may
need to be recognized.
Hardware revenue is generated from the resale of a variety of hardware products, developed and
manufactured primarily by third parties, which are integrated with and complementary to Acsis’
software solutions. These products include computer equipment, RFID chip readers, bar code
printers and scanners and other peripherals. Acsis generally purchases hardware from vendors only
after receiving an order from a customer, and revenue is recognized upon shipment by the vendor to
the customer unless the hardware is an element in an arrangement that includes services that
involve significant customization or modifications to software, in which case, hardware revenue is
bundled with the software and services are recognized on a percentage-of-completion basis.
Alliance Consulting generates revenue primarily from consulting services. Alliance Consulting
generally recognizes revenue when persuasive evidence of an arrangement exists, services are
performed, the service fee is fixed or determinable and collectibility is probable. Revenue from
services is recognized as services are performed. Alliance Consulting also performs certain
services under fixed-price service contracts related to discrete projects. Alliance Consulting
recognizes revenue from these contracts using the percentage-of-completion method, primarily based
on the actual labor hours incurred to date compared to the estimated total hours of the project.
Any losses expected to be incurred on jobs in process are charged to income in the period such
losses become known. Changes in estimates of total costs could result in changes in the amount of
revenue recognized.
Clarient generates revenue from diagnostic services, system sales and fee-per-use charges.
Clarient recognizes revenue for diagnostic services at the time of completion of services at
amounts equal to the contractual rates allowed from third parties including Medicare, insurance
companies and, to a small degree, private-pay patients. These expected amounts are based both on
Medicare allowable rates and Clarient’s collection experience with other third party payors.
35
Table of Contents
Clarient recognizes revenue for fee-per-use agreements based on the greater of actual usage
fees or the minimum monthly rental fee. Under this pricing model, Clarient owns most of the
ACIS instruments that are engaged in service and, accordingly, all related depreciation
and maintenance and service costs are expensed as incurred.
Revenue
for instruments that are sold
is recognized and deferred using the residual method pursuant to the requirements of
SOP 97-2, as amended by Statement of Position No. 98-9, “Modification of SOP 97-2, Software Revenue
Recognition with Respect to Certain Arrangements.” At the outset of the arrangement with the
customer, Clarient defers revenue for the fair value of its undelivered elements (e.g.,
maintenance) and recognizes revenue for the remainder of the arrangement fee attributable to the
elements initially delivered in the arrangement (e.g., software license) when the basic criteria in
SOP 97-2 have been met. Maintenance revenue is recognized ratably over the term of the maintenance
contract, typically twelve months.
Systems sold under a leasing arrangement are accounted for as sales-type leases pursuant to
SFAS No. 13, “Accounting for Leases,” if applicable. Clarient recognizes the net effect of these
transactions as a sale because of the bargain purchase option granted to the lessee.
Clarient has entered
into a distribution and
development agreement with Dako, which includes multiple elements. Those elements include distribution rights,
ACIS instruments,
research and development services, training and maintenance. The agreement calls for an upfront payment and additional payments as
instruments are delivered or milestones are achieved under the research and development component. Clarient accounts for this
arrangement under the percentage-of-completion method using the zero profit margin approach. Under this approach, revenue is
recognized in amounts equal to the costs incurred to provide the products and services. Clarient further limits the amount of revenue
recognized to the amount of fees that are fixed or determinable under the agreement. Because Clarient does not have evidence of fair
value for certain elements that span the term of the agreement, the profit earned will be recognized over the remaining term of the
agreement once the research and development services are complete. As of December 31, 2006, the research and development services were
ongoing.
On March 8, 2007, Clarient sold its technology group business (which developed, manufactured
and marketed the ACIS Automated Image Analysis System) and related intellectual property to Zeiss
MicroImaging, Inc.
Laureate Pharma’s revenue is primarily derived from contract manufacturing work, process
development services, and formulation and filling. Laureate Pharma enters into revenue
arrangements with multiple deliverables in order to meet its customers’ needs. Multiple element
revenue agreements are evaluated under Emerging Issues Task Force (“EITF”) Issue Number 00-21,
“Revenue Arrangements with Multiple Deliverables,” to determine whether the delivered item has
value to the customer on a stand-alone basis and whether objective and reliable evidence of the
fair value of the undelivered item exists. Deliverables in an arrangement that do not meet the
separation criteria in EITF 00-21 are treated as one unit of accounting for purposes of revenue
recognition. Revenue is generally recognized upon the performance of services. Certain services
are performed under fixed price contracts. Revenue from these contracts is recognized on a
percentage—of-completion basis. When current cost estimates indicate a loss is expected to be
incurred, the entire loss is recorded in the period in which it is identified. Changes in
estimates of total costs could result in changes in the amount of revenue recognized.
Pacific Title’s revenue is primarily derived from providing archival and post-production
services to the motion picture and television industry. Pacific Title recognizes revenue generally
upon the performance of services. Pacific Title performs certain services under fixed-price
contracts. Revenue from these contracts is recognized on a percentage-of-completion basis based on
costs incurred to total estimated costs to be incurred. Changes in the estimates of total cost
could result in changes in the amount of revenue recognized. Any anticipated losses on contracts
are expensed when identified.
Recoverability of Long-Lived Assets
We test long-lived assets, including property and equipment and amortizable intangible assets,
for recoverability whenever events or changes in circumstances indicate that we may not be able to
recover the asset’s carrying amount. We evaluate the recoverability by determining whether the
undiscounted cash flows expected to result from the use and eventual disposition of that asset
cover the carrying value at the evaluation date. If the
36
Table of Contents
undiscounted cash flows are not sufficient to recover the carrying value, we measure any
impairment loss as the excess of the carrying amount of the asset over its fair value.
The carrying value of net intangible assets at December 31, 2006 was $16 million. The
carrying value of net property and equipment at December 31, 2006 was $45 million.
Recoverability of Goodwill
We conduct a review for impairment of goodwill at least annually on December 1st.
Additionally, on an interim basis, we assess the impairment of goodwill whenever events or changes
in circumstances indicate that the carrying value may not be recoverable. Factors that we consider
important which could trigger an impairment review include significant underperformance relative to
historical or expected future operating results, significant changes in the manner or use of the
acquired assets or the strategy for the overall business, significant negative industry or economic
trends or a decline in a company’s stock price for a sustained period.
We test for impairment at a level referred to as a reporting unit (same as or one level below
an operating segment as defined in SFAS No. 131, “Disclosures About Segments of an Enterprise and
Related Information”). If we determine that the fair value of a reporting unit is less than its
carrying value, we assess whether goodwill of the reporting unit is impaired. To determine fair
value, we use a number of valuation methods including quoted market prices, discounted cash flows
and revenue and acquisition multiples. Depending on the complexity of the valuation and the
significance of the carrying value of the goodwill to the Consolidated Financial Statements, we may
engage an outside valuation firm to assist us in determining fair value. As an overall check on
the reasonableness of the fair values attributed to our reporting units, we will consider comparing
the aggregate fair values for all reporting units with our average total market capitalization for
a reasonable period of time.
The carrying value of goodwill at December 31, 2006 was $82 million.
Our partner companies operate in industries which are rapidly evolving and extremely
competitive. It is reasonably possible that our accounting estimates with respect to the ultimate
recoverability of the carrying value of goodwill could change in the near term and that the effect
of such changes on our Consolidated Financial Statements could be material. While we believe that
the current recorded carrying value of our goodwill is not impaired, there can be no assurance that
a significant write-down or write-off will not be required in the future. Impairment charges
related to goodwill of consolidated partner companies are included in Goodwill Impairment in the
Consolidated Statements of Operations.
Recoverability of Ownership Interests In and Advances to Companies
On a continuous basis (but no less frequently than at the end of each quarterly period) we
evaluate the carrying value of our equity and cost method partner companies for possible impairment
based on achievement of business plan objectives and milestones, the fair value of each company
relative to its carrying value, the financial condition and prospects of the company and other
relevant factors. We then determine whether there has been an other than temporary decline in the
carrying value of our ownership interest in the company. Impairment to be recognized is measured by
the amount by which the carrying value of the assets exceeds the fair value of the assets.
The fair value of privately held companies is generally determined based on the value at which
independent third parties have invested or have committed to invest in these companies or based on
other valuation methods including discounted cash flows, valuation of comparable public companies
and the valuation of acquisitions of similar companies. The fair value of our ownership interests
in private equity funds is generally determined based on the value of our pro rata portion of the
funds’ net assets and estimated future proceeds from sales of investments provided by the funds’
managers.
The new carrying value of a company is not written-up if circumstances suggest the value of
the company has subsequently recovered.
37
Table of Contents
Our partner companies operate in industries which are rapidly evolving and extremely
competitive. It is reasonably possible that our accounting estimates with respect to the ultimate
recoverability of the carrying value of ownership interests in and advances to partner companies
could change in the near term and that the effect of such changes on our Consolidated Financial
Statements could be material. While we believe that the current recorded carrying values of our
equity and cost method partner companies are not impaired, there can be no assurance that our
future results will confirm this assessment or that a significant write-down or write-off will not
be required in the future.
Total impairment charges related to ownership interests in and advances to companies are
included in the following table:
| Year Ended December 31, | ||||||||||||
| Accounting Method | 2006 | 2005 | 2004 | |||||||||
| (in millions) | ||||||||||||
Equity |
$ | — | $ | — | $ | 3.7 | ||||||
Cost |
— | 1.4 | 3.2 | |||||||||
Total |
$ | — | $ | 1.4 | $ | 6.9 | ||||||
Impairment charges related to equity method companies are included in Equity Loss in the
Consolidated Statements of Operations. Impairment charges related to cost method companies are
included in Other Income, Net in the Consolidated Statements of Operations.
Income Taxes
We are required to estimate income taxes in each of the jurisdictions in which we operate.
This process involves estimating our actual current tax exposure together with assessing temporary
differences resulting from differing treatment of items for tax and accounting purposes. These
differences result in deferred tax assets and liabilities, which are included within our
Consolidated Balance Sheets. We must assess the likelihood that the deferred tax assets will be
recovered from future taxable income and to the extent that we believe recovery is not likely, we
must establish a valuation allowance. To the extent we establish a valuation allowance in a period,
we must include an expense within the tax provision in the Consolidated Statements of Operations.
We have recorded a valuation allowance to reduce our deferred tax assets to an amount that is more
likely than not to be realized in future years. If we determine in the future that it is more
likely than not that the net deferred tax assets would be realized, then the previously provided
valuation allowance would be reversed.
Commitments and Contingencies
From time to time, we are a defendant or plaintiff in various legal actions, which arise in
the normal course of business. Additionally, we have received distributions as both a general
partner and a limited partner from certain private equity funds. Under certain circumstances, we
may be required to return a portion or all the distributions we received as a general partner to
the fund for a further distribution to the fund’s limited partners (the “clawback”). We are also a
guarantor of various third-party obligations and commitments, and are subject to the possibility of
various loss contingencies arising in the ordinary course of business. We are required to assess
the likelihood of any adverse outcomes to these matters as well as potential ranges of probable
losses. A determination of the amount of provision required for these commitments and
contingencies, if any, which would be charged to earnings, is made after careful analysis of each
matter. The provision may change in the future due to new developments or changes in
circumstances. Changes in the provision could increase or decrease our earnings in the period the
changes are made.
Stock-Based Compensation
As permitted by SFAS No. 123, “Accounting for Stock-Based Compensation,” prior to January 1,
2006, we accounted for employee stock-based compensation in accordance with Accounting Principles
Board (APB) Opinion No. 25, “Accounting for Stock Issued to Employees.” Accordingly, no
compensation expense was recorded for stock options issued to employees at fair market value.
On January 1, 2006, we adopted SFAS No. 123 (revised 2004), “Share-Based Payment” (“SFAS No.
123(R)”). SFAS No. 123(R) requires companies to measure all employee stock-based compensation
awards using a fair value
38
Table of Contents
method and record such expense in its consolidated financial statements. We adopted SFAS No.
123(R) using the modified prospective method. Accordingly, prior period amounts have not been
restated. Under this application, we are required to record compensation expense for all awards
granted after the date of adoption and for the unvested portion of previously granted awards that
remain outstanding at the date of adoption.
We estimate the grant date fair value of stock options using the Black-Scholes option-pricing
model which requires the input of highly subjective assumptions. These assumptions include
estimating the expected term of the award and the estimated volatility of our stock price over the
expected term. Changes in these assumptions and in the estimated forfeitures of stock option awards
can materially affect the amount of stock-based compensation recognized in the Consolidated
Statements of Operations. In addition, the requisite service periods for market-based stock option
awards are based on our estimate of the dates on which the market conditions will be met as
determined using a Monte Carlo simulation model. Changes in the derived requisite service period
or achievement of market capitalization targets earlier than estimated can materially affect the
amount of stock-based compensation recognized in the Consolidated Statements of Operations.
Results of Operations
We present our five consolidated partner companies as separate segments — Acsis, Alliance
Consulting, Clarient, Laureate Pharma and Pacific Title. The results of operations of our other
partner companies in which we have less than a majority interest and our ownership in private
equity funds are reported in a segment called “Other Companies.” This segment also includes the
gain or loss on the sale of companies and funds, except for gains and losses included in
discontinued operations.
Our management evaluates segment performance based on segment revenue, operating income (loss)
and income (loss) before income taxes, which reflects the portion of income (loss) allocated to
minority shareholders.
Other items include certain expenses which are not identifiable to the operations of our
operating segments. Other items primarily consists of general and administrative expenses related
to our corporate operations, including employee compensation, insurance and professional fees,
including legal, finance and consulting. Other items also includes interest income, interest
expense and income taxes, which are reviewed by management independent of segment results.
The following tables reflect our consolidated operating data by reportable segment. Each
segment includes the results of our consolidated companies and records our share of income or
losses for entities accounted for under the equity method when applicable. Segment results also
include impairment charges, gains or losses related to the disposition of partner companies and the
mark-to-market of trading securities. All significant inter-segment activity has been eliminated in
consolidation. Accordingly, segment results reported by us exclude the effect of transactions
between us and our subsidiaries and among our subsidiaries.
39
Table of Contents
Our operating results, including net income (loss) before income taxes by segment, were as
follows:
| Year Ended December 31, | ||||||||||||
| 2006 | 2005 | 2004 | ||||||||||
| (In thousands) | ||||||||||||
Acsis |
$ | (8,264 | ) | $ | (2,556 | ) | $ | — | ||||
Alliance Consulting |
127 | (1,194 | ) | (7,736 | ) | |||||||
Clarient |
(9,587 | ) | (9,717 | ) | (12,829 | ) | ||||||
Laureate Pharma |
(9,737 | ) | (10,870 | ) | (270 | ) | ||||||
Pacific Title |
2,384 | 3,748 | 1,157 | |||||||||
Other companies |
(2,455 | ) | (791 | ) | 26,157 | |||||||
Total segments |
(27,532 | ) | (21,380 | ) | 6,479 | |||||||
Other items: |
||||||||||||
Corporate operations |
(17,271 | ) | (16,811 | ) | (31,940 | ) | ||||||
Income tax benefit |
1,023 | 83 | 120 | |||||||||
Total other items |
(16,248 | ) | (16,728 | ) | (31,820 | ) | ||||||
Net loss from continuing operations |
(43,780 | ) | (38,108 | ) | (25,341 | ) | ||||||
Income (loss) from discontinued operations, net of taxes |
89,810 | 6,038 | (29,479 | ) | ||||||||
Net income (loss) |
$ | 46,030 | $ | (32,070 | ) | $ | (54,820 | ) | ||||
Included in the above was stock-based compensation expense, which for the year ended December
31, 2006 reflected the adoption of SFAS No. 123(R) as follows:
| Stock-Based Compensation | ||||||||||||
| Year Ended December 31, | ||||||||||||
| 2006 | 2005 | 2004 | ||||||||||
| (In thousands) | ||||||||||||
Acsis |
$ | 208 | $ | — | $ | — | ||||||
Alliance Consulting |
1,016 | 329 | 578 | |||||||||
Clarient |
1,277 | 516 | 614 | |||||||||
Laureate Pharma |
165 | — | — | |||||||||
Pacific Title |
139 | 555 | 787 | |||||||||
Total segment results |
2,805 | 1,400 | 1,979 | |||||||||
Other items (corporate operations) |
4,037 | 1,265 | 2,273 | |||||||||
| $ | 6,842 | $ | 2,665 | $ | 4,252 | |||||||
There is intense competition in the markets in which these companies operate, and we expect
competition to intensify in the future. Additionally, the markets in which these companies operate
are characterized by rapidly changing technology, evolving industry standards, frequent
introduction of new products and services, shifting distribution channels, evolving government
regulation, frequently changing intellectual property landscapes and changing customer demands.
Their future success depends on each company’s ability to execute its business plan and to adapt to
its respective rapidly changing markets.
40
Table of Contents
Acsis
We acquired 94% of Acsis in December 2005. Results for the year ended December 31, 2005
include only the period from acquisition (December 2, 2005) through December 31, 2005.
Accordingly, the discussion of Acsis’ results of operations compares the quarter ended December 31,
2006 with the quarter ended September 30, 2006.
| Quarter Ended | Quarter Ended | |||||||||||||||
| Year Ended December 31, | December 31, | September 30, | ||||||||||||||
| 2006 | 2005 | 2006 | 2006 | |||||||||||||
| (In thousands) | (In thousands) | |||||||||||||||
Revenue |
$ | 18,634 | $ | 2,022 | $ | 5,493 | $ | 4,156 | ||||||||
Operating expenses: |
||||||||||||||||
Cost of sales |
13,239 | 1,689 | 3,990 | 2,755 | ||||||||||||
Selling, general and administrative |
10,182 | 688 | 2,474 | 2,930 | ||||||||||||
Research and development |
2,501 | 124 | 804 | 616 | ||||||||||||
Purchased in-process research and development |
— | 1,974 | — | — | ||||||||||||
Amortization of intangibles |
1,488 | 126 | 345 | 383 | ||||||||||||
Total operating expenses |
27,410 | 4,601 | 7,613 | 6,684 | ||||||||||||
Operating loss |
(8,776 | ) | (2,579 | ) | (2,120 | ) | (2,528 | ) | ||||||||
Interest, net |
101 | 2 | 32 | 59 | ||||||||||||
Minority interest |
411 | 21 | 87 | 111 | ||||||||||||
Net loss before income taxes |
$ | (8,264 | ) | $ | (2,556 | ) | $ | (2,001 | ) | $ | (2,358 | ) | ||||
Acsis is a leading provider of software and service solutions that assist manufacturing
companies in improving efficiencies throughout the entire supply-chain. Its solutions enable
manufacturers to automate plant floor/warehouse operations and take advantage of emerging
automated-ID technologies, including radio frequency identification (“RFID”) and barcode.
Acsis draws from a variety of technologies and service offerings to create a solution that
matches the client’s business, budget and IT environment. Solutions range from the next generation
of shop floor process automation and data collection using their xDDi enterprise solution suite,
Enterprise Label Management, which enables users to design and generate customer-specific label
forms directly for SAP ERP data and manage from a central location, and Line Manager, an
intelligent appliance to support RFID and barcode-based product tracking for warehouse,
manufacturing, packing and shipping operations, and value-added services for implementing
SAPConsole and xMII. If requested, Acsis will provide all necessary hardware, consulting services
and software to deliver a turnkey data-collection / supply chain solution.
Acsis’ competition generally comes from large, diversified software or consulting businesses
or niche providers with a variety of individual solutions for barcode, RFID or other data
collection systems. Acsis differentiates itself by providing a single, integrated platform which
can be used across the entire enterprise and supply chain to increase efficiencies and reduce
operational costs.
Acsis’ revenue is derived from (i) software fees, which consist of revenue from the licensing
of software, (ii) services revenue, which consist of fees from consulting, implementation and
training services, plus customer support services; and (iii) hardware and reimbursed project
expenses.
In June 2006, Safeguard acquired additional common shares of Acsis for an aggregate purchase
price of $6 million in cash increasing our ownership to 96%. We funded Acsis to support its
long-term growth strategy.
At December 31, 2006, we owned a 96% voting interest in Acsis.
41
Table of Contents
Revenue.
Quarter December 31, 2006 vs. September 30, 2006. Revenue increased $1.3 million, or 32.2%, in the
fourth quarter of 2006 as compared to the third quarter of 2006. The increase was primarily due to
a $1.4 million increase in hardware sales. Hardware sales fluctuate significantly from period to
period given the timing of customer orders. With the launch of three new software products in the
second and third quarters of 2006 and six new license agreements signed in the fourth quarter,
Acsis expects license and services revenue to increase in 2007.
Acsis’ top five customers accounted for approximately 55% of total revenue for the year ended
December 31, 2006. Two customers each accounted for more than 10% of total revenue for the year
ended December 31, 2006.
Operating Expenses.
Quarter December 31, 2006 vs. September 30, 2006. Operating expenses increased $0.9 million, or
13.9%, in the fourth quarter of 2006 as compared to the third quarter of 2006. Gross margins
decreased to 27.4% for the fourth quarter of 2006, from 33.7% in the third quarter of 2006. The
decrease was due to the implementation of several projects of Acsis’ new offerings requiring more
labor hours than anticipated. Selling, general and administrative expense decreased $0.5 million
or 15.5% for the fourth quarter of 2006 as compared to the third quarter of 2006 due to severance
costs included in the third quarter of $0.5 million. Excluding these costs, selling, general and
administrative costs were consistent from the third quarter of 2006 to the fourth quarter of 2006.
Research and development expense increased $0.2 million or 30.5% in the fourth quarter as compared
to the third quarter of 2006. Acsis expects research and development costs to increase in future
periods as it continues to develop new products.
Acsis anticipates the addition of management resources and new sales and product initiatives
during 2006 to assist in growth. As a result of these strategies, Acsis expects continued losses
in 2007.
Included in operating expenses in 2005 was $2.0 million associated with an in-process research
and development charge related to the acquisition of Acsis in December 2005. The amount of the
charge was determined by management, which utilized a third party valuation firm to assist in the
valuation of Acsis’ in-process research and development.
Alliance Consulting
We acquired Alliance Consulting in December 2002. The financial information presented below
does not include the results of operations of Alliance Consulting’s Southwest region business,
which was sold in May 2006 and is included in discontinued operations for all periods presented.
Alliance Consulting completed the sale of that business during the second quarter of 2006, which
resulted in a net gain of $1.6 million. For the years ended December 31, 2006, 2005 and 2004, the
Southwest region generated revenue of $3.1 million, $11.2 million and $21.3 million and net income
of $1.6 million (including the gain on the sale of $1.6 million), $0.9 million and $2.2 million,
respectively.
| Year Ended December 31, | ||||||||||||
| 2006 | 2005 | 2004 | ||||||||||
| (In thousands) | ||||||||||||
Revenue |
$ | 104,571 | $ | 82,604 | $ | 71,814 | ||||||
Operating expenses: |
||||||||||||
Cost of sales |
73,837 | 57,030 | 50,193 | |||||||||
Selling, general and administrative |
28,916 | 25,030 | 28,468 | |||||||||
Amortization of intangibles |
1,010 | 966 | 592 | |||||||||
Total operating expenses |
103,763 | 83,026 | 79,253 | |||||||||
Operating income (loss) |
808 | (422 | ) | (7,439 | ) | |||||||
Other income (loss), net |
157 | (7 | ) | 35 | ||||||||
Interest, net |
(818 | ) | (771 | ) | (356 | ) | ||||||
Minority interest |
(20 | ) | 6 | 24 | ||||||||
Net income (loss) from continuing
operations before income taxes |
$ | 127 | $ | (1,194 | ) | $ | (7,736 | ) | ||||
42
Table of Contents
Alliance Consulting is a leading national business intelligence consultancy providing services
primarily to Fortune 2000 clients in the pharmaceutical, financial services and manufacturing
industries. Alliance Consulting specializes in information management, which is comprised of a
full range of business intelligence solutions from data acquisition and warehousing to master data
management, analytics and reporting; and application services, which includes software development,
integration, testing and application support delivered through a high quality and cost effective
hybrid global delivery model. Alliance Consulting has developed a strategy focused on enabling
business intelligence through the application of deep domain experience and custom-tailored project
teams to deliver software solutions and consulting services.
Alliance Consulting’s fiscal year generally consists of a 52-week period and periodically
consists of a 53-week period because the fiscal year ends on the Saturday closest to December 31.
Fiscal years 2006, 2005 and 2004 ended on December 30, 2006, December 31, 2005 and January 1, 2005,
respectively. Fiscal year 2004 was a 53-week period. References to a year included in this
section refer to a fiscal year rather than a calendar year.
While global economic conditions continue to cause companies to be cautious about increasing
their use of consulting and IT services, Alliance Consulting continues to see growing demand for
its services. However, Alliance Consulting continues to experience pricing pressure from
competitors as well as from clients facing pressure to control costs. In addition, the growing use
of offshore resources to provide lower cost service delivery capabilities within the industry
continues to place pressure on pricing and revenue. Alliance Consulting expects to continue to
focus on maintaining and growing its blue chip client base and providing high quality solutions and
services to its clients.
In July 2006, Alliance Consulting completed the purchase of specific assets and assumed
certain liabilities of Fusion Technologies, Inc., (“Fusion”) a provider of strategic information
technology solutions to rapidly growing organizations within the United States. In October 2004,
Alliance Consulting acquired Mensamind, Inc. (“Mensamind”), a software development company based in
Hyderabad, India. These acquisitions provided Alliance Consulting substantial offshore
capabilities for new and existing clients.
At December 31, 2006, we owned 99% of Alliance Consulting.
Year Ended December 31, 2006 Versus 2005
Revenue. Revenue, including reimbursement of expenses, increased $22.0 million, or 26.6% in 2006
as compared to the prior year. This increase was due to the Fusion acquisition in July 2006 of
approximately $7.8 million, growth in existing accounts as well as the development of new key
accounts; plus the expansion of Alliance Consulting’s Outsourcing, Master Data Management and
Global Delivery services. In Outsourcing engagements, Alliance Consulting assumes responsibility
for managing a client’s business applications with the goal of improving reliability and
performance of those applications while reducing costs. Master Data Management includes business
intelligence and data management as well as corporate performance management. Global Delivery is
Alliance Consulting’s high quality, lower-priced offshore delivery and support service. Revenue
from these services was $32.4 million for 2006 as compared to $24.8 million for 2005.
Alliance Consulting’s top ten customers accounted for approximately 56% of total revenue in
2006 and approximately 60% of total revenue in 2005. The same two customers each represented more
than 10% of total revenue for the years ended December 30, 2006 and December 31, 2005.
Revenue growth is expected in 2007 from further penetration of existing accounts, newly
developed accounts and those from the Fusion acquisition. Alliance Consulting will continue to
leverage its Outsourcing, Master Data Management and Global Delivery capabilities to facilitate
growth in all of its vertical market sectors. Clients continue to award projects in multiple phases
resulting in extended sales cycles and gaps between phases. Alliance Consulting must also compete
against larger IT services companies with greater resources and more developed offshore delivery
organizations.
Cost of Sales. Cost of sales increased $16.8 million, or 29.5% in 2006 as compared to the prior
year. This increase was primarily a result of growth in revenues. Gross margin declined from 31.0%
in 2005 to 29.4% in 2006
43
Table of Contents
primarily due to an increase in reimbursable expenses, cost over-runs on certain fixed fee
engagements and higher staffing costs; partially offset by the addition of higher-margin
engagements from the Fusion acquisition.
Alliance Consulting expects gross margins to continue to be affected by general economic
uncertainty, increases in overall pricing pressures within the industry, discounts required for
longer-term engagements, increased employee and contractor costs resulting from greater competition
within the talent pool due to declining unemployment levels, wage inflation in India as the demand
for those resources increases, resource availability, ability to retain key resources and
efficiency in project management.
Selling, General and Administrative. Selling, general and administrative expenses increased $3.9
million, or 15.5% in 2006 as compared to the prior year. Selling, general and administrative
expenses were 27.7% of revenue in 2006 as compared to 30.3% of revenue in 2005. The increase in
dollars was primarily from the addition of Fusion selling, general and administrative expenses of
approximately $2.0 million, incremental stock-based compensation charges of approximately $0.7
million due to the adoption of SFAS No. 123(R), an increase in variable compensation due to growth
in revenues, a restructuring charge of $0.5 million taken to consolidate multiple facilities within
the same market, recruitment fees of $0.2 million associated with expanding the sales organization
and $0.2 million associated with expanding existing facilities, primarily in India. The decrease
as a percentage of revenue was due to the company’s fixed costs and benefits from cost savings
initiatives during the year.
Selling, general and administrative costs are expected to increase as Alliance Consulting’s
business continues to grow. As a percentage of revenue, however, costs are expected to decrease as
certain costs are not expected to recur and certain costs are fixed. Alliance Consulting also
expects to continue realizing benefits from cost savings initiatives and realignment of support and
sales positions made throughout the year.
Interest, Net. Interest expense remained relatively flat in 2006 as compared to 2005, as a result
of higher interest rates partially offset by lower outstanding debt balances during the year.
Net Income (Loss) Before Income Taxes. Net income for the year ended December 31, 2006 was $0.1
million compared to net loss of $1.2 million in 2005 due to growth in revenues, benefits from cost
saving initiatives and the Fusion acquisition; partially offset by the decline in gross margins,
restructuring expenses incurred and incremental stock-based compensation expense due to the
adoption of SFAS No. 123(R).
Year Ended December 31, 2005 Versus 2004
Revenue. Revenue, including reimbursement of expenses, increased $10.8 million, or 15.0% in 2005
as compared to 2004. This increase was due to growth in existing accounts as well as the
development of new key accounts, expansion of Alliance Consulting’s outsourcing services and new
service offerings introduced in 2004, Master Data Management and Global Delivery. Revenue
associated with these new services generated an aggregate of $10.9 million during 2005 as compared
to $2.0 million in 2004.
Cost of Sales. Cost of sales increased $6.8 million, or 13.6% in 2005 as compared to 2004. This
increase was primarily a result of growth in revenues. Gross margin improved from 30.1% in 2004 to
31.0% in 2005 due to a shift in product mix more towards higher value, higher margin business,
including Master Data Management and Global Delivery, and less reimbursable expenses combined with
improvements in project management as well as improved utilization. Partially offsetting these
improvements were discounts of $0.4 million made to customers in exchange for multi-year
engagements.
Selling, General and Administrative. Selling, general and administrative costs decreased $3.4
million, or 12.1% in 2005 as compared to 2004. Selling, general and administrative expenses were
30.3% of revenue in 2005 as compared to 39.6% of revenue in 2004. The decrease in dollars was due
to the cost savings associated with reducing the non-billable workforce during 2004 and 2005,
transitioning certain support functions to Alliance Consulting India, relocating Alliance
Consulting’s corporate headquarters and staffing other sales offices appropriately to accommodate
existing and projected staffing needs, and decreased depreciation because more assets became
fully-depreciated during 2004 and 2005 without offsetting capital expenditures being made.
Alliance Consulting’s 2004 selling, general and administrative also included non-capitalizable
expenses associated with the Mensamind acquisition of $0.9 million, severance associated with former
44
Table of Contents
executives, a restructuring
charge relating to the buy out provisions of the Corporate facility and higher non-cash
compensation costs for certain other executives. Offsetting these savings were incremental costs
associated with recognizing a full year’s costs from the Mensamind acquisition, severance relating
to a senior manager and increased variable compensation directly related to the improved financial
performance as compared to 2004.
Amortization. Amortization expense associated with amortizable intangible assets increased $0.4
million or 63.2% to $1.0 million in 2005 as compared to $0.6 million in 2004. The increase was due
to a full year of amortization expenses in 2005 of intangible assets as a result of Alliance
Consulting’s acquisition of Mensamind during October 2004.
Interest, Net. Interest expense increased $0.4 million or 116.6% in 2005 as compared to 2004.
Alliance Consulting attributes the increase to an increase in the average outstanding balances
under Alliance Consulting’s facility as well as increased interest rates on outstanding borrowings.
Net Loss Before Income Taxes. Net loss decreased $6.5 million, or 84.6% in 2005 as compared to
2004. The improvement was directly related to the growth in higher margin revenue and the decrease
in selling, general and administrative expenses.
Clarient
| Year Ended December 31, | ||||||||||||
| 2006 | 2005 | 2004 | ||||||||||
| (In thousands) | ||||||||||||
Revenue |
$ | 33,605 | $ | 20,150 | $ | 9,769 | ||||||
Operating expenses: |
||||||||||||
Cost of sales |
17,808 | 11,254 | 7,486 | |||||||||
Selling, general and administrative |
26,013 | 19,723 | 17,728 | |||||||||
Research and development |
4,476 | 3,670 | 4,101 | |||||||||
Purchased in-process research and development |
— | 209 | 89 | |||||||||
Amortization of intangibles |
915 | 1,275 | 1,339 | |||||||||
Total operating expenses |
49,212 | 36,131 | 30,743 | |||||||||
Operating loss |
(15,607 | ) | (15,981 | ) | (20,974 | ) | ||||||
Other loss |
(39 | ) | — | — | ||||||||
Interest, net |
(670 | ) | (180 | ) | (93 | ) | ||||||
Minority interest |
6,729 | 6,444 | 8,238 | |||||||||
Net loss before income taxes |
$ | (9,587 | ) | $ | (9,717 | ) | $ | (12,829 | ) | |||
Clarient is a comprehensive cancer diagnostics company providing cellular assessment and
cancer characterization to community pathologists, academic researchers, university hospitals and
biopharmaceutical companies. Clarient addresses these customers’ needs by leveraging its
proprietary bright field microscopy technology to provide precise, reproducible results that
targeted cancer therapies and drug discovery efforts require. Clarient leverages
ACIS to provide
a broad range of oncology testing services (for community pathologists focused on cancer diagnosis
and prognosis) and biopharmaceutical services (in support of companies and researchers developing
new cancer therapies).
Clarient generates revenue from diagnostic services, system sales and fee-per-use charges.
45
Table of Contents
The decision to provide in-house laboratory services was made in 2004 to give Clarient an
opportunity to capture a significant service-related revenue stream over the much broader and
expanding cancer diagnostic testing marketplace while also optimizing the level of service and
accuracy provided to remote pathology customers. Clarient believes that they are positioned to
participate in this growth because of their proprietary analysis capabilities, depth of experience
of the staff in their diagnostic laboratory, relationships with the pharmaceutical companies, and
demonstrated ability to develop unique assays to support new diagnostic tests.
Clarient operates primarily in two businesses: 1) the services group which delivers critical
oncology testing services to community pathologists, biopharmaceutical companies and other
researchers; and 2) the technology group which is engaged in the development, manufacture and
marketing of an automated cellular imaging system that is designed to assist physicians in making
critical medical decisions.
In September 2006, Clarient completed its acquisition of Trestle Holdings, Inc. (“Trestle”)
and Trestle Acquisition Corp. (a wholly-owned subsidiary of Trestle). The purchase strategically
positioned Clarient as a leading provider in the anatomical pathology market integrating image
analysis, high-speed scanning capabilities and virtual microscopy into one offering. In September
2006, Safeguard acquired additional common shares of Clarient for $3.0 million, increasing our
ownership to 60%. Clarient used the proceeds to support its acquisition of Trestle.
On March 8, 2007, Clarient sold its technology group business (which developed, manufactured
and marketed the ACIS Automated Image Analysis System) and related intellectual property to Zeiss
MicroImaging, Inc. (the “ACIS Sale”) for an aggregate purchase price of $12.5 million (including $1.5 million in contingent purchase price).
As of December 31, 2006, we owned a 60% voting interest in Clarient.
Year Ended December 31, 2006 Versus 2005
Revenue. Revenue increased $13.5 million, or 66.8%, in 2006 as compared to 2005. Revenue from
Clarient’s service group increased $16.5 million, or 144%, from $11.4 million in 2005 to $27.9
million in 2006. This increase resulted from the execution of Clarient’s marketing and sales
strategy to increase Clarient’s sales to new customers and to enter into new managed care
contracts. This increase was also driven by increasing the number of available tests being
performed that include immunohistochemistry, flow cytometry and florescent in-situ hybridization
(FISH). Clarient anticipates that diagnostic services revenues will continue to increase as a
result of increased revenue from existing customers, additional penetration of new customers
(including managed care providers) by Clarient’s sales force and its offering of a more
comprehensive suite of advanced cancer diagnostics.
Partially offsetting the increase in revenues from the services group was a decline of $3.0
million in the technology group. The change was primarily the result of a decrease in instrument
systems revenue from $4.4 million in 2005 to $2.0 million in 2006, a decrease of 53%, and a decline
in per click revenue of $1.5 million from $4.0 million in 2005 to $2.5 million in 2006, a decrease
of 38%. The decline was partially offset by an increase in development revenue in 2006 of $1.2
million compared to $0.4 million in 2005.
Cost of Sales. Cost of sales increased $6.6 million, or 58.2%, in 2006 as compared to 2005. Cost
of sales for the services group in 2006 was $15.6 million compared to $8.8 million in 2005. Gross
margins for Clarient’s services group for 2006 were 44% compared to 23% in 2005. The increase in
gross margin in 2006 was attributable to achieving economies of scale in Clarient’s diagnostic
laboratory operations. Clarient anticipates similar gross margin results for 2007.
Cost of sales in the technology group was $2.2 million in 2006 as compared to $2.4 million in
2005. Gross margins for Clarient’s technology group were 62% in 2006 and 72% in 2005. The
decrease in gross margin was a result of lower than expected sales volume combined with the
anticipated lower per-system sales price as Clarient moved to its distributor sales arrangement
with Dako.
46
Table of Contents
Selling, General and Administrative. Selling, general and administrative expenses increased $6.3
million, or 31.9%, in 2006 as compared to 2005. Expenses related to both selling, general and
administrative and diagnostic services administration are included in this category. Selling,
general and administrative expenses for 2006 increased approximately $3.6 million, or 27.0%, to
$17.0 million as compared to $13.4 million for the comparable period in 2005. The increase in
expenses in 2006 was primarily due to increases in rent expense related to Clarient’s new facility,
increases in selling expenses to support the growing diagnostics services business, higher
stock-based compensation expense due to the implementation of SFAS No. 123(R) and relocation and
recruiting expenses. Clarient anticipates sales expense to support its growing diagnostics
services business will continue to grow in 2007, and expects general and administrative expenses to
decline as a percentage of revenues as Clarient’s infrastructure costs stabilize.
Also contributing to the overall increase in selling, general and administrative expenses was
diagnostic services administration expenses, which were $9.0 million in 2006 as compared to $6.3
million in 2005. The increase was primarily due to higher collection costs due to an increase in
services group revenue for the period, and the addition of medical and administrative staff to
support this rapidly growing segment of Clarient’s business. Clarient expects these costs to
continue to increase due to higher collection costs on an anticipated continued increase in
services group revenue.
Research and Development. Research and development expenses increased $0.8 million, or 22.0%, in
2006 as compared to 2005. This increase was primarily attributable to personnel and consultants
supporting the development activity under Clarient’s agreement with Dako and the addition of
employees from the Trestle acquisition. While development expenses were higher, Clarient earned
development fees under the terms of its distribution and development agreement with Dako, which
were recognized in revenue. As a result of the ACIS Sale, Clarient
expects research and development expenses to
decline substantially in 2007.
Net Loss Before Income Taxes. Net loss decreased $0.1 million, or 1.3%, in 2006 as compared to
2005. The improvement was related to increases in revenue and improved gross margin in the
services group, partially offset by increases in selling, general and administrative expenses and
research and development expenses.
Year Ended December 31, 2005 Versus 2004
Revenue. Revenue increased $10.4 million, or 106.3%, in 2005 as compared to 2004. Clarient
attributes this increase to its diagnostic services offerings, which totaled $11.4 million in 2005
compared to $2.2 million in 2004, when Clarient first began to offer its laboratory services.
Revenue generated from system sales increased $2.6 million in 2005 as compared to 2004. A total of
44 ACIS systems were sold in 2005 as compared to 12 system sales in 2004. The increases were
partially offset by a decline in fee-per-use revenue caused by a reduction in the aggregate of
ACIS placements as a result of customers electing to purchase the equipment following the
expiration of their lease and certain customers returning their ACIS equipment in order to utilize
the services of Clarient’s diagnostic services laboratory.
Cost of Sales. Cost of sales increased $3.8 million or 50.3% in 2005 as compared to 2004. Clarient
attributes this increase primarily to cost of sales related to diagnostic services, which was $8.8
million in 2005. These services commenced late in the second quarter of 2004. Costs were
approximately 77% of diagnostic services revenue in 2005, producing a gross margin of 23%. Cost of
sales related to system sales and fee-per-use declined in 2005 as compared to 2004. Gross margins
for instrument systems were 72% in 2005 as compared to 52% in 2004. The improvement was due
primarily to lower costs for systems sold, which in many cases were refurbished older systems and
also due to lower costs of field service.
Selling, General and Administrative. Selling, general and administrative costs increased $2.0
million or 11.3% in 2005 as compared to 2004. Clarient attributes this increase primarily to
diagnostic services administration. The expense was $2.8 million higher in 2005 as compared to
2004. Partially offsetting this increase was a decrease due to higher expenses in the prior year
from non-cash compensation charges related to stock options and restricted stock, outside
consulting costs for interim CEO management services, and the reduction of personnel as a result of
the fourth quarter 2004 workforce reduction.
47
Table of Contents
Research and Development. Research and development costs decreased $0.4 million or 10.5% in 2005
as compared to 2004. Clarient attributes the decline primarily to the reduction in personnel that
resulted from its fourth quarter 2004 workforce reduction.
Net Loss Before Income Taxes. Net loss before income taxes decreased $3.1 million or 24.3% in 2005
as compared to 2004. The decline was primarily attributable to the reasons discussed above,
partially offset by a $1.8 million decline in minority interest.
Laureate Pharma
We acquired 100% of Laureate Pharma in December 2004. Results for the year ended December 31,
2004 include only the period from acquisition (December 3, 2004) through December 31, 2004. The
financial information presented below does not include the results of operations of the Totowa
facility, which was sold in December 2005 and is included in discontinued operations. For the year
ended December 31, 2005, the Totowa operation generated revenue of $3.5 million and net income of
$5.4 million, including a gain on the sale of $7.7 million.
| Year Ended December 31, | ||||||||||||
| 2006 | 2005 | 2004 | ||||||||||
| (In thousands) | ||||||||||||
Revenue |
$ | 11,714 | $ | 7,709 | $ | 884 | ||||||
Operating expenses: |
||||||||||||
Cost of sales |
16,060 | 13,919 | 842 | |||||||||
Selling, general and administrative |
4,783 | 4,261 | 293 | |||||||||
Total operating expenses |
20,843 | 18,180 | 1,135 | |||||||||
Operating loss |
(9,129 | ) | (10,471 | ) | (251 | ) | ||||||
Interest, net |
(608 | ) | (399 | ) | (19 | ) | ||||||
Net loss from continuing operations before income taxes |
$ | (9,737 | ) | $ | (10,870 | ) | $ | (270 | ) | |||
Laureate Pharma is a full-service Contract Manufacturing Organization (CMO) providing critical
development and Current Good Manufacturing Practices (cGMP) manufacturing services. Laureate Pharma
seeks to become a leader in this segment of the biopharmaceutical industry by delivering superior
development and manufacturing services to its customers.
Laureate Pharma’s broad range of services includes: bioprocessing, quality control and quality
assurance. Laureate Pharma provides process development and manufacturing services on a contract
basis to biopharmaceutical companies. Laureate Pharma operates a facility in Princeton, New
Jersey.
Laureate Pharma’s customers generally include small to mid-sized biotechnology and
pharmaceutical companies seeking outsourced bioprocessing manufacturing and development services.
Laureate Pharma’s customers are often dependent on the availability of funding to pursue drugs that
are in early stages of clinical trials, and thus have high failure rates. The loss of one or more
customers can result in significant swings in profitability from quarter to quarter and year to
year. Although there has been a trend among biopharmaceutical companies to outsource drug
production functions, this trend may not continue. Many of Laureate Pharma’s contracts are short
term in duration. As a result, Laureate Pharma seeks new contracts to sustain its revenue.
In 2006, Laureate Pharma began an expansion of its biopharmaceutical manufacturing facility to
increase capacity and broaden its service offerings.
As of December 31, 2006, we owned a 100% voting interest in Laureate Pharma.
48
Table of Contents
Year Ended December 31, 2006 Versus 2005
Revenue. Revenue increased $4.0 million, or 52.0%, in 2006 as compared to 2005. The increase was
primarily due to $4.3 million in increased revenues from new client contracts. Laureate Pharma
expects revenue to increase in 2007 due to new client contracts.
Four customers each represented more than 10% of total revenue for the year ended December 31,
2006. Two customers each represented more than 10% of Laureate Pharma’s revenue from continuing
operations for the year ended December 31, 2005.
Cost of Sales. Cost of sales increased $2.1 million, or 15.4%, in 2006 as compared to 2005
primarily due to increased materials and lab supplies of $1.1 million and increased staffing costs
of $1.3 million to support continued revenue growth, partially offset by lower operating expenses
of $0.2 million. Cost of sales is expected to increase in 2007 due to the expected growth in
revenue.
Selling, General and Administrative. Selling, general and administrative expense increased $0.5
million, or 12.2%, in 2006 as compared to 2005 due to increased staffing and stock-based
compensation of $0.2 million. Selling, general and administrative expenses are expected to
increase in 2007 due to additional headcount and marketing expenses.
Net Loss Before Income Taxes. Net loss decreased $1.1 million, or 10.4%, in 2006 as compared to
2005. The decline in net loss was primarily attributable to the increase in revenue in 2006.
Year ended December 31, 2005.
Revenue. Revenue in the fourth quarter of 2005 increased by $0.4 million or 37.3% as compared to
revenue in the third quarter of 2005 of $1.1 million. Laureate Pharma attributes this increase to a
new client contract beginning in the fourth quarter, partially offset by the cancellation and
timing delays related to other customers.
Operating Expenses. Operating expenses increased $0.5 million or 11.3% in the fourth quarter of
2005 as compared to operating expenses in the third quarter of 2005 of $4.1 million. Laureate
Pharma attributes the increase primarily to increased personnel added in the fourth quarter.
Pacific Title
| Year Ended December 31, | ||||||||||||
| 2006 | 2005 | 2004 | ||||||||||
| (In thousands) | ||||||||||||
Revenue |
$ | 29,536 | $ | 31,346 | $ | 25,609 | ||||||
Operating expenses: |
||||||||||||
Cost of sales |
21,446 | 21,289 | 18,691 | |||||||||
Selling, general and
administrative |
5,722 | 6,413 | 5,692 | |||||||||
Total operating expenses |
27,168 | 27,702 | 24,383 | |||||||||
Operating income |
2,368 | 3,644 | 1,226 | |||||||||
Other income, net |
14 | 272 | 81 | |||||||||
Interest, net |
2 | (53 | ) | (40 | ) | |||||||
Minority interest |
— | (115 | ) | (110 | ) | |||||||
Net income before income taxes |
$ | 2,384 | $ | 3,748 | $ | 1,157 | ||||||
Pacific Title is a leading provider of a broad range of digital and photo-chemical services
for post-production and archival applications in the Hollywood motion picture and television
industry. Pacific Title provides a complete array of state-of-the art digital post-production
capabilities both for new releases and restoration of film libraries, leading the transformation
from optical, analog image reproduction and processing with digital image processing technologies,
which we believe is more cost-effective and flexible. In 2005, Pacific Title introduced YCM, which
is
49
Table of Contents
a proprietary method of archiving films, involving the transfer of the film to three color
strips: (yellow, cyan and magenta), which can be stored for 100 years.
As of December 31, 2006, we owned a 100% voting interest in Pacific Title.
Year Ended December 31, 2006 Versus 2005
Revenue. Revenue decreased $1.8 million, or 5.8%, in 2006 as compared to 2005. The decrease was
due to decreased visual effects revenue of $2.1 million, trailer revenues of $1.9 million and scan
and record revenues of $1.5 million, partially offset by increases in digital intermediate and YCM
archiving revenue of $3.8 million. The lower trailer revenues were due to the loss of a large
client, while the reduction in visual effects work related to a second half slow down within the
industry. Increased revenues from the first full year of digital intermediate and YCM film
archiving services partially offset some of the decline.
In 2006, three customers each represented more than 10% of Pacific Title’s revenue, compared
to four customers in 2005.
Cost of Sales. Cost of sales increased $0.2 million, or 0.7%, in 2006 as compared to 2005 despite
the decrease in revenues. The increase was primarily attributable to increased staffing and wages
and benefits as well as $0.2 million in incremental costs associated with the YCM business. These
increases were offset by $0.6 million in equipment lease costs related to leases that had expired.
Pacific Title expects margins to improve modestly in 2007 due to product mix and certain cost
control measures put in place in the fourth quarter of 2006.
Selling, General and Administrative. Selling, general and administrative expense decreased $0.7
million, or 10.8%, in 2006 as compared to 2005. The decline was primarily due to a $0.5 million
reduction in management incentive bonuses and a $0.4 million reduction in deferred stock unit
amortization expense.
Net Income before Income Taxes. Net income declined $1.4 million, or 36.4%, in 2006 as compared to
2005. The decline was primarily due to the decline in revenues and increased cost of sales,
partially offset by the decreases in selling, general and administrative expense.
Year Ended December 31, 2005 Versus 2004
Revenue. Total revenue increased $5.7 million or 22.4% to $31.3 million in 2005 as compared to
$25.6 million in 2004. Pacific title attributed the increase to increases in the traditional
business of trailer production due to the combination of a pricing increase in early 2005 and
increased volume and third party scanning and recording, supplemented by revenue from two new
business lines, digital intermediate and YCM revenue. Modest increases in visual effects and
scanning and recording were offset by continued declines in analog and photochemical businesses.
Cost of Sales. Cost of sales increased $2.6 million or 13.9% to $21.3 million in 2005 as compared
to $18.7 million in 2004. Pacific Title attributes this increase to increases in labor and film
costs, mainly related to increased sales and increases in depreciation and maintenance expenses
related to increased capital expenditures and warranties of newer equipment expiring. Gross margin
increased to 32% in 2005 as compared to 27% in 2004, due to utilization of under-utilized capacity,
offset by lower margins on its newer offerings until scale is achieved.
Selling, General and Administrative. Selling, general and administrative expenses increased $0.7
million or 12.7% to $6.4 million in 2005 as compared to $5.7 million in 2004. Pacific Title
attributes the increase to increases in sales staffing and wages, commissions and management
performance bonuses due to improved company performance.
Net Income before Income Taxes. Net income increased $2.6 million in 2005. The increase was
primarily due to increased revenues and improved gross profit margin.
50
Table of Contents
Other Companies
| Year Ended December 31, | ||||||||||||
| 2006 | 2005 | 2004 | ||||||||||
| (In thousands) | ||||||||||||
Revenue |
$ | — | $ | — | $ | 1,278 | ||||||
Total operating expenses |
— | — | 2,674 | |||||||||
Operating loss |
— | — | (1,396 | ) | ||||||||
Other income, net |
812 | 5,826 | 40,939 | |||||||||
Interest, net |
— | — | (10 | ) | ||||||||
Minority interest |
— | — | 584 | |||||||||
Equity loss |
(3,267 | ) | (6,617 | ) | (13,960 | ) | ||||||
Net income (loss) before income taxes |
$ | (2,455 | ) | $ | (791 | ) | $ | 26,157 | ||||
Revenue for the Other Companies segment in 2004 was primarily derived from Tangram, through
its sale in February 2004.
Other Income, Net
| Year Ended December 31, | ||||||||||||
| 2006 | 2005 | 2004 | ||||||||||
| (In thousands) | ||||||||||||
Gain on sale of companies and funds, net |
$ | 1,181 | $ | 7,292 | $ | 44,486 | ||||||
Gain (loss) on trading securities |
330 | (229 | ) | (396 | ) | |||||||
Impairment charges |
— | (1,425 | ) | (3,197 | ) | |||||||
Other |
(699 | ) | 188 | 46 | ||||||||
| $ | 812 | $ | 5,826 | $ | 40,939 | |||||||
Gain on sale of companies and funds for the year ended December 31, 2006 of $1.2 million
primarily related to the sale of a cost method investment whose carrying value was zero.
Gain on sale of companies and funds for the year ended December 31, 2005 of $7.3 million, was
primarily attributable to gains on the sales of certain interests in private equity funds. Total
proceeds from the sale of these interests in private equity funds during 2005 were $27.6 million.
As a result of the sale, we were also relieved of $9.1 million of future fund commitments.
Gain on sale of companies and funds for the year ended December 31, 2004 of $44.5 million
included a gain of $31.7 million related to the sale of our interest in Sanchez and a gain of $8.5
million related to our sale of Tangram. Also included was $2.7 million attributable to a
distribution from a bankruptcy proceeding and $1.5 million relating to the final payment of an
installment sale of a company sold in 1997. Total net cash proceeds for sales of companies and
funds were $37.5 million in 2004.
Gain on trading securities in 2006 primarily reflected a net gain of $0.4 million on the sale
of our holdings in Traffic.com.
Loss on trading securities in 2005 reflected the loss on the sale of holdings in stock
distributed from a private equity fund, which were sold during the second quarter of 2005. Loss on
trading securities in 2004 primarily reflected the adjustment to fair value of our holdings in
Opsware and the subsequent loss on sale of Opsware stock of $0.1 million.
We have recorded impairment charges for certain holdings accounted for under the cost method
determined to have experienced an other-than-temporary decline in value in accordance with our
existing policy regarding impairment of ownership interests in and advances to companies.
51
Table of Contents
Equity Loss. Equity loss fluctuates with the number of partner companies accounted for under the
equity method, our voting ownership percentage in these partner companies and the net results of
operations of these partner companies. We recognize our share of losses to the extent we have cost
basis in the equity investee, or we have outstanding commitments or guarantees. Certain amounts
recorded to reflect our share of the income or losses of our partner companies accounted for under
the equity method are based on estimates and on unaudited results of operations of those partner
companies and may require adjustments in the future when audits of these entities are made final.
We report our share of the results of our equity method partner companies on a one quarter lag.
| Year Ended December 31, | ||||||||||||
| 2006 | 2005 | 2004 | ||||||||||
| (In thousands) | ||||||||||||
Share of our equity method companies’ results of operations |
$ | (2,854 | ) | $ | (2,319 | ) | $ | (3,484 | ) | |||
Share of private equity funds’ results of operations |
(413 | ) | (4,298 | ) | (6,759 | ) | ||||||
Impairment charges |
— | — | (3,717 | ) | ||||||||
| $ | (3,267 | ) | $ | (6,617 | ) | $ | (13,960 | ) | ||||
During 2006, we acquired interests in four companies accounted for under the equity method:
Advantage Healthcare Solutions, NuPathe, Portico Systems and Rubicor Medical. Included in equity
loss in 2006 were in-process research and development charges of $1.0 million and $0.6 million
related to the allocations of purchase price of NuPathe and Rubicor Medical, respectively. New
holdings in growth-stage companies are expected to lead to larger equity losses until those
companies reach scale and achieve profitability.
During 2005, we restructured our ownership holdings in four private equity funds from a
general partner to a special limited partner interest and we began accounting for these funds on
the cost method. In December 2005, we sold most of our holdings in certain private equity funds.
The decrease in equity loss related to private equity funds in 2006 compared to 2005 was a result
of the sale of these holdings. These equity funds accounted for $3.4 million and $5.3 million of
equity loss in 2005 and 2004, respectively.
Corporate Operations
| Year Ended December 31, | ||||||||||||
| 2006 | 2005 | 2004 | ||||||||||
| (In thousands) | ||||||||||||
General and administrative costs, net |
$ | (20,112 | ) | $ | (16,616 | ) | $ | (16,783 | ) | |||
Stock-based compensation |
(4,037 | ) | (1,265 | ) | (2,273 | ) | ||||||
Depreciation |
(197 | ) | (182 | ) | (203 | ) | ||||||
Interest income |
6,703 | 4,871 | 2,409 | |||||||||
Interest expense |
(4,617 | ) | (4,914 | ) | (8,864 | ) | ||||||
Recovery (impairment) — related party |
360 | 28 | (3,400 | ) | ||||||||
Other income (loss), net |
4,629 | 1,267 | (2,826 | ) | ||||||||
| $ | (17,271 | ) | $ | (16,811 | ) | $ | (31,940 | ) | ||||
General and Administrative Costs, Net. Our general and administrative expenses consist primarily
of employee compensation, insurance, outside services such as legal, accounting and consulting, and
travel-related costs. General and administrative costs increased $3.5 million in 2006 as compared
to 2005. The increase was primarily related to a $1.5 severance charge in 2006 and a $1.4 increase
in employee costs due to new hires to support Safeguard’s long-term strategy, partially offset by a
$0.8 decrease in insurance expense. General and administrative costs decreased $0.2 million in
2005 as compared to 2004. The net decrease was primarily attributable to a decline in insurance
expense.
Stock-Based Compensation. Stock-based compensation consists primarily of expense related to stock
option grants and grants of restricted stock and deferred stock units to our employees. The
increase of $2.8 million for 2006 as compared to 2005 was primarily attributable to the adoption
of SFAS No. 123(R) on January 1, 2006. Prior to the adoption of SFAS 123(R) the Company recognized
expense related to restricted stock and deferred stock units but not stock options. Stock-based
compensation expense for 2006 included $1.9 million related to market-based awards and $2.1 million
related to service-based awards, respectively. Stock based compensation expense related to
corporate operations is included in Selling, general and administrative in the Consolidated
Statements of Operations.
52
Table of Contents
Interest Income. Interest income includes all interest earned on cash and marketable security
balances. Interest income increased $1.8 million in 2006 as compared to 2005 due to higher
interest rates partially offset by lower invested cash balances in 2006 as compared to 2005.
Interest income increased $2.5 million in 2005 as compared to 2004 due to increased interest rates
earned on invested cash balances.
Interest Expense. Interest expense is primarily related to our 2.625% convertible senior
debentures with a stated maturity of 2024. Interest expense decreased $0.3 million in 2006 as
compared to 2005. The decline was attributable to the repurchase of $21 million of face value of
the 2024 Debentures in 2006. Interest expense decreased $4.0 million in 2005 as compared to 2004.
The decline was attributable to the retirement of the 2006 Notes in 2004, including expenses in
2004 of $1.4 million due to the accelerated amortization of deferred issuance costs.
Recovery (Impairment) — related party. In May 2001, we entered into a loan agreement with Mr.
Musser, our former CEO. In December 2006, we restructured the obligation so that we could obtain
new collateral. We received cash of $1.0 million from the sale of collateral, which exceeded our
then carrying value of the loan. The excess of $0.4 million is reflected as Recovery-related party
in the Consolidated Statements of Operations. Future cash receipts in excess of the carrying value
of the note will be recognized as Recovery-related party. The carrying value of the loan at
December 31, 2006 was zero.
Other. Included in 2006 was a net gain of $4.3 million on the repurchase of $21 million of face
value of the 2024 Debentures. Included in this category for 2005 was a $1.0 million gain related
to the sale of a legacy asset. Included in this category in 2004 were costs associated with the
repurchase of our 2006 Notes, including $1.8 million due to the accelerated amortization of
deferred issuance costs and $1.4 million related to commissions and premiums paid.
Income Tax (Expense) Benefit
Our consolidated net income tax benefit for 2006, was $1.0 million. We recognized tax expense
of $0.3 million related to our share of net state tax expenses recorded by subsidiaries. We
recognized a $1.3 million tax benefit related to uncertain tax positions for which the statute of
limitations expired during the period in the applicable tax jurisdictions. We have recorded a
valuation allowance to reduce our net deferred tax asset to an amount that is more likely than not
to be realized in future years. Accordingly, the net operating loss benefit that would have been
recognized in 2006 was offset by a valuation allowance.
Discontinued Operations
In October 2006, we completed the sale of our interest in Mantas for net proceeds of $112.8
million, including $19.3 million held in escrow, to i-flex® solutions, ltd., an affiliate of Oracle
Corporation. As a result of the sale, we recorded a gain of $83.9 million in the fourth quarter of
2006. The results of Mantas are reported in discontinued operations for all periods through the
date of its sale. Mantas sold its telecommunications business and certain related assets and
liabilities in the first quarter of 2006 for $2.1 million in cash. As a result of the sale, Mantas
recorded a gain of $1.9 million in the first quarter of 2006 which is also reported in discontinued
operations.
Alliance Consulting completed the sale of its Southwest region in May 2006 for proceeds of
$4.5 million, including cash of $3.0 million and stock of the acquiror of $1.5 million which was
subsequently sold. As a result of the sale, Alliance Consulting recorded a gain of $1.6 million in
the second quarter of 2006. Alliance Consulting’s Southwest region is reported in discontinued
operations for all periods presented through the date of its sale.
In December 2005, Laureate Pharma sold its Totowa, New Jersey facility for $16.0 million in
cash and recorded a gain of $7.7 million on the transaction. The operating results of the Totowa
facility are reported in discontinued operations in 2005.
In October 2004, we sold our interest in CompuCom for $128 million in gross cash proceeds and
recorded a gain of $1.8 million on the sale. The results of CompuCom are reported in discontinued
operations in 2004 through the date of its sale.
53
Table of Contents
The income from discontinued operations in 2006 of $89.8 million was primarily attributable to
the gain on the sale of Mantas and the gain on sale of Alliance Consulting’s Southwest region.
The income from discontinued operations in 2005 of $6.0 million was primarily attributable to
the gain on the sale of the Totowa, New Jersey facility by Laureate Pharma partially offset by
losses from Totowa and the Mantas telecommunications business. The loss from discontinued
operations in 2004 of $29.5 million was primarily attributable to impairment charges in 2004
related to the sale of CompuCom of $19.8 million, net of a $1.8 million gain on sale, $11.9 million
loss from Mantas, partially offset by $2.2 million of income from Alliance Consulting’s Southwest
region.
Liquidity And Capital Resources
Parent Company
We fund our operations with cash on hand as well as proceeds from sales of and distributions
from partner companies, private equity funds and marketable securities. In prior periods, we have
also used sales of our equity and issuance of debt as sources of liquidity. Our ability to
generate liquidity from sales of partner companies, sales of marketable securities and from equity
and debt issuances has been adversely affected from time to time by the decline in the US capital
markets and other factors.
In February 2004, we completed the sale of $150 million of 2.625% convertible senior
debentures with a stated maturity of March 15, 2024 (the “2024 Debentures”). We used all of the
net proceeds of this offering of approximately $146 million to retire a majority of the 2006 Notes
through one or more privately negotiated transactions. The remainder of the 2006 Notes were
retired subsequently in 2004.
As of December 31, 2006, at the parent company level, we had $60.0 million of cash and cash
equivalents and $94.1 million of marketable securities for a total of $154.1 million. In addition
to the amounts above, we had $9.6 million in escrow associated with our interest payments due on
the 2024 Debentures through March 2009, $19.4 million of restricted cash held in escrow, including
accrued interest, associated with our sale of Mantas and our consolidated subsidiaries had cash and
cash equivalents of $11.0 million.
On a consolidated basis, proceeds from sale of discontinued operations were $99.6 million in
2006, $14.7 million in 2005 and $125.9 million in 2004. Proceeds from sales of and distributions
from partner companies and private equity funds were $1.5 million in 2006, $28 million in 2005 and
$39 million in 2004. Proceeds from sales of available-for-sale and trading securities were $3.6
million in 2006, $0.2 million in 2005 and $15 million in 2004.
In May 2006, we renewed our revolving credit facility that provides for borrowings and
issuances of letters of credit and guarantees of up to $55 million. Borrowing availability under
the facility is reduced by the amounts outstanding for our borrowings and letters of credit and
amounts guaranteed under partner company facilities maintained with that same lender. This credit
facility matures in May 2007 and bears interest at the prime rate (8.25% at December 31, 2006) for
outstanding borrowings. The credit facility is subject to an unused commitment fee of 0.125%,
which is subject to reduction based on deposits maintained at the bank. The facility requires cash
collateral equal to one times our borrowings and letters of credit and amounts borrowed by partner
companies under the guaranteed portion of the partner company facilities maintained at the same
bank. As of December 31, 2006, three subsidiaries were not in compliance with certain financial
covenants under their respective facilities and subsequently received waivers from the lender.
In November 2006, we initiated an additional revolving credit facility with a separate bank
that provides for borrowings and issuances of letters of credit and guarantees of up to $20
million. Borrowing availability under the facility is reduced by the amounts outstanding for our
borrowings and letters of credit and amounts guaranteed under partner company facilities maintained
with that same lender. This credit facility bears interest at the prime rate for outstanding
borrowings. The credit facility is subject to an unused commitment fee of 0.125%, which is subject
to reduction based on deposits maintained at the bank. The facility requires cash collateral equal
to one times our borrowings and letters of credit and amounts borrowed by partner companies under
the guaranteed portion of the partner company facilities maintained at the same bank. The credit
facility matures in November 2007.
54
Table of Contents
Availability under our revolving credit facilities at December 31, 2006 was as follows
(in thousands):
| Total | ||||
Size of facilities |
$ | 75,000 | ||
Subsidiary facilities at same banks (a) |
(28,000 | ) | ||
Outstanding letter of credit (b) |
(6,336 | ) | ||
Amount available at December 31, 2006 |
$ | 40,664 | ||
| (a) | Our ability to borrow under the credit facilities is limited by the amounts outstanding for our borrowings and letters of credit and amounts guaranteed under partner company facilities maintained at the same respective banks. Of the total facilities, $25.5 million was outstanding under these facilities at December 31, 2006 and was included as debt on the Consolidated Balance Sheet. | |
| (b) | In connection with the sale of CompuCom, we provided to the landlord of CompuCom’s Dallas headquarters, a letter of credit, which will expire on March 19, 2019, in an amount equal to $6.3 million. |
On February 28, 2007, all subsidiary facilities were extended for one year, with the exception
of Acsis’ facility, which expires in August 2008 and Pacific Title’s facility which was not renewed
by Pacific Title and under which there were no borrowings. In addition to the extension of the
maturity dates, a subsidiary’s working capital line was increased by $5.5 million and that same
subsidiary entered into a $6 million equipment facility, all of
which we guaranteed. Our $10 million guarantee on a subsidiary
facility was decreased to $5 million and related interest rates on outstanding borrowings were
also changed. In January 2007, Clarient increased its facility by $3.5 million, all of which we
guaranteed. As a result of these amendments, our availability under the facilities has decreased
by $10.3 million. Availability under the facilities at
March 22, 2007 was $30.4 million.
We have committed capital of approximately $6.2 million comprising commitments made to various
private equity funds in prior years and a conditional commitment to provide a partner company with
additional funding, to be funded over the next several years, including approximately $4.9 million
which is expected to be funded in the next twelve months. We do not intend to commit to new
investments in additional private equity funds and may seek to further reduce our current ownership
interests in, and our existing commitments to the funds in which we hold interests.
The transactions we enter into in pursuit of our strategy could increase or decrease our
liquidity at any point in time. As we seek to acquire interests in information technology and life
sciences companies or provide additional funding to existing partner companies, we may be required
to expend our cash or incur debt, which will decrease our liquidity. Conversely, as we dispose of
our interests in partner companies from time-to-time we may receive proceeds from such sales which
could increase our liquidity. From time to time, we are engaged in discussions concerning
acquisitions and dispositions which, if consummated, could impact our liquidity, perhaps
significantly.
In May 2001, we entered into a $26.5 loan agreement with Warren V. Musser, our former Chairman
and Chief Executive Officer. Through September 30, 2006, we recognized net impairment charges
against the loan of $15.4 million to the estimated value of the collateral that we in held at each
respective date. Our efforts to collect Mr. Musser’s outstanding loan obligation have included the
sale of existing collateral, obtaining and selling additional collateral, litigation and negotiated
resolution. Since 2001 and through September 30, 2006 we received a total of $15.2 million in cash
payments on the loan. In December 2006, we restructured the obligation to reduce the amount
outstanding to $14.8 million, bearing interest rate of 5% per annum, so that we could obtain new
collateral, which is expected to be the primary source of repayment, along with additional
collateral required to be provided to us over time. Cash payments, when received, will reduce the
carrying value of the note, and thereafter, will be recognized as Recovery-related party in our
Consolidated Statements of Operations. Subsequent to the restructuring of the obligation and prior
to December 31, 2006, we received cash of approximately $1.0 million from the sale of collateral.
We have received distributions as both a general partner and a limited partner from certain
private equity funds. Under certain circumstances, we may be required to return a portion or all
the distributions we received as a general partner to the fund for further distribution to the
fund’s limited partners (the “clawback”). Assuming for these
55
Table of Contents
purposes only that the funds were liquidated or dissolved on December 31, 2006 and the only
distributions from the funds were equal to the carrying value of the funds on the December 31, 2006
financial statements, the maximum clawback we would be required to return for our general partner
interest is $8 million. As of December 31, 2006 management estimated this liability to be
approximately $6.7 million, of which $5.3 million was reflected in accrued expenses and other
current liabilities and $1.4 million was reflected in other long-term liabilities on the
Consolidated Balance Sheets.
Our previous ownership in the general partners of the funds which have potential clawback
liabilities range from 19-30%. The clawback liability is joint and several, such that we may be
required to fund the clawback for other general partners should they default. The funds have taken
several steps to reduce the potential liabilities should other general partners default, including
withholding all general partner distributions and placing them in escrow and adding rights of
set-off among certain funds. We believe our liability for the default of other general partners is
remote.
We have outstanding $129 million of 2.625% convertible senior debentures with a stated
maturity of March 15, 2024. Interest on these 2024 Debentures is payable semi-annually. At the
note holders’ option, the notes are convertible into our common stock before the close of business
on March 14, 2024 subject to certain conditions. The conversion rate of the notes at December 31,
2006 was $7.2174 of principal amount per share. The closing price of our common stock on December
31, 2006 was $2.42. The note holders may require repurchase of the 2024 Debentures on March 21,
2011, March 20, 2014 or March 20, 2019 at a repurchase price equal to 100% of their respective
amount plus accrued and unpaid interest. The note holders may also require repurchase of the 2024
Debentures upon certain events, including sale of all or substantially all of our common stock or
assets, liquidation, dissolution or a change in control. Subject to certain conditions, we may
redeem all or some of the 2024 Debentures commencing March 20, 2009. During 2006, we repurchased
$21 million of face value of the 2024 Debentures for $16.4 million in cash, including accrued
interest.
For the reasons we presented above, we believe our cash and cash equivalents at December 31,
2006, availability under our revolving credit facilities and other internal sources of cash flow
will be sufficient to fund our cash requirements for at least the next twelve months, including
commitments to our existing companies and funds, our current operating plan to acquire interests in
new partner companies, potential monetization activities, possible additional funding of existing
partner companies and our general corporate requirements.
Consolidated Subsidiaries
Most of our consolidated subsidiaries incurred losses in 2006 and may need additional capital
to fund their operations. From time-to-time, some or all of our consolidated subsidiaries may
require additional debt or equity financing or credit support from us to fund planned expansion
activities. If we decide not to provide sufficient capital resources to allow them to reach a
positive cash flow position, and they are unable to raise capital from outside resources, they may
need to scale back their operations. If Alliance Consulting and Pacific Title meet their business
plans for 2007 and the related milestones established by us, we believe they will have sufficient
cash or availability under established lines of credit to fund their operations for at least the
next twelve months. We expect Acsis and Clarient will require additional capital in 2007 to fund
their business plans, and we believe that Laureate Pharma may need additional capital in 2007. As
described below, we have recently provided a revolving line of credit to Clarient, and we intend to
support Acsis and Laureate Pharma capital requirements as needed.
Consolidated subsidiaries have outstanding credit facilities that provide for borrowings of up
to $57.5 million. These facilities contain financial and non-financial covenants and expire at
various points in the first quarter of 2007, with the exception of Acsis’ credit facility, which
was renewed in August 2006 and expires in 2008. As of December 31, 2006, three subsidiaries were not in compliance with certain financial
covenants under their respective facilities and subsequently received waivers from the lender.
As of December 31, 2006, outstanding borrowings under these facilities were $25.5 million.
On March 7, 2007, we provided a subordinated revolving credit line (the “Mezzanine Facility”)
to Clarient. Under the Mezzanine Facility, which expires
December 8, 2008, we committed to provide
Clarient access to up to $6 million in working capital funding. Amounts funded under the Mezzanine
Facility will earn interest at an annual
56
Table of Contents
rate of 12%. The Mezzanine Facility was originally $12 million, but was reduced by $6 million
as a result of the ACIS Sale.
In September 2006, Clarient entered into a $5 million senior secured revolving credit
agreement. Borrowing availability under the agreement is based on the
level of Clarient’s qualified
accounts receivable, less certain reserves. The agreement has a two-year term and bears interest
at variable rates based on the lower of LIBOR plus 3.25% or the prime rate plus 0.5%. As of
December 31, 2006, Clarient borrowed $2.5 million and had no availability under this facility based
on the level of qualified accounts receivable. As of December 31,
2006, Clarient was not in compliance with a financial covenant under
this agreement and subsequently received a waiver from the lender.
Clarient also entered into a Master
Purchase Agreement pursuant to which it sold its ACIS cost-per-test units that were previously leased to customers for a
gross amount of $2.7 million in 2006.
Analysis of Parent Company Cash Flows
Cash flow activity for the Parent Company was as follows:
| Year Ended December 31, | ||||||||||||
| 2006 | 2005 | 2004 | ||||||||||
| (In thousands) | ||||||||||||
Net cash used in operating activities |
$ | (12,039 | ) | $ | (13,534 | ) | $ | (24,463 | ) | |||
Net cash (used in) provided by investing activities |
(16,159 | ) | (16,000 | ) | 86,070 | |||||||
Net cash provided by (used in) financing activities |
(20,169 | ) | 9,572 | (54,863 | ) | |||||||
| $ | (48,367 | ) | $ | (19,962 | ) | $ | 6,744 | |||||
Cash Used In Operating Activities
2006 vs. 2005. Cash used in operating activities decreased $1.5 million in 2006 as compared to
2005. The decrease was primarily due to a changes in working capital and an increase in interest
income as a result of higher average interest rates, partially offset by an increase in operating
costs.
2005 vs. 2004. Cash used in operating activities decreased $10.9 million in 2005 as compared to
2004. The decrease was primarily due to a reduction in interest expense as a result of the
retirement of the 2006 Notes, an increase in interest income and change in working capital.
Cash (Used In) Provided by Investing Activities
Cash provided by (used in) investing activities primarily reflects the acquisition of
ownership interests in companies from third parties, partially offset by proceeds from the sales of
non-strategic assets and private equity funds.
2006 vs. 2005. Cash (used in) investing activities increased $0.2 million in 2006 as compared to
2005. The increase was primarily due to an $7.6 million increase in cash used to acquire ownership
interests in companies and subsidiaries, a $64.2 million increase in cash used to purchase
short-term investments and a $27.9 million decrease in proceeds from sales of and distributions
from companies, partially offset by an increase in proceeds from sale of discontinued operations of
$93.4 million and a $3.3 million increase in proceeds from sales of available-for-sale and trading
securities.
2005 vs. 2004. Cash (used in) provided by investing activities declined $102.1 million in 2005 as
compared to 2004. The decline was primarily attributable to $125.9 million received in 2004 from
the sale of CompuCom, a $14.5 million decline in proceeds from sales of available-for-sale and
trading securities, as well as a $9.6 million decline in proceeds from sales of and distributions
from companies, partially offset by $13.3 million less cash used to acquire ownership interest in
companies and subsidiaries, net of cash acquired, and a net increase of $27.8 million of cash
provided by sale of restricted cash and short-term investments. In December 2005, we sold our
holdings in eight private equity funds for $24 million in cash proceeds. Included in 2004 was
$32.1 million in cash proceeds related to our sale of Sanchez and proceeds from sales of
available-for-sale and trading securities of $14.8 million. Partially offsetting these amounts in
2004 was a $12.5 million investment in Clarient as compared to $9.0 million in 2005.
57
Table of Contents
Also included in 2004 was $5.0 million repayment of an advance to a related party. The 2004 period
reflected a net increase of $26.0 million in short-term investments, including commercial paper and
certificates of deposit, as the company invested in longer maturity securities to take advantage of
higher interest rates.
Cash (Used In) Provided by Financing Activities
2006 vs. 2005. Cash provided by (used in) financing activities decreased $29.7 million in 2006 as
compared to 2005, primarily due to the repurchase of a portion of our convertible senior debentures
for $16.2 million, excluding accrued interest, and the repayment of intercompany advances from a
subsidiary.
2005 vs. 2004. Cash provided by financing activities increased $64.4 million in 2005 as compared
to 2004. The activity in 2004 related to net proceeds of $145.1 million from the issuance of our
2024 Debentures, offset by $201.4 million which was used to redeem the 2006 Notes.
Consolidated Working Capital From Continuing Operations
Consolidated working capital from continuing operations decreased to $137 million at December
31, 2006 compared to $146 million at December 31, 2005. The decrease is primarily attributable to
cash used to fund new and follow-on holdings and to fund continuing operations, partially offset by
proceeds from sale of discontinued operations.
Analysis of Consolidated Cash Flows
Cash flow activity was as follows, including cash flows from Mantas’ business for which cash
was included in current assets from discontinued operations for all periods presented.
| Year Ended December 31, | ||||||||||||
| 2006 | 2005 | 2004 | ||||||||||
| (In thousands) | ||||||||||||
Net cash (used in) provided by operating activities |
$ | (18,379 | ) | $ | (21,910 | ) | $ | 19,123 | ||||
Net cash (used in) provided by investing activities |
(27,590 | ) | 1,411 | 87,432 | ||||||||
Net cash provided by (used in) financing activities |
(5,527 | ) | 2,360 | (34,826 | ) | |||||||
| $ | (51,496 | ) | $ | (18,139 | ) | $ | 71,729 | |||||
Cash (Used In) Provided by Operating Activities
2006 vs. 2005. Net cash used in operating activities decreased $3.5 million in 2006 as compared to
2005. The decrease was primarily due to favorable changes in working capital, offset partially by
results of continuing operations of partner companies.
2005 vs. 2004. Net cash used in operating activities increased $41.0 million in 2005 as compared to
2004. The increase was primarily attributable to working capital changes partially offset by
improved results at partner companies.
Cash Provided by Investing Activities
Cash provided by investing activities primarily reflects the acquisition of ownership
interests in partner companies from third parties, partially offset by proceeds from the sales of
non-strategic assets and private equity funds.
2006 vs. 2005. Net cash used in investing activities increased $29.0 million in 2006 as compared to
2005. The increase was primarily attributable to a $64.2 million increase in cash used to purchase
short-term investments, a $8.6 million increase in cash used to acquire ownership interests in
companies and funds, a $8.8 million increase in cash used for acquisitions by subsidiaries
and a decrease of $26.7 million in proceeds from sales of and distributions from companies,
partially offset by a $85.0 million increase in proceeds from sale of discontinued operations.
58
Table of Contents
2005 vs. 2004. Cash provided by investing activities decreased by $86.0 million in 2005 as compared
to 2004. A decrease of $111.2 million was attributable to a decline in proceeds from discontinued
operations. Included in 2005, were $14.7 million net cash proceeds related to the sale of Laureate
Pharma’s Totowa, New Jersey facility. Included in 2004 were proceeds of $125.9 million related to
the sale of CompuCom. The decrease was also attributable to a $14.5 million decline in proceeds
from sales of available-for-sale and trading securities and $10.9 million decline in proceeds from
sales of and distributions from partner companies and private equity funds. Included in 2004 was
$32.1 million in cash proceeds related to our sale of Sanchez and proceeds from sales of
available-for-sale and trading securities of $14.8 million.
Also included in 2004 was a net increase of $26.0 million in short-term investments, including
commercial paper and certificates of deposit, as the company invested in longer maturity securities
to take advantage of higher interest rates.
Cash Provided by (Used In) Provided by Financing Activities
2006 vs. 2005. Net cash (used in) provided by financing activities decreased $7.9 million in 2006
as compared to 2005, primarily due to the repurchase of a portion of our convertible senior
debentures for $16.2 million, excluding accrued interest, partially offset by increased borrowings
on revolving credit facilities.
2005 vs. 2004. Net cash provided by financing activities increased $37.2 million in 2005 as
compared to 2004. Included in 2005 was $6.2 million related to issuance of subsidiary common stock
to third parties by Clarient, as compared to $13.5 million in 2004. The activity in 2004 related
to net proceeds of $145.1 million from the issuance of our 2024 Debentures, offset by $201.4
million which was used to redeem the 2006 Notes.
Contractual Cash Obligations and Other Commercial Commitments
The following table summarizes our contractual obligations and other commercial commitments as
of December 31, 2006, by period due or expiration of the commitment.
| Payments Due by Period | ||||||||||||||||||||
| 2008 and | 2010 and | Due after | ||||||||||||||||||
| Total | 2007 | 2009 | 2011 | 2011 | ||||||||||||||||
| (In millions) | ||||||||||||||||||||
Contractual Cash Obligations: |
||||||||||||||||||||
Lines of credit (a) |
$ | 25.0 | $ | 25.0 | $ | — | $ | — | $ | — | ||||||||||
Long-term debt (a) |
4.9 | 1.8 | 3.1 | — | — | |||||||||||||||
Capital leases |
4.1 | 2.1 | 2.0 | — | — | |||||||||||||||
Convertible senior debentures (b) |
129.0 | — | — | — | 129.0 | |||||||||||||||
Operating leases |
24.8 | 5.9 | 9.0 | 3.6 | 6.3 | |||||||||||||||
Funding commitments (c) |
6.2 | 4.9 | 1.2 | 0.1 | — | |||||||||||||||
Potential clawback liabilities (d) |
6.7 | 5.3 | — | — | 1.4 | |||||||||||||||
Other long-term obligations (e) |
3.6 | 0.8 | 1.6 | 1.2 | — | |||||||||||||||
Total Contractual Cash Obligations |
$ | 204.3 | $ | 45.8 | $ | 16.9 | $ | 4.9 | $ | 136.7 | ||||||||||
| Amount of Commitment Expiration by Period | ||||||||||||||||||||
| 2008 and | 2010 and | Due after | ||||||||||||||||||
| Total | 2007 | 2009 | 2011 | 2011 | ||||||||||||||||
| (in millions) | ||||||||||||||||||||
Other Commitments: |
||||||||||||||||||||
Letters of credit (f) |
$ | 9.4 | $ | 3.1 | $ | — | $ | — | $ | 6.3 | ||||||||||
| (a) | We have various forms of debt including lines of credit, term loans and equipment leases. Of our total outstanding guarantees of $36.5 million, $25.5 million of outstanding debt associated with the guarantees was included on the Consolidated Balance Sheets at December 31, 2006. See Note 17 to the Consolidated Financial Statements. The remaining $11.0 million was not reflected on the Consolidated Balance Sheets or in the above table. |
59
Table of Contents
| (b) | In February 2004, we completed the issuance of $150 million of the 2024 Debentures with a stated maturity of March 15, 2024. During 2006, we repurchased $21 million of the face value of the 2024 Debentures for $16.4 million in cash. The 2024 Debenture holders may require the Company to repurchase the 2024 Debentures on March 21, 2011, March 20, 2014 or March 20, 2019 at a repurchase price equal to 100% of their respective face amount plus accrued and unpaid interest. | |
| (c) | These amounts include funding commitments to private equity funds and private companies. The amounts have been included in the respective years based on estimated timing of capital calls provided to us by the funds’ management. Also included is our $3.0 million conditional commitment to provide a partner company with additional funding. | |
| (d) | We have received distributions as both a general partner and a limited partner from certain private equity funds. Under certain circumstances, we may be required to return a portion or all the distributions we received as a general partner to the fund for a further distribution to the fund’s limited partners (the “clawback”). Assuming the funds were liquidated or dissolved on December 31, 2006 and the only value provided by the funds was the carrying values represented on the December 31, 2006 financial statements, the maximum clawback we would be required to return is $8 million. As of December 31, 2006, management estimated its liability to be approximately $6.7 million, of which $5.3 million was reflected in accrued expenses and other current liabilities and $1.4 million was reflected in other long-term liabilities on the Consolidated Balance Sheets. | |
| (e) | Reflects the amount payable to our former Chairman and CEO under a consulting contract. | |
| (f) | Letters of credit include a $6.3 million letter of credit provided to the landlord of CompuCom’s Dallas headquarters lease in connection with the sale of CompuCom and $3.1 million of letters of credit issued by subsidiaries supporting their office leases. |
We have agreements with certain employees that provide for severance payments to the employee
in the event the employee is terminated without cause or if the employee terminates his employment
for “good reason.” The maximum aggregate cash exposure under the agreements was approximately $8
million at December 31, 2006.
As of December 31, 2006, Safeguard and its subsidiaries consolidated for tax purposes had
federal net operating loss carryforwards and federal capital loss carryforwards of approximately
$254 million and $140 million, respectively. The net operating loss carryforwards expire in various
amounts from 2007 to 2024. The capital loss carryforwards expire in various amounts from 2007 to
2008. Limitations on utilization of both the net operating loss carryforwards and capital loss
carryforwards may apply.
We are involved in various claims and legal actions arising in the ordinary course of
business. In the opinion of management, the ultimate disposition of these matters will not have a
material adverse effect on the consolidated financial position or results of operations.
Recent Accounting Pronouncements
In September 2006, the United States Securities and Exchange Commission issued Staff
Accounting Bulletin No. 108, “Considering the Effects of Prior Year Misstatements when Quantifying
Misstatements in Current Year Financial Statements” (“SAB 108”). SAB 108 requires companies to
evaluate the materiality of identified unadjusted errors using both the income statement approach
and the balance sheet approach. In the initial year of adoption, if a company determines that an
adjustment to prior year financial statements is required under either approach, SAB 108 allows for
a one-time cumulative-effect adjustment to beginning retained earnings. SAB 108 is effective for
interim periods of the first fiscal year ending after November 15, 2006. The adoption of SAB No.
108 did not have an impact on our consolidated financial position, results of operations or cash
flows.
In September 2006, the FASB issued SFAS No. 157, “Fair Value Measurements” (“SFAS No. 157”).
SFAS No. 157 defines fair value, establishes a framework for measuring fair value in generally
accepted accounting principles and expands disclosures about fair value measurements. SFAS No. 157
is effective for financial
60
Table of Contents
statements issued for fiscal years beginning after November 15, 2007, and interim periods
within those fiscal years. We do not expect the adoption of SFAS No. 157 to have a material impact
on our financial statements.
In July 2006, the FASB issued FASB Interpretation No. 48, “Accounting for Uncertainty in
Income Taxes” (“FIN 48”). FIN 48 defines the threshold for recognizing the benefits of tax return
positions in the financial statements as “more-likely-than-not” to be sustained upon examination by
the applicable taxing authority. FIN 48 also includes guidance concerning accounting for income tax
uncertainties in interim periods and increases the level of disclosures associated with any
recorded income tax uncertainties. FIN 48 is effective for fiscal years beginning after December
15, 2006. We do not believe adoption of FIN 48 will have a material effect on our consolidated
financial position, results of operations or cash flows and will consist of reclassification of
certain income tax-related liabilities.
In November 2005, the FASB issued FASB Staff Position SFAS 123(R)-3, “Transition Election
Related to Accounting for the Tax Effects of Share-based Payment Awards”, that provides an elective
alternative transition method of calculating the pool of excess tax benefits available to absorb
tax deficiencies recognized subsequent to the adoption of SFAS No. 123(R) (the “APIC Pool”) to the
method otherwise required by paragraph 81 of SFAS No. 123(R). In the fourth quarter of 2006, we
adopted the short-cut method to calculate the APIC Pool.
In December 2004, the FASB issued SFAS No. 123 (revised 2004), “Share-Based Payment” (“SFAS
No. 123(R)”). SFAS No. 123(R) requires companies to measure all employee stock-based compensation
awards using a fair value method and record such expense in its consolidated financial statements.
In addition, the adoption of SFAS No. 123(R) requires additional accounting and disclosure related
to the income tax and cash flow effects resulting from share-based payment arrangements. We
adopted SFAS No. 123(R) on January 1, 2006 using the modified prospective method. See Note 12 to
the Consolidated Financial Statements.
Item 7A. Quantitative and Qualitative Disclosures About Market Risk
We are exposed to equity price risks on the marketable portion of our securities. These
securities include equity positions in partner companies, many of which have experienced
significant volatility in their stock prices. Historically, we have not attempted to reduce or
eliminate our market exposure on securities. Based on closing market prices at December 31, 2006,
the fair market value of our holdings in public securities was approximately $73.3 million. A 20%
decrease in equity prices would result in an approximate $14.7 million decrease in the fair value
of our publicly traded securities.
In February 2004, we completed the issuance of $150 million of fixed rate notes with a stated
maturity of March 2024. In 2006, we repurchased a total of $21 million face value of the 2024
Debentures. Interest payments of approximately $1.7 million each are due March and September of
each year. The holders of these 2024 Debentures may require repurchase of the notes on March 21,
2011, March 20, 2014 or March 20, 2019 at a repurchase price equal to 100% of their respective
amount plus accrued and unpaid interest. On October 8, 2004, we utilized approximately $16.7
million of the proceeds from the CompuCom sale to escrow interest payments due through March 15,
2009.
| Fair | ||||||||||||||||||||
| Market | ||||||||||||||||||||
| After | Value at | |||||||||||||||||||
| Liabilities | 2007 | 2008 | 2009 | 2009 | 12/31/06 | |||||||||||||||
Convertible Senior
Debentures due by year (in
millions) |
$ | — | $ | — | $ | — | $ | 129.0 | $ | 104.5 | ||||||||||
Fixed Interest Rate |
2.625 | % | 2.625 | % | 2.625 | % | 2.625 | % | ||||||||||||
Interest Expense (in millions) |
$ | 3.4 | $ | 3.4 | $ | 3.4 | $ | 54.9 | ||||||||||||
At December 31, 2006, our outstanding debt totaled $34.0 million, which consisted of fixed
rate debt of $6.0 million and variable-rate debt of $28.0 million. Based on our 2006 average
outstanding borrowings under our variable-rate debt, a one-percentage point increase in interest
rates would negatively impact our annual pre-tax earnings and cash flows by approximately $0.5
million.
We have historically had very low exposure to changes in foreign currency exchange rates, and
as such, have not used derivative financial instruments to manage foreign currency fluctuation
risk.
61
Table of Contents
Item 8. Financial Statements and Supplementary Data
The following Consolidated Financial Statements, and the related Notes thereto, of Safeguard
Scientifics, Inc. and the Report of Independent Registered Public Accounting Firm as filed as a
part of this Form 10-K.
| Page | ||||
| 63 | ||||
| 64 | ||||
| 66 | ||||
| 67 | ||||
| 68 | ||||
| 69 | ||||
| 70 | ||||
| 71 | ||||
| 72 | ||||
62
Table of Contents
MANAGEMENT’S REPORT ON INTERNAL CONTROL
OVER FINANCIAL REPORTING
OVER FINANCIAL REPORTING
Our Management is responsible for establishing and maintaining adequate internal control over
financial reporting. Internal control over financial reporting is a process designed to provide
reasonable assurance regarding the reliability of financial reporting and the preparation of
financial statements for external purposes in accordance with generally accepted accounting
principles. Our internal control over financial reporting includes those policies and procedures
that pertain to the maintenance of records that, in reasonable detail, accurately and fairly
reflect the transactions and dispositions of our assets; provide reasonable assurance that
transactions are recorded as necessary to permit preparation of financial statements in accordance
with generally accepted accounting principles, and that our receipts and expenditures are being
made only in accordance with authorizations of our management and directors; and provide
reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or
disposition of our assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent
or detect misstatements. Also, projections of any evaluation of effectiveness to future periods
are subject to the risk that controls may become inadequate because of changes in conditions, or
that the degree of compliance with the policies or procedures may deteriorate.
Management evaluated our internal control over financial reporting as of December 31, 2006.
In making this assessment, management used the criteria set forth by the Committee of Sponsoring
Organizations of the Treadway Commission in Internal Control-Integrated Framework (COSO). As a
result of this assessment and based on the criteria in the COSO framework, management has concluded
that, as of December 31, 2006, our internal control over financial reporting was effective.
Our independent registered public accounting firm, KPMG LLP, has audited management’s
assessment of our internal control over financial reporting. Their opinion on management’s
assessment and the effectiveness of our internal control over financial reporting and their opinion
on our financial statements appear on the following pages.
63
Table of Contents
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
The Board of Directors and Shareholders
Safeguard Scientifics, Inc.:
Safeguard Scientifics, Inc.:
We have audited management’s assessment, included in the accompanying Management’s Report on
Internal Control Over Financial Reporting appearing on page 63 of the financial statements, that
Safeguard Scientifics, Inc. maintained effective internal control over financial reporting as of
December 31, 2006, based on criteria established in Internal Control—Integrated Framework issued
by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Management of
Safeguard Scientifics, Inc. is responsible for maintaining effective internal control over
financial reporting and for its assessment of the effectiveness of internal control over financial
reporting. Our responsibility is to express an opinion on management’s assessment and an opinion on
the effectiveness of the Company’s internal control over financial reporting based on our audit.
We conducted our audit in accordance with the standards of the Public Company Accounting Oversight
Board (United States). Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether effective internal control over financial reporting was
maintained in all material respects. Our audit included obtaining an understanding of internal
control over financial reporting, evaluating management’s assessment, testing and evaluating the
design and operating effectiveness of internal control, and performing such other procedures as we
considered necessary in the circumstances. We believe that our audit provides a reasonable basis
for our opinion.
A company’s internal control over financial reporting is a process designed to provide reasonable
assurance regarding the reliability of financial reporting and the preparation of financial
statements for external purposes in accordance with generally accepted accounting principles. A
company’s internal control over financial reporting includes those policies and procedures that (1)
pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the
transactions and dispositions of the assets of the company; (2) provide reasonable assurance that
transactions are recorded as necessary to permit preparation of financial statements in accordance
with generally accepted accounting principles, and that receipts and expenditures of the company
are being made only in accordance with authorizations of management and directors of the company;
and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized
acquisition, use, or disposition of the company’s assets that could have a material effect on the
financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or
detect misstatements. Also, projections of any evaluation of effectiveness to future periods are
subject to the risk that controls may become inadequate because of changes in conditions, or that
the degree of compliance with the policies or procedures may deteriorate.
In our opinion, management’s assessment that Safeguard Scientifics, Inc. maintained effective
internal control over financial reporting as of December 31, 2006, is fairly stated, in all
material respects, based on criteria established in Internal Control—Integrated Framework issued
by COSO. Also, in our opinion, Safeguard Scientifics, Inc. maintained, in all material respects,
effective internal control over financial reporting as of December 31, 2006, based on criteria
established in Internal Control—Integrated Framework issued by COSO.
64
Table of Contents
We also have audited, in accordance with the standards of the Public Company Accounting Oversight
Board (United States), the consolidated balance sheets of Safeguard Scientifics, Inc. and
subsidiaries as of December 31, 2006 and 2005, and the related consolidated statements of
operations, comprehensive loss, shareholders’ equity and cash flows for each of the years in the
three-year period ended December 31, 2006, and our report dated
March 27, 2007 expressed an
unqualified opinion on those consolidated financial statements.
/s/ KPMG LLP
Philadelphia, Pennsylvania
March 27, 2007
March 27, 2007
65
Table of Contents
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
The Board of Directors and Shareholders
Safeguard Scientifics, Inc.:
Safeguard Scientifics, Inc.:
We have audited the accompanying consolidated balance sheets of Safeguard Scientifics, Inc.
(the “Company”) and subsidiaries as of December 31, 2006 and 2005, and the related consolidated
statements of operations, comprehensive income (loss), shareholders’ equity and cash flows for each
of the years in the three-year period ended December 31, 2006. These consolidated financial
statements are the responsibility of the Company’s management. Our responsibility is to express an
opinion on these consolidated financial statements based on our audits.
We conducted our audits in accordance with the standards of the Public Company Accounting
Oversight Board (United States). Those standards require that we plan and perform the audit to
obtain reasonable assurance about whether the financial statements are free of material
misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and
disclosures in the financial statements. An audit also includes assessing the accounting principles
used and significant estimates made by management, as well as evaluating the overall financial
statement presentation. We believe that our audits provide a reasonable basis for our opinion.
In our opinion, the consolidated financial statements referred to above present fairly, in all
material respects, the financial position of Safeguard Scientifics, Inc. and subsidiaries as of
December 31, 2006 and 2005, and the results of their operations and their cash flows for each of
the years in the three-year period ended December 31, 2006, in conformity with U.S. generally
accepted accounting principles.
As discussed in Note 1, to the consolidated financial statements, the Company adopted SFAS No.
123R, Share-Based Payment, on January 1, 2006.
We also have audited, in accordance with the standards of the Public Company Accounting
Oversight Board (United States), the effectiveness of internal control over financial reporting of
Safeguard Scientifics, Inc. as of December 31, 2006, based on criteria established in Internal
Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway
Commission (COSO), and our report dated March 27, 2007 expressed an unqualified opinion on
management’s assessment of, and the effective operation of, internal control over financial
reporting.
/s/ KPMG LLP
Philadelphia, Pennsylvania
March 27, 2007
March 27, 2007
66
Table of Contents
SAFEGUARD SCIENTIFICS, INC.
CONSOLIDATED BALANCE SHEETS
CONSOLIDATED BALANCE SHEETS
| As of December 31, | ||||||||
| 2006 | 2005 | |||||||
| (In thousands except per | ||||||||
| share data) | ||||||||
| ASSETS |
||||||||
Current Assets: |
||||||||
Cash and cash equivalents |
$ | 71,251 | $ | 124,916 | ||||
Restricted cash — current |
— | 1,098 | ||||||
Marketable securities |
94,155 | 31,770 | ||||||
Restricted marketable securities |
3,869 | 3,805 | ||||||
Accounts receivable, less allowances ($1,793 — 2006; $1,720 — 2005) |
38,560 | 41,006 | ||||||
Prepaid expenses and other current assets |
7,151 | 5,498 | ||||||
Current assets of discontinued operations |
— | 12,263 | ||||||
Total current assets |
214,986 | 220,356 | ||||||
Property and equipment, net |
44,889 | 37,739 | ||||||
Ownership interests in and advances to companies |
54,548 | 17,897 | ||||||
Long-term marketable securities |
487 | 3,311 | ||||||
Long-term restricted marketable securities |
5,737 | 9,457 | ||||||
Intangible assets, net |
16,426 | 15,312 | ||||||
Goodwill |
82,498 | 77,972 | ||||||
Cash held in escrow |
19,630 | — | ||||||
Other |
4,180 | 5,563 | ||||||
Non-current assets of discontinued operations |
— | 28,695 | ||||||
Total Assets |
$ | 443,381 | $ | 416,302 | ||||
| LIABILITIES AND SHAREHOLDERS’ EQUITY |
||||||||
Current Liabilities: |
||||||||
Current portion of credit line borrowings |
$ | 25,014 | $ | 13,023 | ||||
Current maturities of long-term debt |
3,938 | 3,374 | ||||||
Current portion of convertible senior debentures |
— | 5,000 | ||||||
Accounts payable |
11,111 | 10,358 | ||||||
Accrued compensation and benefits |
14,614 | 12,310 | ||||||
Accrued expenses and other current liabilities |
19,165 | 14,567 | ||||||
Deferred revenue |
4,250 | 3,465 | ||||||
Current liabilities of discontinued operations |
— | 12,718 | ||||||
Total current liabilities |
78,092 | 74,815 | ||||||
Long-term debt |
5,067 | 5,170 | ||||||
Other long-term liabilities |
10,918 | 14,013 | ||||||
Convertible senior debentures |
129,000 | 145,000 | ||||||
Deferred taxes |
911 | 895 | ||||||
Minority interest |
5,491 | 10,478 | ||||||
Non-current liabilities of discontinued operations |
— | 956 | ||||||
Commitments and contingencies
Redeemable subsidiary stock-based compensation |
2,021 | — | ||||||
Shareholders’ Equity: |
||||||||
Preferred stock, $0.10 par value; 1,000 shares authorized |
— | — | ||||||
Common stock, $0.10 par value; 500,000 shares authorized; 120,419
and 119,935 shares issued and outstanding in 2006 and 2005,
respectively |
12,042 | 11,993 | ||||||
Additional paid-in capital |
750,361 | 747,953 | ||||||
Accumulated deficit |
(551,058 | ) | (597,088 | ) | ||||
Accumulated other comprehensive income |
536 | 3,166 | ||||||
Treasury stock, at cost (2 shares-2005) |
— | (6 | ) | |||||
Unamortized deferred compensation |
— | (1,043 | ) | |||||
Total shareholders’ equity |
211,881 | 164,975 | ||||||
Total Liabilities and Shareholders’ Equity |
$ | 443,381 | $ | 416,302 | ||||
See Notes to Consolidated Financial Statements.
67
Table of Contents
SAFEGUARD SCIENTIFICS, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
CONSOLIDATED STATEMENTS OF OPERATIONS
| Year Ended December 31, | ||||||||||||
| 2006 | 2005 | 2004 | ||||||||||
| (In thousands except per share data) | ||||||||||||
Revenue: |
||||||||||||
Product sales |
$ | 10,668 | $ | 5,898 | $ | 2,211 | ||||||
Service sales |
187,392 | 137,933 | 107,143 | |||||||||
Total revenue |
198,060 | 143,831 | 109,354 | |||||||||
Operating Expenses: |
||||||||||||
Cost of sales — product |
7,556 | 1,921 | 2,532 | |||||||||
Cost of sales — service |
134,834 | 103,260 | 74,882 | |||||||||
Selling, general and administrative |
99,962 | 74,178 | 73,053 | |||||||||
Research and development |
6,977 | 3,794 | 4,699 | |||||||||
Purchased in-process research and development |
— | 2,183 | 89 | |||||||||
Amortization of intangibles |
3,413 | 2,367 | 2,192 | |||||||||
Total operating expenses |
252,742 | 187,703 | 157,447 | |||||||||
Operating loss |
(54,682 | ) | (43,872 | ) | (48,093 | ) | ||||||
Other income, net |
5,573 | 7,338 | 38,803 | |||||||||
Recovery (impairment) — related party |
360 | 28 | (3,400 | ) | ||||||||
Interest income |
6,914 | 4,984 | 2,612 | |||||||||
Interest expense |
(6,821 | ) | (6,428 | ) | (9,585 | ) | ||||||
Equity loss |
(3,267 | ) | (6,597 | ) | (14,534 | ) | ||||||
Minority interest |
7,120 | 6,356 | 8,736 | |||||||||
Net loss from continuing operations before income taxes |
(44,803 | ) | (38,191 | ) | (25,461 | ) | ||||||
Income tax benefit |
1,023 | 83 | 120 | |||||||||
Net loss from continuing operations |
(43,780 | ) | (38,108 | ) | (25,341 | ) | ||||||
Income (loss) from discontinued operations, net of tax |
89,810 | 6,038 | (29,479 | ) | ||||||||
Net income (loss) |
$ | 46,030 | $ | (32,070 | ) | $ | (54,820 | ) | ||||
Basic Income (Loss) Per Share: |
||||||||||||
Net loss from continuing operations |
$ | (0.36 | ) | $ | (0.32 | ) | $ | (0.21 | ) | |||
Net income (loss) from discontinued operations |
0.74 | 0.05 | (0.25 | ) | ||||||||
Net income (loss) per share |
$ | 0.38 | $ | (0.27 | ) | $ | (0.46 | ) | ||||
Diluted Income (Loss) Per Share: |
||||||||||||
Net loss from continuing operations |
$ | (0.36 | ) | $ | (0.32 | ) | $ | (0.21 | ) | |||
Net income (loss) from discontinued operations |
0.74 | 0.05 | (0.25 | ) | ||||||||
Net income (loss) per share |
$ | 0.38 | $ | (0.27 | ) | $ | (0.46 | ) | ||||
Shares used in computing basic and diluted income
(loss) per share |
121,476 | 120,845 | 119,965 | |||||||||
See Notes to Consolidated Financial Statements.
68
Table of Contents
SAFEGUARD SCIENTIFICS, INC.
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
| Year Ended December 31, | ||||||||||||
| 2006 | 2005 | 2004 | ||||||||||
| (In thousands) | ||||||||||||
Net loss from continuing operations |
$ | (43,780 | ) | $ | (38,108 | ) | $ | (25,341 | ) | |||
Other comprehensive income (loss), before taxes: |
||||||||||||
Foreign currency translation adjustments |
5 | 69 | (45 | ) | ||||||||
Unrealized holding gains (losses) in available-for-sale securities |
(2,824 | ) | (8,653 | ) | 11,964 | |||||||
Other comprehensive income (loss) from continuing operations |
(2,819 | ) | (8,584 | ) | 11,919 | |||||||
Comprehensive loss from continuing operations |
(46,599 | ) | (46,692 | ) | (13,422 | ) | ||||||
Income (loss) from discontinued operations |
89,810 | 6,038 | (29,479 | ) | ||||||||
Other comprehensive income (loss) from discontinued operations |
189 | (36 | ) | (94 | ) | |||||||
Comprehensive income (loss) |
$ | 43,400 | $ | (40,690 | ) | $ | (42,995 | ) | ||||
See Notes to Consolidated Financial Statements.
69
Table of Contents
SAFEGUARD SCIENTIFICS, INC.
CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY
CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY
| Accumulated | |||||||||||||||||||||||||||||||||||||
| Other | |||||||||||||||||||||||||||||||||||||
| Additional | Comprehensive | Unamortized | |||||||||||||||||||||||||||||||||||
| Common Stock | Paid-In | Accumulated | Income | Treasury Stock | Deferred | ||||||||||||||||||||||||||||||||
| Shares | Amount | Capital | Deficit | (Loss) | Shares | Amount | Compensation | Total | |||||||||||||||||||||||||||||
| (In thousands) | |||||||||||||||||||||||||||||||||||||
Balance — December 31, 2003 |
119,450 | $ | 11,945 | $ | 737,560 | $ | (510,198 | ) | $ | (39 | ) | 53 | $ | (191 | ) | $ | (2,906 | ) | $ | 236,171 | |||||||||||||||||
Net loss |
— | — | — | (54,820 | ) | — | — | — | — | (54,820 | ) | ||||||||||||||||||||||||||
Stock options exercised, net |
369 | 37 | 1,104 | — | — | (73 | ) | 251 | — | 1,392 | |||||||||||||||||||||||||||
Acceleration of vesting of stock
options |
— | — | 130 | — | — | — | — | — | 130 | ||||||||||||||||||||||||||||
Amortization of deferred
compensation |
— | — | — | — | — | — | — | 2,729 | 2,729 | ||||||||||||||||||||||||||||
Impact of subsidiary equity
transactions |
— | — | 4,088 | — | — | — | — | (389 | ) | 3,699 | |||||||||||||||||||||||||||
Issuance of restricted stock, net |
74 | 7 | 3,109 | — | — | 20 | (60 | ) | (2,952 | ) | 104 | ||||||||||||||||||||||||||
Other comprehensive income |
— | — | — | — | 11,825 | — | — | — | 11,825 | ||||||||||||||||||||||||||||
Balance — December 31, 2004 |
119,893 | 11,989 | 745,991 | (565,018 | ) | 11,786 | — | — | (3,518 | ) | 201,230 | ||||||||||||||||||||||||||
Net loss |
— | — | — | (32,070 | ) | — | — | — | — | (32,070 | ) | ||||||||||||||||||||||||||
Stock options exercised, net |
42 | 4 | 48 | — | — | (2 | ) | 9 | — | 61 | |||||||||||||||||||||||||||
Acceleration of vesting of
restricted stock |
— | — | — | — | — | — | — | 279 | 279 | ||||||||||||||||||||||||||||
Amortization of deferred
compensation, net of forfeitures |
— | — | (203 | ) | — | — | — | — | 1,371 | 1,168 | |||||||||||||||||||||||||||
Impact of subsidiary equity
transactions |
— | — | 1,859 | — | — | — | — | 838 | 2,697 | ||||||||||||||||||||||||||||
Issuance of restricted stock, net |
— | — | 113 | — | — | 4 | (15 | ) | (13 | ) | 85 | ||||||||||||||||||||||||||
Employee stock option expense |
— | — | 145 | — | — | — | — | — | 145 | ||||||||||||||||||||||||||||
Other comprehensive loss |
— | — | — | — | (8,620 | ) | — | — | — | (8,620 | ) | ||||||||||||||||||||||||||
Balance — December 31, 2005 |
119,935 | 11,993 | 747,953 | (597,088 | ) | 3,166 | 2 | (6 | ) | (1,043 | ) | 164,975 | |||||||||||||||||||||||||
Net income |
— | — | — | 46,030 | — | — | — | — | 46,030 | ||||||||||||||||||||||||||||
Stock options exercised, net |
236 | 25 | 346 | — | — | (2 | ) | 6 | — | 377 | |||||||||||||||||||||||||||
Reclassification of unamortized
deferred compensation |
— | — | (1,043 | ) | — | — | — | — | 1,043 | — | |||||||||||||||||||||||||||
Reclassification of redeemable
subsidiary stock-based
compensation |
— | — | (2,021 | ) | — | — | — | — | — | (2,021 | ) | ||||||||||||||||||||||||||
Impact of subsidiary equity
transactions |
— | — | (1,763 | ) | — | — | — | — | — | (1,763 | ) | ||||||||||||||||||||||||||
Issuance of restricted stock, net |
248 | 24 | 47 | — | — | — | — | — | 71 | ||||||||||||||||||||||||||||
Stock-based compensation expense |
— | — | 6,842 | — | — | — | — | — | 6,842 | ||||||||||||||||||||||||||||
Other comprehensive loss |
— | — | — | — | (2,630 | ) | — | — | — | (2,630 | ) | ||||||||||||||||||||||||||
Balance — December 31, 2006 |
120,419 | $ | 12,042 | $ | 750,361 | $ | (551,058 | ) | $ | 536 | — | $ | — | $ | — | $ | 211,881 | ||||||||||||||||||||
See Notes to Consolidated Financial Statements.
70
Table of Contents
SAFEGUARD SCIENTIFICS, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
CONSOLIDATED STATEMENTS OF CASH FLOWS
| Year Ended December 31, | ||||||||||||
| 2006 | 2005 | 2004 | ||||||||||
| (In thousands) | ||||||||||||
Cash Flows from Operating Activities: |
||||||||||||
Net income (loss) |
$ | 46,030 | $ | (32,070 | ) | $ | (54,820 | ) | ||||
Adjustments to reconcile to net cash provided by (used in) operating activities: |
||||||||||||
(Income) loss from discontinued operations |
(89,810 | ) | (6,038 | ) | 29,479 | |||||||
Depreciation and amortization |
14,562 | 11,496 | 9,440 | |||||||||
Purchased in-process research and development |
— | 2,183 | — | |||||||||
Deferred income taxes |
16 | (51 | ) | 62 | ||||||||
Equity loss |
3,267 | 6,597 | 14,534 | |||||||||
Other income, net |
(5,573 | ) | (7,338 | ) | (38,803 | ) | ||||||
Impairment |
— | — | — | |||||||||
(Recovery) impairment — related party |
(360 | ) | (28 | ) | 3,400 | |||||||
Non-cash compensation charges |
6,842 | 2,613 | 4,210 | |||||||||
Minority interest |
(7,120 | ) | (6,356 | ) | (8,438 | ) | ||||||
Changes in assets and liabilities, net of effect of acquisitions and dispositions: |
||||||||||||
Accounts receivable, net |
2,231 | (1,771 | ) | (2,769 | ) | |||||||
Accounts payable, accrued expenses, deferred revenue and other |
9,361 | 7,349 | (4,356 | ) | ||||||||
Cash flows from operating activities of discontinued operations |
2,175 | 1,504 | 67,184 | |||||||||
Net cash (used in) provided by operating activities |
(18,379 | ) | (21,910 | ) | 19,123 | |||||||
Cash Flows from Investing Activities: |
||||||||||||
Proceeds from sales of available-for-sale and trading securities |
3,551 | 241 | 14,784 | |||||||||
Proceeds from sales of and distributions from companies and funds |
1,530 | 28,242 | 39,085 | |||||||||
Advances to companies |
— | (2,299 | ) | (1,015 | ) | |||||||
Repayment of advances to companies |
— | — | 400 | |||||||||
Acquisitions of ownership interests in companies and funds, net of cash acquired |
(43,596 | ) | (35,034 | ) | (34,797 | ) | ||||||
Acquisitions by subsidiaries, net of cash acquired |
(8,778 | ) | — | (57 | ) | |||||||
Repayment of note receivable-related party, net |
360 | 1,413 | 7,162 | |||||||||
Increase in restricted cash and marketable securities |
(208,514 | ) | (55,602 | ) | (37,660 | ) | ||||||
Decrease in restricted cash and marketable securities |
146,129 | 57,387 | 11,643 | |||||||||
Purchase of restricted securities |
— | — | (16,715 | ) | ||||||||
Proceeds from sales of property and equipment |
445 | 4,212 | — | |||||||||
Capital expenditures |
(17,949 | ) | (11,966 | ) | (9,597 | ) | ||||||
Capitalized software costs |
(171 | ) | (171 | ) | (4,300 | ) | ||||||
Proceeds from sale of discontinued operations, net |
99,649 | 14,680 | 125,853 | |||||||||
Other, net |
(153 | ) | 663 | 4,182 | ||||||||
Cash flows from investing activities of discontinued operations |
(93 | ) | (355 | ) | (11,536 | ) | ||||||
Net cash (used in) provided by investing activities |
(27,590 | ) | 1,411 | 87,432 | ||||||||
Cash Flows from Financing Activities: |
||||||||||||
Proceeds from convertible senior debentures |
— | — | 150,000 | |||||||||
Payments of offering costs on convertible senior debentures |
— | — | (4,887 | ) | ||||||||
Repurchase of convertible senior debentures |
(16,215 | ) | — | — | ||||||||
Repurchase of convertible subordinated notes |
— | — | (200,000 | ) | ||||||||
Payments of costs to repurchase convertible subordinated notes |
— | — | (1,368 | ) | ||||||||
Borrowings on revolving credit facilities |
137,221 | 101,936 | 67,931 | |||||||||
Repayments on revolving credit facilities |
(125,206 | ) | (100,521 | ) | (62,496 | ) | ||||||
Borrowings on term debt |
5,112 | 2,072 | 2,796 | |||||||||
Repayments on term debt |
(4,648 | ) | (6,944 | ) | (2,291 | ) | ||||||
Decrease (increase) in restricted cash |
(232 | ) | 508 | 44 | ||||||||
Issuance of Company common stock, net |
448 | 61 | 1,392 | |||||||||
Issuance of subsidiary common stock, net |
432 | 6,196 | 4,176 | |||||||||
Purchase of subsidiary common stock, net |
(1,112 | ) | (611 | ) | — | |||||||
Offering costs on issuance of subsidiary common stock |
(70 | ) | (343 | ) | (1,580 | ) | ||||||
Cash flows from financing activities of discontinued operations |
(1,257 | ) | 6 | 11,457 | ||||||||
Net cash provided by (used in) financing activities |
(5,527 | ) | 2,360 | (34,826 | ) | |||||||
Net Increase (Decrease) in Cash and Cash Equivalents |
(51,496 | ) | (18,139 | ) | 71,729 | |||||||
Changes in Cash and Cash Equivalents from Mantas and CompuCom included in assets
of discontinued operations |
(2,169 | ) | (343 | ) | (58,007 | ) | ||||||
| (53,665 | ) | (18,482 | ) | 13,722 | ||||||||
Cash and Cash Equivalents at beginning of period |
$ | 124,916 | $ | 143,398 | $ | 129,676 | ||||||
Total Cash and Cash Equivalents |
$ | 71,251 | $ | 124,916 | $ | 143,398 | ||||||
See Notes to Consolidated Financial Statements.
71
Table of Contents
SAFEGUARD SCIENTIFICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
1. Significant Accounting Policies
Description of the Company
Safeguard Scientifics, Inc. (“Safeguard” or the “Company”) seeks to build value in
growth-stage technology and life sciences businesses. The Company provides growth capital as well
as a range of strategic, operational and management resources to our partner companies. The
Company participates in expansion financings, carve-outs, management buy-outs, recapitalizations,
industry consolidations and early-stage financings. The Company’s vision is to be the preferred
catalyst for creating great technology and life sciences companies.
The Company strives to create long-term value for its shareholders through building value in
its partner companies. Safeguard helps its partner companies in their efforts to increase market
penetration, grow revenue and improve cash flow in order to create long-term value. The Company
concentrates on companies that operate in two categories:
| • | Technology — including companies focused on providing software as a service (SaaS), technology-enabled services and information technology services for analytics, enterprise applications and infrastructure, security and communication; and | ||
| • | Life Sciences — including companies focused on specialty pharmaceuticals, drug delivery, diagnostics and medical devices. |
Basis of Presentation
The Consolidated Financial Statements include the accounts of the Company and all subsidiaries
in which it directly or indirectly owns more than 50% of the outstanding voting securities.
The Company’s Consolidated Statements of Operations, Comprehensive Income (Loss) and Cash
Flows from continuing operations include the following subsidiaries:
| Year Ended | ||||
| December 31, 2006 | December 31, 2005 | December 31, 2004 | ||
Acsis, Inc. (“Acsis”) Alliance Consulting Group Associates, Inc. (“Alliance Consulting”) Clarient, Inc. (“Clarient”) Laureate Pharma, Inc. (“Laureate Pharma”) Pacific Title & Art Studio, Inc. (“Pacific Title”) |
Acsis (since December 2005)
Alliance Consulting Clarient Laureate Pharma Pacific Title |
Alliance Consulting Clarient Laureate Pharma (since December 2004) Pacific Title Tangram (through February 2004) |
||
The Company’s Consolidated Balance Sheets include the following majority-owned subsidiaries:
| December 31, 2006 and 2005 |
Acsis |
Alliance Consulting |
Clarient |
Laureate Pharma |
Pacific Title |
72
Table of Contents
SAFEGUARD SCIENTIFICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)
Alliance Consulting operates on a 52- or 53-week fiscal year, ending on the Saturday closest
to December 31. Alliance Consulting’s last three fiscal years have ended on December 30, 2006,
December 31, 2005 and January 1, 2005. Fiscal years 2006 and 2005 were periods of 52 weeks, and
2004 was a period of 53 weeks. The Company and all other subsidiaries operate on a calendar year.
During
2006, 2005 and 2004, certain consolidated companies, or components
thereof, were sold. See Note 2 for discontinued operations treatment of Mantas, Alliance Consulting’s
Southwest region, Laureate Pharma’s Totowa facility and CompuCom.
Tangram was consolidated through February 20, 2004 at which time it was sold to Opsware, Inc.
in a stock and debt for stock exchange. The Company recorded an $8.5 million gain on the
transaction, which is included in Other Income, Net in the Consolidated Statements of Operations
for the year ended December 31, 2004.
Principles of Accounting for Ownership Interests in Companies
The Company’s ownership interests in its companies are accounted for under three methods:
consolidation, equity or cost. The applicable accounting method is generally determined based on
the Company’s voting interest in the entity.
Consolidation Method. The partner companies in which the Company directly or indirectly owns
more than 50% of the outstanding voting securities are accounted for under the consolidation method
of accounting. Under this method, these partner companies’ financial statements are included within
the Company’s Consolidated Financial Statements. All significant intercompany accounts and
transactions have been eliminated. Participation of other shareholders in the net assets and in the
income or losses of these consolidated companies is reflected in Minority Interest in the
Consolidated Balance Sheets and Statements of Operations. Minority Interest adjusts the Company’s
consolidated operating results to reflect only the Company’s share of the earnings or losses of the
consolidated partner company. However, if there is no minority interest balance remaining on the
Consolidated Balance Sheets related to the respective company, the Company records 100% of the
consolidated partner company’s losses; the Company records 100% of subsequent earnings of the
partner company to the extent of such previously recognized losses in the excess of the Company’s
proportionate share. The results of operations and cash flows of a consolidated company are
included through the latest interim period in which the Company owned a 50% or greater voting
interest. Upon dilution of control below 50%, the accounting method is adjusted to either the
equity or cost method of accounting.
Equity Method. The partner companies whose results are not consolidated, but over whom the
Company exercises significant influence, are accounted for under the equity method of accounting.
Whether or not the Company exercises significant influence with respect to a partner company
depends on an evaluation of several factors including, among others, representation on the partner
company’s board of directors and ownership level, which is generally a 20% to 50% interest in the
voting securities of a partner company, including voting rights associated with the Company’s
holdings in common, preferred and other convertible instruments in the company. The Company also
accounts for its interests in some private equity funds under the equity method of accounting,
based on its respective general and limited partner interests. Under the equity method of
accounting, a partner company’s financial statements are not reflected within the Company’s
Consolidated Financial Statements, however, the Company’s share of the income or loss of the
partner company is reflected in Equity Loss in the Consolidated Statements of Operations. The
carrying value of equity method companies is included in Ownership Interests In and Advances to
Companies on the Consolidated Balance Sheets. The Company reports its share of the income or loss
of the equity method partner companies on a one quarter lag. This reporting lag could result in a
delay in recognition of the impact of changes in the business or operations of these partner
companies.
73
Table of Contents
SAFEGUARD SCIENTIFICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)
When the Company’s investment in an equity method partner company is reduced to zero, no
further losses are recorded in the Company’s Consolidated Statements of Operations unless the
Company has outstanding guarantee obligations or has committed additional funding to the equity
method company. When the equity method company subsequently reports income, the Company will not
record its share of such income until it equals the amount of the Company’s share of losses not
previously recognized.
Cost Method. Companies not consolidated or accounted for under the equity method are
accounted for under the cost method of accounting. Under the cost method, the Company’s share of
the income or losses of such partner companies is not included in the Company’s Consolidated
Statements of Operations. The carrying value of cost method companies is included in Ownership
Interests In and Advances to Companies on the Consolidated Balance Sheets.
In addition to the Company’s holdings in voting and non-voting equity and debt securities, it
also periodically makes advances to its partner companies in the form of promissory notes which are
accounted for in accordance with Statement of Financial Accounting Standards (SFAS) No. 114,
“Accounting By Creditors for Impairment of a Loan.”
Impairment. On a continuous basis, but no less frequently than at the end of each quarterly
period, the Company evaluates the carrying value of its equity and cost method partner companies
for possible impairment based on achievement of business plan objectives and milestones, the fair
value of each partner company relative to its carrying value, the financial condition and prospects
of the partner company and other relevant factors. The business plan objectives and milestones the
Company considers include, among others, those related to financial performance, such as
achievement of planned financial results or completion of capital raising activities, and those
that are not primarily financial in nature, such as hiring of key employees or the establishment of
strategic relationships. Management then determines whether there has been an other than temporary
decline in the carrying value of its ownership interest in the company. Impairment is measured by
the amount by which the carrying amount of the assets exceeds their fair values.
The fair value of privately held companies is generally determined based on the value at which
independent third parties have invested or have committed to invest in these companies or based on
other valuation methods, including discounted cash flows, valuation of comparable public companies
and the valuation of acquisitions of similar companies. The fair value of the Company’s ownership
interests in private equity funds is generally determined based on the value of its pro rata
portion of the fair value of the funds’ net assets.
Impairment charges related to goodwill of consolidated partner companies are included in
Goodwill Impairment in the Consolidated Statements of Operations. Impairment charges related to
equity method companies are included in Equity Loss in the Consolidated Statements of Operations.
Impairment charges related to cost method companies are included in Other Income, Net in the
Consolidated Statements of Operations.
The new cost basis of a company is not written-up if circumstances suggest the value of the
company has subsequently recovered.
Accounting Estimates
The preparation of the Consolidated Financial Statements in accordance with accounting
principles generally accepted in the United States of America requires management to make estimates
and judgments that affect amounts reported in the financial statements and accompanying notes.
Actual results may differ from these estimates. These estimates include the evaluation of the
recoverability of the Company’s ownership interests in and advances to companies and investments in
marketable securities, the evaluation of the recoverability of goodwill, intangible assets and
property and equipment, revenue recognition, income taxes, stock-based compensation and commitments
and contingencies.
74
Table of Contents
SAFEGUARD SCIENTIFICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)
Certain amounts recorded to reflect the Company’s share of losses of companies accounted for
under the equity method are based on unaudited results of operations of those companies and may
require adjustments in the future when audits of these entities’ financial statements are made
final.
It is reasonably possible that the Company’s accounting estimates with respect to the ultimate
recoverability of the carrying value of the Company’s ownership interests in and advances to
companies, goodwill and intangible assets and the estimated useful life of amortizable intangible
assets could change in the near term and that the effect of such changes on the financial
statements could be material. At December 31, 2006, the Company believes the recorded amount of
carrying value of the Company’s ownership interests in and advances to companies, goodwill and
intangible assets is not impaired, although there can be no assurance that the Company’s future
results will confirm this assessment, that a significant write-down or write-off will not be
required in the future, or that a significant loss will not be recorded in the future upon the sale
of a company.
Reclassifications
Certain prior year amounts have been reclassified to conform to the current year presentation
including the reclassification to discontinued operations of Mantas which was sold in October 2006,
Alliance Consulting’s Southwest region which was sold in May 2006, Laureate Pharma’s Totowa, New
Jersey operation which was sold in December 2005 and CompuCom which was sold in October 2004. The
impact of these reclassifications did not affect the Company’s net income (loss).
The Company has separately disclosed the operating, investing and financing portions of the
cash flows attributable to its discontinued operations. Included in these amounts were net cash
flows of $0.1 million, $0.7 million and $2.2 million in 2006, 2005 and 2004, respectively,
attributable to Alliance Consulting’s Southwest region and the Laureate Pharma Totowa operation.
Because these businesses did not maintain separate bank accounts, any net cash provided by (used
in) these businesses increased (decreased) the cash and cash equivalents balance of the Company’s
continuing operations as shown on the Consolidated Balance Sheets. Cash flows related to Mantas in
2006, 2005, and 2004 and CompuCom in 2004 are adjusted in our Statement of Cash Flows to reconcile
to cash and cash equivalents associated with continuing operations.
Cash and Cash Equivalents, Short-Term Marketable Securities and Restricted Cash
The Company considers all highly liquid instruments with an original maturity of 90 days or
less at the time of purchase to be cash equivalents. Cash and cash equivalents consist of deposits
that are readily convertible into cash. The Company determines the appropriate classification of marketable securities at the time of
purchase and reevaluates such designation as of each balance sheet date. Held-to-maturity
securities are carried at amortized cost, which approximates fair value. Short-term marketable
securities consist of held-to-maturity securities, primarily consisting of commercial paper and
certificates of deposits. Restricted cash is primarily invested in money market instruments.
Restricted Marketable Securities
Restricted marketable securities include held-to-maturity securities, as it is the Company’s
ability and intent to hold these securities to maturity. The securities are U.S. Treasury
securities with various maturity dates. Pursuant to terms of the 2.625% convertible senior
debentures due March 15, 2024 (“2024 Debentures”) as a result of the sale of CompuCom in 2004, the
Company pledged the securities to an escrow agent for interest payments through March 15, 2009 on
the 2024 Debentures resulting in their classification as restricted on the Consolidated Balance
Sheets (See Note 4).
75
Table of Contents
SAFEGUARD SCIENTIFICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)
Long-Term Marketable Securities
The Company records its ownership interest in cost method equity securities that have readily
determinable fair value as available-for-sale or trading securities in accordance with SFAS No.
115, “Accounting for Certain Investments in Debt and Equity Securities.” Available-for-sale
securities are carried at fair value, based on quoted market prices, with the unrealized gains and
losses, net of tax, reported as a separate component of shareholders’ equity. Unrealized losses
are charged against net loss when a decline in the fair value is determined to be other than
temporary. Trading securities are carried at fair value, based on quoted market prices, with the
unrealized gain or loss included in Other Income, Net, in the Consolidated Statements of
Operations. The Company records its ownership interest in debt securities at amortized cost because
it has the ability and intent to hold these securities until maturity.
Financial Instruments
The Company’s financial instruments, principally cash and cash equivalents, restricted cash,
marketable securities, restricted marketable securities, accounts receivable, notes receivable,
accounts payable, and accrued expenses are carried at cost which approximates fair value due to the
short-term maturity of these instruments. The Company’s long-term debt is carried at cost which
approximates fair value as the debt bears interest at rates approximating current market rates. At
December 31, 2006, the market value of the Company’s 2024 Debentures was approximately $104 million
based on quoted market prices.
Property and Equipment
Property and equipment are stated at cost. Equipment under capital leases is stated at the
present value of minimum lease payments. Provision for depreciation and amortization is based on
the lesser of the estimated useful lives of the assets or the remaining lease term (buildings and
leasehold improvements, 5 to 15 years; machinery and equipment, 3 to 15 years) and is computed
using the straight-line method.
Intangible Assets, net
Intangible assets with indefinite useful lives are not amortized but instead are tested for
impairment at least annually, in accordance with SFAS No. 142, “Goodwill and Other Intangible
Assets.” Intangible assets with definite useful lives are amortized over their respective
estimated useful lives to their estimated residual value.
Purchased in-process research and development (“IPR&D”) represents the value assigned in a
purchase business combination to research and development projects of the acquired business that
had commenced but had not yet been completed at the date of acquisition and which have no
alternative future use. In accordance with SFAS No. 2, “Accounting for Research and Development
Costs,” as clarified by FASB Interpretation No. 4, “Applicability of FASB Statement No. 2 to
Business Combinations Accounted for by the Purchase Method,” amounts assigned to IPR&D meeting the
above criteria must be charged to expense as part of the allocation of the purchase price of the
business combination.
Goodwill
Goodwill is tested for impairment at least annually, in accordance with SFAS No. 142.
76
Table of Contents
SAFEGUARD SCIENTIFICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)
Impairment of Long-Lived Assets and Long-Lived Assets to Be Disposed of
In accordance with SFAS No. 144, “Accounting for the Impairment or Disposal of Long-Lived
Assets,” the Company reviews long-lived assets, including property and equipment and amortizable
intangibles, for impairment whenever events or changes in circumstances indicate that the carrying
amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured
by a comparison of the carrying amount of an asset to forecasted undiscounted cash flows expected
to be generated by the asset. If such assets are considered to be impaired, the impairment to be
recognized is measured by the amount by which the carrying amount of the assets exceeds the fair
value of the assets.
Recoverability of Note Receivable — Related Party
The Company evaluates the recoverability of its Note Receivable — Related Party in accordance
with SFAS No. 114 “Accounting by Creditors for Impairment of a Loan — an Amendment of FASB
Statements No. 5 and 15”. Under SFAS No. 114, a loan is impaired when, based on current information
and events, it is probable that a creditor will be unable to collect all amounts due according to
the contractual terms of the loan agreement. Impairment charges are included in Recovery
(Impairment) — Related Party in the Consolidated Statements of Operations. The Company does not
accrue interest when a note is considered impaired. All cash receipts from impaired notes are
applied to reduce the original principal amount of such note until the principal has been fully
recovered, and would be recognized as interest income thereafter. Cash receipts in excess of the
carrying value of the note are recognized as a reduction of impairment expense until such time that
the original principal has been recovered.
Deferred Revenue
Deferred revenue represents cash collections on contracts in advance of performance of
services or delivery of products and is recognized as revenue when the related services are
performed or products are delivered.
Revenue Recognition
During 2006, 2005 and 2004, the Company’s revenue from continuing operations was primarily
attributable to Acsis (since December 2005), Alliance Consulting, Clarient, Laureate Pharma (since
December 2004) and Pacific Title.
Acsis generates revenue from (i) software fees, which consist of revenue from the licensing of
software, (ii) services revenue, which consist of fees from consulting, implementation and
training services, plus customer support services; and (iii) hardware and reimbursed project
expenses.
Acsis recognizes software fees in accordance with Statement of Position No. 97-2, “Software
Revenue Recognition” (“SOP 97-2”), as amended. Although Acsis follows specific and detailed
guidelines in measuring revenue, the application of those guidelines requires judgment including:
(i) whether a software arrangement includes multiple elements, and if so, whether vendor-specific
objective evidence of fair value exists for those elements; (ii) whether customizations or
modifications of the software are significant; and (iii) whether collection of the software fee is
probable. Additionally, Acsis specifically evaluates any other terms in its license transactions,
including by not limited to, options to purchase additional software at a future date, extended
payment terms and functionality commitments not delivered with the software. Acsis recognizes
software license revenue when the following criteria are met: (1) a signed contract is obtained;
(2) delivery of the products has occurred; (3) the license fee is fixed or determinable; and (4)
collectibility is probable. Acsis generally recognizes license revenue using the “residual method”
when there is vendor-specific objective evidence of the fair values of all undelivered elements in
a multiple-element arrangement that is not accounted for using long-term contract accounting. For
those contracts that contain significant customization or modifications, license revenue is
recognized using the percentage-of-completion method.
77
Table of Contents
SAFEGUARD SCIENTIFICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)
Most of Acsis’ software arrangements include professional services. Acsis provides
professional services under service agreements on a time and material-basis or based on a
fixed-price arrangement. The revenues from Acsis’ time and material based professional consulting
and implementation services are recognized as the work is performed, provided that the customer has
a contractual obligation to pay, the fee is non-refundable and collection is probable. Delays in
project implementation will result in delays in revenue recognition. Acsis recognizes revenues
from professional consulting services under fixed-price arrangements using the
proportional-performance method based on direct labor costs incurred to date as a percentage of
total estimated labor costs required to complete the project. Revisions to the estimates are
reflected in the period in which changes become known. Project losses are provided for in their
entirety in the period they become known, without regard to the percentage-of-completion. If Acsis
does not accurately estimate the resources required or the scope of work to be performed, or if
Acsis does not manage their projects properly within the planned periods of time, then future
consulting margins on its projects may be negatively affected or losses on existing contracts may
need to be recognized.
Hardware revenue is generated from the resale of a variety of hardware products, developed and
manufactured primarily by third parties, which are integrated with and complementary to Acsis’
software solutions. These products include computer equipment, RFID chip readers, bar code
printers and scanners and other peripherals. Acsis generally purchase hardware from its vendors
only after receiving an order from a customer, and revenue is recognized upon shipment by the
vendor to the customer unless the hardware is an element in an arrangement that includes services
that involve significant customization or modifications to software, in which case, hardware
revenue is bundled with the software and services are recognized on a percentage-of-completion
basis.
Alliance Consulting generates revenue primarily from consulting services. Alliance Consulting
generally recognizes revenue when persuasive evidence of an arrangement exists, services are
performed, the service fee is fixed or determinable and collectibility is probable. Revenue from
services is recognized as services are performed. Alliance Consulting also performs certain
services under fixed-price service contracts related to discrete projects. Alliance Consulting
recognizes revenue from these contracts using the percentage-of-completion method, primarily based
on the actual labor hours incurred to date compared to the estimated total hours of the project.
Any losses expected to be incurred on jobs in process are charged to income in the period such
losses become known. Changes in estimates of total costs could result in changes in the amount of
revenue recognized.
Clarient generates revenue from diagnostic services, system sales and fee-per-use charges.
Clarient recognizes revenue for diagnostic services at the time of completion of services at
amounts equal to the contractual rates allowed from third parties including Medicare, insurance
companies and, to a small degree, private patients. These expected amounts are based both on
Medicare allowable rates and Clarient’s collection experience with other third party payors.
Clarient recognizes revenue for fee-per-use agreements based on the greater of actual usage fees or
the minimum monthly rental fee. Under this pricing model, Clarient owns most of the
ACIS instruments that are engaged in service and, accordingly, all related depreciation
and maintenance and service costs are expensed as incurred.
Revenue for instruments that are sold
is recognized and deferred using the residual method pursuant to the requirements of
Statement of Position No. 97-2, “Software Revenue Recognition” (SOP 97-2), as amended by Statement
of Position No. 98-9, “Modification of SOP 97-2, Software Revenue Recognition with Respect to
Certain Arrangements.” At the outset of the arrangement with the customer, Clarient defers revenue
for the fair value of its undelivered elements (e.g., maintenance) and recognizes revenue for the
remainder of the arrangement fee attributable to the elements initially delivered in the
arrangement (e.g., software license) when the basic criteria in SOP 97-2 have been met. Maintenance
revenue is recognized ratably over the term of the maintenance contract, typically twelve months.
78
Table of Contents
SAFEGUARD SCIENTIFICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)
Systems sold under a leasing arrangement are
accounted for as sales-type leases pursuant to SFAS No. 13, “Accounting for Leases,” if applicable.
Clarient recognizes the net effect of these transactions as a sale because of the bargain purchase
option granted to the lessee.
Clarient has entered into a distribution and
development agreement with Dako, which includes multiple elements. Those elements include distribution rights,
ACIS instruments,
research and development services, training and maintenance. The agreement calls for an upfront payment and additional payments as
instruments are delivered or milestones are achieved under the research and development component. Clarient accounts for this arrangement
under the percentage-of-completion method using the zero profit margin approach. Under this approach, revenue is recognized in amounts
equal to the costs incurred to provide the products and services. Clarient further limits the amount of revenue recognized to the amount of
fees that are fixed or determinable under the agreement. Because Clarient does not have evidence of fair value for certain elements that
span the term of the agreement, the profit earned will be recognized over the remaining term of the agreement once the research and
development services are complete. As of December 31, 2006, the research and development services were ongoing.
Laureate Pharma’s revenue is primarily derived from contract manufacturing work, process
development services, and formulation and filling. Laureate Pharma enters into revenue
arrangements with multiple deliverables in order to meet its customers’ needs. Multiple element
revenue agreements are evaluated under Emerging Issues Task Force (“EITF”) Issue Number 00-21,
“Revenue Arrangements with Multiple Deliverables,” to determine whether the delivered item has
value to the customer on a stand-alone basis and whether objective and reliable evidence of the
fair value of the undelivered item exists. Deliverables in an arrangement that do not meet the
separation criteria in EITF 00-21 are treated as one unit of accounting for purposes of revenue
recognition. Revenue is generally recognized upon the performance of services. Certain services
are performed under fixed price contracts. Revenue from these contracts are recognized on a
percentage-of-completion basis. When current cost estimates indicate a loss is expected to be
incurred, the entire loss is recorded in the period in which it is identified.
Pacific Title’s revenue is primarily derived from providing archival, title and special
effects services to the motion picture and television industry. Revenue is generally recognized
upon the performance of services. Certain services are performed under fixed price contracts.
Revenue from these contracts are recognized on a percentage-of-completion basis based on costs
incurred to total estimated costs to be incurred. Any anticipated losses on contracts are expensed
when identified.
Defined Contribution Plans
Defined contribution plans are contributory and cover eligible employees of the Company and
certain subsidiaries. The Company’s defined contribution plan allows eligible employees, as defined
in the plan, to contribute to the plan up to 75% of their pre-tax compensation, subject to the
maximum contributions allowed by the Internal Revenue Code. The Company determines the amount, if
any, of the employer-paid matching contribution at the end of each calendar year. Additionally, the
Company may make annual discretionary contributions under the plan based on a participant’s
eligible compensation. Certain subsidiaries also generally match from 25% to 50% of the first 3% to
6% of employee contributions to these plans. Amounts expensed relating to all plans were $0.9
million in 2006, $0.8 million in 2005 and $0.5 million in 2004.
79
Table of Contents
SAFEGUARD SCIENTIFICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)
Income Taxes
Income taxes are accounted for in accordance with SFAS No. 109, “Accounting for Income Taxes”,
under the asset and liability method whereby deferred tax assets and liabilities are recognized for
the estimated future tax consequences attributable to differences between the financial statement
carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax
assets and liabilities are measured using enacted tax rates in effect for the year in which the
temporary differences are expected to be recovered or settled. The effect on deferred tax assets
and liabilities of a change in tax rates is recognized in income in the period that includes the
enactment date. Management provides valuation allowances against the net deferred tax asset for
amounts which are not considered more likely than not to be realized.
Net Income (Loss) Per Share
Net income (loss) per share (EPS) is computed using the weighted average number of common
shares outstanding during each year. Diluted EPS includes common stock equivalents (unless
anti-dilutive) which would arise from the exercise of stock options and conversion of other
convertible securities and is adjusted, if applicable, for the effect on net income (loss) of such
transactions. Diluted EPS calculations adjust net income (loss) for the dilutive effect of common
stock equivalents and convertible securities issued by the Company’s public subsidiaries or equity
companies.
Comprehensive Income (Loss)
Comprehensive income (loss) is the change in equity of a business enterprise during a period
from non-owner sources. Excluding net income (loss), the Company’s sources of other comprehensive
income (loss) are from net unrealized appreciation (depreciation) on available-for-sale securities
and foreign currency translation adjustments. Reclassification adjustments result from the
recognition in net income (loss) of unrealized gains or losses that were included in comprehensive
income (loss) in prior periods.
Segment Information
The Company reports segment data based on the management approach which designates the
internal reporting which is used by management for making operating decisions and assessing
performance as the source of the Company’s reportable operating segments.
New Accounting Pronouncements
In September 2006, the United States Securities and Exchange Commission issued Staff
Accounting Bulletin No. 108, “Considering the Effects of Prior Year Misstatements when Quantifying
Misstatements in Current Year Financial Statements” (“SAB 108”). SAB 108 requires companies to
evaluate the materiality of identified unadjusted errors using both the income statement approach
and the balance sheet approach. In the initial year of adoption, if a company determines that an
adjustment to prior year financial statements is required under either approach, SAB 108 allows for
a one-time cumulative-effect adjustment to beginning retained earnings. SAB 108 is effective for
interim periods of the first fiscal year ending after November 15, 2006. The adoption of SAB No.
108 did not have an impact on the Company’s consolidated financial position, results of operations
or cash flows.
In September 2006, the FASB issued SFAS No. 157, “Fair Value Measurements” (“SFAS No. 157”).
SFAS No. 157 defines fair value, establishes a framework for measuring fair value in generally
accepted accounting principles and expands disclosures about fair value measurements. SFAS No. 157
is effective for financial statements issued for fiscal years beginning after November 15, 2007,
and interim periods within those fiscal years. The Company does not expect the adoption of SFAS
No. 157 to have a material impact on its financial statements.
80
Table of Contents
SAFEGUARD SCIENTIFICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)
In July 2006, the FASB issued FASB Interpretation No. 48, “Accounting for Uncertainty in
Income Taxes” (“FIN 48”). FIN 48 defines the threshold for recognizing the benefits of tax return
positions in the financial statements as “more-likely-than-not” to be sustained upon examination by
the applicable taxing authority. FIN 48 also includes guidance concerning accounting for income tax
uncertainties in interim periods and increases the level of disclosures associated with any
recorded income tax uncertainties. FIN 48 is effective for fiscal years beginning after December
15, 2006. The Company does not believe adoption of FIN 48 will have a material effect on its
consolidated financial position, results of operations or cash flows and will consist of
reclassification of certain income tax-related liabilities.
In November 2005, the FASB issued FASB Staff Position SFAS 123(R)-3, “Transition Election
Related to Accounting for the Tax Effects of Share-based Payment Awards”, that provides an elective
alternative transition method of calculating the pool of excess tax benefits available to absorb
tax deficiencies recognized subsequent to the adoption of SFAS No. 123(R) (the “APIC Pool”) to the
method otherwise required by paragraph 81 of SFAS No. 123(R). In the fourth quarter of 2006, the
Company adopted the short-cut method to calculate the APIC Pool.
In December 2004, the FASB issued SFAS No. 123 (revised 2004), “Share-Based Payment” (“SFAS
No. 123(R)”). SFAS No. 123(R) requires companies to measure all employee stock-based compensation
awards using a fair value method and record such expense in its consolidated financial statements.
In addition, the adoption of SFAS No. 123(R) requires additional accounting and disclosure related
to the income tax and cash flow effects resulting from share-based payment arrangements. The
Company adopted SFAS No. 123(R) on January 1, 2006 using the modified prospective method. See Note
12.
2. Discontinued Operations
Mantas
In October 2006, the Company completed the sale of its interest in Mantas for net cash
proceeds of approximately $112.8 million, including $19.3 million held in escrow. The Company
recorded a pre-tax gain of $83.9 million in the fourth quarter of 2006. Mantas is reported in
discontinued operations for all periods presented. Mantas sold its telecommunications business and
certain related assets and liabilities in the first quarter of 2006 for $2.1 million in cash. As a
result of the sale, Mantas recorded a gain of $1.9 million in the first quarter of 2006 which is
also reported in discontinued operations. Goodwill of $19.9 million related to Mantas was included
in discontinued operations.
Alliance Consulting — Southwest Region
Alliance Consulting completed the sale of its Southwest region in May 2006 for proceeds of
$4.5 million, including cash of $3.0 million and stock of the acquiror of $1.5 million which was
subsequently sold. As a result of the sale, Alliance Consulting recorded a gain of $1.6 million in
the second quarter of 2006. Alliance Consulting’s Southwest region is reported in discontinued
operations for all periods presented. Goodwill of $3.0 million related to the Southwest region was
included in discontinued operations.
Laureate Pharma — Totowa Facility
In December 2005, Laureate Pharma sold its Totowa operations for $16.0 million in cash.
Laureate Pharma recognized a $7.7 million gain on the transaction. The Totowa facility is reported
in discontinued operations in 2005.
CompuCom
In October 2004, the Company completed the sale of its interest in CompuCom for approximately
$128 million in gross cash proceeds. The Company recorded a gain on the sale of approximately
$1.8 million in 2004.
81
Table of Contents
SAFEGUARD SCIENTIFICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)
In connection with the sale:
| • | The Company provided a $6.3 million letter of credit to the landlord of CompuCom’s Dallas headquarters lease which will expire on March 19, 2019. | ||
| • | In October 2004, the Company used approximately $16.7 million of the proceeds to escrow interest payments due through March 15, 2009, on the Company’s 2024 Debentures pursuant to the terms of the 2024 Debentures. A total of $9.6 million is included in Restricted Marketable Securities on the Consolidated Balance Sheet at December 31, 2006, of which $3.9 million is classified as a current asset. See Note 4. |
In connection with this transaction the Company recognized in the Consolidated Financial
Statements goodwill impairment of $42.7 million, comprising $33.4 million recorded by CompuCom in
its operating results and $9.3 million recorded by the Company, which is reported within
discontinued operations for the year ended December 31, 2004.
Results of the discontinued operations were as follows:
| Year Ended December 31, | ||||||||||||
| 2006 | 2005 | 2004 | ||||||||||
| (in thousands) | ||||||||||||
Revenue |
$ | 29,476 | $ | 49,223 | $ | 983,501 | ||||||
Operating expenses |
(27,050 | ) | (50,813 | ) | (983,636 | ) | ||||||
Goodwill impairment |
— | — | (42,719 | ) | ||||||||
Other |
84 | (29 | ) | (1,488 | ) | |||||||
Income (loss) before income taxes
and minority interest |
2,510 | (1,619 | ) | (44,342 | ) | |||||||
Income tax (expense) benefit |
(228 | ) | (40 | ) | 2,928 | |||||||
Income (loss) before minority interest |
2,282 | (1,659 | ) | (41,414 | ) | |||||||
Minority interest |
— | — | 10,137 | |||||||||
Net income (loss) from operations |
2,282 | (1,659 | ) | (31,277 | ) | |||||||
Gain on disposal, net of tax |
87,528 | 7,697 | 1,798 | |||||||||
Income (loss) from discontinued operations, net of
tax |
$ | 89,810 | $ | 6,038 | $ | (29,479 | ) | |||||
82
Table of Contents
SAFEGUARD SCIENTIFICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)
The assets and liabilities of discontinued operations were as follows:
| December 31, 2005 | ||||
| (in thousands) | ||||
Cash |
$ | 2,637 | ||
Restricted cash |
250 | |||
Accounts receivable, less allowances |
8,752 | |||
Other current assets |
624 | |||
Total current assets |
12,263 | |||
Property and equipment, net |
1,954 | |||
Intangibles |
306 | |||
Goodwill |
22,867 | |||
Other assets |
3,568 | |||
Total non-current assets |
28,695 | |||
Total Assets |
$ | 40,958 | ||
Current debt |
$ | 1,506 | ||
Accounts payable |
1,022 | |||
Accrued expenses |
4,474 | |||
Deferred revenue |
5,716 | |||
Total current liabilities |
12,718 | |||
Other long-term liabilities |
956 | |||
Total Liabilities |
$ | 13,674 | ||
Carrying value |
$ | 27,284 | ||
3. Business Combinations
Acquisitions by the Company — 2006
In November 2006, the Company acquired 32% of Advantedge Healthcare Solutions (“AHS”) for $5.8
million in cash. AHS is a New York based technology-enabled service provider that delivers medical
billing services to physician groups. The Company accounts for its holdings in AHS under the
equity method.
In September 2006,
the Company acquired additional common shares of Clarient for $3 million
in cash to fund Clarient’s acquisition of Trestle Holdings, Inc. (“Trestle”). As a result of the
funding, the Company’s ownership in Clarient increased to 60%. The difference between the
Company’s cost and its interest in the underlying net assets of Clarient has been allocated to
intangible assets of $0.8 million with estimated useful lives of 5 years and to fixed assets of
$0.2 million with estimated depreciable lives of 3 years.
In September 2006, the Company acquired 24% of NuPathe, Inc. for $3 million in cash. NuPathe
develops therapeutics in conjunction with novel transdermal delivery technologies. The Company
accounts for its holdings in NuPathe under the equity method. The difference between the Company’s
cost and its interest in the underlying net assets of NuPathe has been allocated to
in-process-research and development resulting in a $1.0 million charge, which is reflected in
Equity loss in the Consolidated Statement of Operations for 2006 and goodwill as reflected in the
carrying value in Ownership interests in and advances to companies on the Consolidated Balance
Sheet.
In August 2006, the Company acquired 47% of Portico Systems (“Portico”) for $6 million in
cash. Portico is a software solutions provider for regional and national health plans looking to
optimize provider network operations and streamline business processes. The Company accounts for
its holdings in Portico under the equity method. The difference between the Company’s cost and its
interest in the underlying net assets of Portico has been allocated to intangible assets and
goodwill, as reflected in the carrying value in Ownership interests in and advances to companies on
the Consolidated Balance Sheet.
83
Table of Contents
SAFEGUARD SCIENTIFICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)
In August 2006, the Company acquired 36% of Rubicor Medical, Inc. (“Rubicor”) for $20 million
in cash. Rubicor develops and distributes technologically advanced, disposable, minimally-invasive
breast biopsy devices. The Company accounts for its holdings in Rubicor under the equity method.
The difference between the Company’s cost and its interest in the underlying net assets of Rubicor
has been allocated to in-process-research and development resulting in a $0.6 million charge, which
is reflected in Equity loss in the Consolidated Statement of Operations for 2006 and intangible
assets as reflected in the carrying value in Ownership interests in and advances to companies on
the Consolidated Balance Sheet.
In June 2006, the Company acquired additional common shares of Acsis for an aggregate purchase
price of $6 million in cash at the same per share value as the December 2005 acquisition. The
result of the June 2006 incremental equity purchase was an increase in ownership in Acsis to 96%.
The capital provided is being used by Acsis to support its long-term growth strategy.
In April 2006, the Company acquired 12% of Authentium, Inc. for $5.5 million in cash.
Autentium is a provider of security software to internet service providers. The Company accounts
for its holdings in Authentium under the cost method.
Acquisitions by the Company — 2005
In December 2005, the Company acquired 94% of Acsis, Inc. for approximately $26 million in
cash plus options with a fair market value of $1.7 million. Acsis provides enterprise data
collection solutions to global manufacturers. The Acsis transaction was accounted for as a
purchase and, accordingly, the Consolidated Financial Statements reflect the operations of Acsis
from the acquisition date.
The following table summarizes the fair values of assets acquired and liabilities assumed:
| Acsis | ||||
| (In thousands) | ||||
Working capital |
$ | 4,265 | ||
Property and equipment |
1,263 | |||
Intangible assets |
8,366 | |||
Purchased in-process research and development |
1,974 | |||
Goodwill |
11,534 | |||
Total purchase price |
$ | 27,402 | ||
The intangible assets of Acsis consist of a covenant not-to-compete, with a one year
life, developed technology, with a three year life, customer-related intangibles with a 10 year
life, and a tradename with a 20 year life. Property and equipment are being depreciated over their
weighted average lives (3 years to 5 years). The acquired in-process research and development
costs were charged to earnings in 2005.
In November 2005, Clarient entered into a securities purchase agreement with a limited number
of accredited investors pursuant to which Clarient agreed to issue shares of common stock and
warrants to purchase additional shares of common stock for an aggregate purchase price of $15
million. Of the total placement of $15 million, the Company funded $9 million to Clarient. The
Company participated in the private placement to support the diagnostic services business line
expansion as well as maintaining the Company’s controlling interest. Of the total purchase price,
$8.4 million was allocated to working capital, $0.2 million was allocated to property and
equipment, $0.2 million was allocated to intangible assets and $0.2 million was allocated to
in-process research and development.
In April and June 2005, the Company acquired additional shares of Pacific Title from minority
shareholders for a total of $1.3 million, increasing its ownership in Pacific Title from 93% to
100%. Of the total purchase price, $1.2 million was allocated to working capital and $0.1 million
was allocated to property and equipment.
84
Table of Contents
SAFEGUARD SCIENTIFICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)
Acquisitions by Subsidiaries
Acquisitions by Subsidiaries — 2006
In September 2006, Clarient completed the purchase of substantially all of the assets of
Trestle Holdings, Inc. (“Trestle”) for approximately $3.4 million of cash, assumed liabilities and
transaction costs.
In July 2006, Alliance Consulting completed the acquisition of Fusion Technologies for $5.6
million including $5.3 million in cash and $0.3 million in its stock.
The companies have not completed the allocations of purchase price for the acquisitions listed
above. The following table summarizes the estimated fair values of assets acquired and liabilities
assumed:
| Alliance | ||||||||
| Consulting | Clarient | |||||||
| (In thousands) | ||||||||
Working capital |
$ | 70 | $ | (34 | ) | |||
Property and equipment |
443 | 76 | ||||||
Intangible assets |
730 | 2,820 | ||||||
Goodwill |
4,373 | 550 | ||||||
Total purchase price |
$ | 5,616 | $ | 3,412 | ||||
The intangible assets acquired by Alliance Consulting consist of customer lists with a seven
year life and property and equipment which are being depreciated over their weighted average lives
(3 to 5 years). The intangible assets acquired by Clarient consist of developed technology with a
7 to 10 year life, a tradename with a 10 year life and other which consists of customer
relationships and service with 10 to 15 year lives. Property and equipment of Clarient are being
depreciated over their weighted average lives (3 years).
In October 2004, Alliance Consulting acquired 100% of the issued and outstanding stock of
Mensamind, Inc. for approximately $2.1 million, of which $0.9 million was payable in cash and the
remaining $1.2 million in issuance of Alliance Consulting stock options, and transaction costs.
Mensamind provides offshore IT consulting services. The Company has completed the allocation of
purchase price for the acquisition of Mensamind. The following summarizes the fair values of
assets and liabilities assumed.
| (in thousands) | ||||
Working capital |
$ | (850 | ) | |
Property and equipment |
232 | |||
Intangible assets |
1,500 | |||
Goodwill |
1,327 | |||
Total purchase price |
$ | 2,209 | ||
85
Table of Contents
SAFEGUARD SCIENTIFICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)
Pro Forma Financial Information
The following unaudited pro forma financial information presents the combined results of
operations of the Company as if the acquisitions had occurred as of the beginning of the periods
presented, after giving effect to certain adjustments, including amortization of intangibles with
definite useful lives. The pro forma results of operations are not indicative of the actual results
that would have occurred had the acquisitions been consummated at the beginning of the period
presented and are not intended to be a projection of future results.
| Year Ended December 31, | ||||||||
| 2006 | 2005 | |||||||
| (In thousands except per | ||||||||
| share data) | ||||||||
Total revenues |
$ | 205,698 | $ | 174,899 | ||||
Net loss from continuing operations |
$ | (45,132 | ) | $ | (41,870 | ) | ||
Net loss per share from continuing operations — basic and diluted |
$ | (0.37 | ) | $ | (0.35 | ) | ||
4. Marketable Securities
Marketable securities included the following:
| Current | Non Current | |||||||||||||||
| 2006 | 2005 | 2006 | 2005 | |||||||||||||
| (in thousands) | (in thousands) | |||||||||||||||
Held-to-maturity: |
||||||||||||||||
Certificates of deposit |
$ | — | $ | 12,289 | $ | — | $ | — | ||||||||
U.S. Treasury securities |
— | 2,845 | — | |||||||||||||
Mortgage and asset-backed securities |
— | 2,457 | — | — | ||||||||||||
Commercial paper |
94,155 | 14,179 | — | — | ||||||||||||
| 94,155 | 31,770 | — | — | |||||||||||||
Restricted U.S. Treasury securities |
3,869 | 3,805 | 5,737 | 9,457 | ||||||||||||
| 98,024 | 35,575 | 5,737 | 9,457 | |||||||||||||
Available-for-sale: |
||||||||||||||||
Equity securities |
— | — | 487 | 3,311 | ||||||||||||
| $ | 98,024 | $ | 35,575 | $ | 6,224 | $ | 12,768 | |||||||||
As of December 31, 2006, the contractual maturities of securities were as follows:
| Years to Maturity | ||||||||||||||||
| (in thousands) | ||||||||||||||||
| Less Than | One to | No Single | ||||||||||||||
| One Year | Five Years | Maturity Date | Total | |||||||||||||
Held-to-maturity |
$ | 98,024 | $ | 5,737 | $ | — | $ | 103,761 | ||||||||
Available-for-sale |
— | — | 487 | 487 | ||||||||||||
| $ | 98,024 | $ | 5,737 | $ | 487 | $ | 104,248 | |||||||||
As of December 31, 2006 and December 31, 2005, the Company’s investment in available-for-sale
securities had generated, on a cumulative basis, unrealized gains of $0.5 million and $3.3 million,
respectively, which are reflected in Accumulated Other Comprehensive Income on the Consolidated
Balance Sheets. For the year ended December 31, 2006, the Company recorded unrealized losses of
$0.6 million, associated with the Company’s investment in trading securities (sold in the fourth
quarter of 2006), which are reflected in Other Income, Net in the Consolidated Statements of
Operations.
86
Table of Contents
SAFEGUARD SCIENTIFICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)
5. Property and Equipment
Property and equipment consisted of the following:
| As of December 31, | ||||||||
| 2006 | 2005 | |||||||
| (In thousands) | ||||||||
Building and improvements |
$ | 23,484 | $ | 17,483 | ||||
Machinery and equipment |
64,685 | 57,894 | ||||||
| 88,169 | 75,377 | |||||||
Accumulated depreciation and amortization |
(43,280 | ) | (37,638 | ) | ||||
| $ | 44,889 | $ | 37,739 | |||||
6. Ownership Interests in and Advances to Companies
The following summarizes the carrying value of the Company’s ownership interests in and
advances to companies and funds accounted for under the equity method or cost method of accounting.
| As of December 31, | ||||||||
| 2006 | 2005 | |||||||
| (In thousands) | ||||||||
Equity Method: |
||||||||
Companies |
$ | 32,155 | $ | — | ||||
Private Equity Funds |
5,290 | 5,877 | ||||||
| 37,445 | 5,877 | |||||||
Cost Method: |
||||||||
Companies |
14,283 | 9,557 | ||||||
Private Equity Funds |
2,820 | 2,463 | ||||||
| $ | 54,548 | $ | 17,897 | |||||
In 2005, the Company sold certain interests in private equity funds and recorded a gain of $7
million. Following the sale, the Company retained an indirect interest in certain publicly-traded
securities held by a private equity fund and the carried interest in a portion of its general
partner interest in certain funds. During 2006, the Company received a distribution of the
publicly-traded securities and sold these securities for a gain of $0.1 million.
In 2004, the Company recorded impairment charges totaling $3.7 million for companies and funds
accounted for under the equity method. Impairment charges related to cost method companies were
$1.4 million and $3.2 million for the years ended December 31, 2005 and 2004, respectively. The
amount of each impairment charge was determined by comparing the carrying value of the company to
its estimated fair value. Impairment charges associated with equity method companies are included
in Equity Loss in the Consolidated Statements of Operations. Impairment charges related to cost
method companies are included in Other Income, Net in the Consolidated Statements of Operations.
87
Table of Contents
SAFEGUARD SCIENTIFICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)
The following unaudited summarized financial information for our companies and funds accounted
for under the equity method at December 31, 2006 and 2005 and for the three years ended December
31, 2006, 2005 and 2004, has been compiled from the unaudited financial statements of our
respective companies and funds and reflects certain historical adjustments. Revenue and net loss of
the companies and funds are excluded for periods prior to their acquisition and subsequent to their
disposition.
| As of December 31, | ||||||||
| 2006 | 2005 | |||||||
| (In thousands) | ||||||||
Balance Sheets: |
||||||||
Current assets |
$ | 41,025 | $ | 37,871 | ||||
Non-current assets |
104,413 | 121,190 | ||||||
Total Assets |
$ | 145,438 | $ | 159,061 | ||||
Current liabilities |
$ | 6,021 | $ | 20,133 | ||||
Non-current liabilities |
310 | 1,436 | ||||||
Shareholders’ equity |
139,107 | 137,492 | ||||||
Total Liabilities and Shareholders’ Equity |
$ | 145,438 | $ | 159,061 | ||||
| Year Ended December 31, | ||||||||||||
| 2006 | 2005 | 2004 | ||||||||||
| (In thousands) | ||||||||||||
Results of Operations: |
||||||||||||
Revenue |
$ | 956 | $ | 14,772 | $ | 7,509 | ||||||
Net Loss |
$ | (25,544 | ) | $ | (35,302 | ) | $ | (64,713 | ) | |||
The Company reports its share of the income or loss of the equity method partner companies on
a one quarter lag.
7. Goodwill and Other Intangible Assets
The following is a summary of changes in the carrying amount of goodwill by segment (in
thousands):
| Alliance | ||||||||||||||||
| Consulting | Clarient | Acsis | Total | |||||||||||||
Balance at December 31, 2004 |
$ | 51,627 | $ | 14,259 | $ | — | $ | 65,886 | ||||||||
Additions |
— | — | 11,931 | 11,931 | ||||||||||||
Purchase price adjustments (1) |
155 | — | — | 155 | ||||||||||||
Balance at December 31, 2005 |
51,782 | 14,259 | 11,931 | 77,972 | ||||||||||||
Additions |
4,373 | 550 | — | 4,923 | ||||||||||||
Purchase price adjustments (1) |
— | — | (397 | ) | (397 | ) | ||||||||||
Balance at December 31, 2006 |
$ | 56,155 | $ | 14,809 | $ | 11,534 | $ | 82,498 | ||||||||
| (1) | The above purchase price adjustments represent activity to complete the final purchase price allocation. |
As discussed in Note 3, certain purchase price adjustments are not final.
88
Table of Contents
SAFEGUARD SCIENTIFICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)
Intangible assets with definite useful lives are amortized over their respective estimated
useful lives to their estimated residual values. The following table provides a summary of the
Company’s intangible assets with definite and indefinite useful lives:
| December 31, 2006 | ||||||||||||||||
| Gross | ||||||||||||||||
| Amortization | Carrying | Accumulated | ||||||||||||||
| Period | Value | Amortization | Net | |||||||||||||
| (In thousands) | ||||||||||||||||
Customer-related |
7 — 10 years | $ | 10,089 | $ | 2,737 | $ | 7,352 | |||||||||
Technology-related |
3 — 10 years | 9,914 | 6,412 | 3,502 | ||||||||||||
Process-related |
3 years | 1,363 | 984 | 379 | ||||||||||||
Trade names |
10 — 20 years | 1,372 | 70 | 1,302 | ||||||||||||
Covenant not-to-compete |
1 year | 470 | 470 | — | ||||||||||||
Other |
10 — 15 years | 1,350 | 26 | 1,324 | ||||||||||||
| 24,558 | 10,699 | 13,859 | ||||||||||||||
Trade names |
Indefinite | 2,567 | — | 2,567 | ||||||||||||
Total |
$ | 27,125 | $ | 10,699 | $ | 16,426 | ||||||||||
| December 31, 2005 | ||||||||||||||||
| Gross | ||||||||||||||||
| Amortization | Carrying | Accumulated | ||||||||||||||
| Period | Value | Amortization | Net | |||||||||||||
| (In thousands) | ||||||||||||||||
Customer-related |
7 — 10-years | $ | 8,991 | $ | 1,626 | $ | 7,365 | |||||||||
Technology-related |
3 — 10 years | 7,993 | 5,094 | 2,899 | ||||||||||||
Process-related |
3 years | 1,363 | 530 | 833 | ||||||||||||
Trade names |
20 years | 1,222 | 5 | 1,217 | ||||||||||||
Covenant not-to-compete |
1 year | 470 | 39 | 431 | ||||||||||||
| 20,039 | 7,294 | 12,745 | ||||||||||||||
Trade names |
Indefinite | 2,567 | — | 2,567 | ||||||||||||
Total |
$ | 22,606 | $ | 7,294 | $ | 15,312 | ||||||||||
Amortization expense related to intangible assets was $3.4 million, $2.4 million and $2.2
million for the years ended December 31, 2006, 2005 and 2004, respectively. The following table
provides estimated future amortization expense related to intangible assets (assuming there is not
a writedown associated with these intangible assets causing an acceleration of expense):
| Total | ||||
| (In thousands) | ||||
2007 |
$ | 2,687 | ||
2008 |
2,269 | |||
2009 |
1,808 | |||
2010 |
1,225 | |||
2011 and thereafter |
5,870 | |||
| $ | 13,859 | |||
89
Table of Contents
SAFEGUARD SCIENTIFICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)
8. Long-term Debt and Credit Arrangements
Consolidated long-term debt consisted of the following:
| As of December 31, | ||||||||
| 2006 | 2005 | |||||||
| (In thousands) | ||||||||
Subsidiary credit line borrowings (guaranteed by the Company) |
$ | 22,546 | $ | 13,023 | ||||
Subsidiary credit line borrowings (not guaranteed by the Company) |
2,468 | — | ||||||
Subsidiary term loans (guaranteed by the Company) |
3,000 | 4,000 | ||||||
| 28,014 | 17,023 | |||||||
Other
borrowings |
1,861 | 849 | ||||||
Capital lease obligations |
4,144 | 3,695 | ||||||
| 34,019 | 21,567 | |||||||
Less current maturities |
(28,952 | ) | (16,397 | ) | ||||
Total long-term debt, less current portion |
$ | 5,067 | $ | 5,170 | ||||
In May 2006, the Company renewed its revolving credit facility that provides for borrowings
and issuances of letters of credit and guarantees of up to $55 million. Borrowing availability
under the facility is reduced by the amounts outstanding for the Company’s borrowings and letters
of credit and amounts guaranteed under partner company facilities maintained with that same lender.
This credit facility matures in May 2007 and bears interest at the prime rate (8.25% at December
31, 2006) for outstanding borrowings. The credit facility is subject to an unused commitment fee of
0.125%, which is subject to reduction based on deposits maintained at the bank. The facility
requires cash collateral equal to one times the Company’s borrowings and letters of credit and
amounts borrowed by partner company facilities maintained with that same bank. As of December 31,
2006, three subsidiaries were not in compliance with certain financial covenants under their
respective facilities and subsequently received waivers from the lender.
In November 2006, the Company entered into an additional revolving credit facility with a
separate bank that provides for borrowings and issuances of letters of credit and guarantees of up
to $20 million. Borrowing availability under the facility is reduced by the amounts outstanding
for the Company’s borrowings and letters of credit and amounts guaranteed under partner company
facilities maintained with that same lender. This credit facility bears interest at the prime rate
for outstanding borrowings. The credit facility is subject to an unused commitment fee of 0.125%,
which is subject to reduction based on deposits maintained at the bank. The facility requires cash
collateral equal to one times the Company’s borrowings and letters of credit and amounts borrowed
by partner companies under the guaranteed portion of the partner company facilities maintained at
the same bank. The credit facility matures in November 2007.
Availability under the revolving credit facilities at December 31, 2006 was as follows:
| Total | ||||
Size of facilities |
$ | 75,000 | ||
Subsidiary facilities at same banks (a) |
(28,000 | ) | ||
Outstanding letter of credit (b) |
(6,336 | ) | ||
Amount available at December 31, 2006 |
$ | 40,664 | ||
| (a) | The Company’s ability to borrow under its credit facilities is limited by the amounts outstanding for the Company’s borrowings and letters of credit and amounts guaranteed under partner company facilities maintained at the same respective banks. Of the total facilities, $25.5 million was outstanding under these facilities at December 31, 2006 and was included as debt on the Consolidated Balance Sheet. |
90
Table of Contents
SAFEGUARD SCIENTIFICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)
| (b) | In connection with the sale of CompuCom, the Company provided to the landlord of CompuCom’s Dallas headquarters, a letter of credit, which will expire on March 19, 2019, in an amount equal to $6.3 million. |
As a result of the sale of the Company’s holdings in Mantas in October 2006, the Company’s
guarantee related to the Mantas facility was released in September 2006, thereby increasing the
Company’s availability under its credit facility by $3.5 million.
On February 28, 2007, all subsidiary facilities were extended for one year, with the exception
of Acsis’ facility, which expires in August 2008 and Pacific Title’s facility which was not renewed
by Pacific Title and under which there were no borrowings. In addition to the extension of the
maturity dates, a subsidiary’s working capital line was increased by $5.5 million and that same
subsidiary entered into a $6 million equipment facility, all of
which the Company guaranteed. Our $10 million guarantee on a subsidiary
facility was decreased to $5 million and related interest rates on outstanding borrowings were
also changed. In January 2007, Clarient increased its facility by $3.5 million, all of which was
guaranteed by the Company. As a result of these amendments, the Company’s availability under the
facilities has decreased by $10.3 million. Availability under
the facilities at March 22, 2007 was
$30.4 million.
Borrowings are secured by substantially all of the assets of the respective subsidiaries.
These obligations bear interest at variable rates ranging between the prime rate minus 0.5% and the
prime rate plus 1.0%. These facilities contain financial and non-financial covenants.
In September 2006, Clarient entered into a $5 million
senior secured revolving credit agreement. Borrowing availability under the agreement is based on the level of Clarient’s qualified
accounts receivable, less certain reserves. The agreement has a two-year term and bears interest at variable rates based on the lower of
LIBOR plus 3.25% or the prime rate plus 0.5%. As of December 31, 2006, Clarient borrowed $2.5 million and had no availability under this
facility based on the level of qualified accounts receivable. As of December 31, 2006, Clarient was not in compliance with a financial
covenant under this agreement and subsequently received a waiver from the lender.
Debt as of December 31, 2006 bore interest at fixed rates between 4.62% and 20.33% and
variable rates indexed to the prime rate plus 1.75%. Debt as of December 31, 2005 bore interest at
fixed rates between 4.0% and 22% and variable rates indexed to the prime rate plus 1.75%.
The Company’s debt matures as follows:
| Total | ||||
| (In thousands) | ||||
2007 |
$ | 28,952 | ||
2008 |
3,154 | |||
2009 |
1,898 | |||
2010 |
15 | |||
2011 and thereafter |
— | |||
Total debt |
$ | 34,019 | ||
9. Convertible Subordinated Notes and Convertible Senior Debentures
In June 1999, the Company issued $200 million of 5% convertible subordinated notes due June
15, 2006. During 2004, the Company repurchased or redeemed all of these 2006 Notes for an
aggregate cost of $201.4 million, including transaction costs. The Company recorded $1.8 million
of expense for the year ended December 31, 2004 related to the acceleration of deferred debt
issuance costs associated with the 2006 Notes, which is included in Other Income, Net in the
Consolidated Statements of Operations.
91
Table of Contents
SAFEGUARD SCIENTIFICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)
In February 2004, the Company completed the sale of $150 million of 2.625% convertible senior
debentures with a stated maturity of March 15, 2024. Interest on these 2024 Debentures is payable
semi-annually. At the debenture holders’ option, the 2024 Debentures are convertible into our
common stock through March 14, 2024, subject to certain conditions. The conversion rate of the
debentures at December 31, 2006 was $7.2174 of principal amount per share. The closing price of
the Company’s common stock at December 31, 2006 was $2.42. At December 31, 2006, the market value
of the 2024 Debentures was approximately $104 million based on quoted market prices. The 2024
Debenture holders may require the Company to repurchase the 2024 Debentures on March 21, 2011,
March 20, 2014 or March 20, 2019 at a repurchase price equal to 100% of their respective face
amount plus accrued and unpaid interest. The 2024 Debenture holders may also require repurchase of
the 2024 Debentures upon certain events, including sale of all or substantially all of our common
stock or assets, liquidation, dissolution or a change in control. Subject to certain conditions,
the Company may redeem all or some of the 2024 Debentures commencing March 20, 2009. During 2006,
the Company repurchased $21 million of face value of the 2024 Debentures for $16.4 million in cash,
including accrued interest. The Company recorded $0.4 million of expense related to the
acceleration of deferred debt issuance costs associated with the 2024 Debentures, resulting in a
net gain of $4.3 million, which is included in Other Income, Net in the Consolidated Statements of
Operations.
As required by the terms of the 2024 Debentures, after completing the sale of CompuCom, the
Company escrowed $16.7 million on October 8, 2004 for interest payments through March 15, 2009 on
the 2024 Debentures (see Notes 2 and 4). A total of $9.6 million is included in Restricted
Marketable Securities on the Consolidated Balance Sheet at December 31, 2006, of which $3.9 million
is classified as a current asset.
10. Accrued Expenses and Other Current Liabilities
Accrued expenses consisted of the following:
| As of December 31, | ||||||||
| 2006 | 2005 | |||||||
| (In thousands) | ||||||||
Accrued professional fees |
$ | 2,925 | $ | 2,727 | ||||
Other |
16,240 | 11,840 | ||||||
| $ | 19,165 | $ | 14,567 | |||||
11. Shareholders’ Equity
Preferred Stock
Shares of preferred stock, par value $0.10 per share, are voting and are issuable in one or
more series with rights and preferences as to dividends, redemption, liquidation, sinking funds,
and conversion determined by the Board of Directors. At December 31, 2006 and 2005, there were one
million shares authorized and none outstanding.
92
Table of Contents
SAFEGUARD SCIENTIFICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)
Shareholders’ Rights Plan
In February 2000, the Company adopted a shareholders’ rights plan. Under the plan, each
shareholder of record on March 24, 2000 received the right to purchase 1/1000 of a share of the
Company’s Series A Junior Participating Preferred Stock at the rate of one right for each share of
the Company’s common stock then held of record. Each 1/1000 of a share of the Company’s Series A
Junior Participating Preferred Stock is designed to be equivalent in voting and dividend rights to
one share of the Company’s common stock. The rights will be exercisable only if a person or group
acquires beneficial ownership of 15% or more of the Company’s common stock or commences a tender or
exchange offer that would result in such a person or group owning 15% or more of the Company’s
common stock. If the rights do become exercisable, the Company’s shareholders, other than the
shareholders that caused the rights to become exercisable, will be able to exercise each right at
an exercise price of $300 and receive shares of the Company’s common stock having a market value
equal to approximately twice the exercise price. As an alternative to paying the exercise price in
cash, if the directors of the Company so determine, shareholders may elect to exercise their rights
and, without the payment of any exercise price, receive half the number of shares of common stock
that would have been received had the exercise price been paid in cash.
12. Stock-Based Compensation
On January 1, 2006, the Company adopted SFAS No. 123 (revised 2004), “Share-Based Payment”
(“SFAS No. 123(R)”). SFAS No. 123(R) requires companies to measure all employee stock-based
compensation awards using a fair value method and record such expense in its consolidated financial
statements. The Company adopted SFAS No. 123(R) using the modified prospective method.
Accordingly, prior period amounts have not been restated. Under this application, the Company is
required to record compensation expense for all awards granted after the date of adoption and for
the unvested portion of previously granted awards that remain outstanding at the date of adoption.
Equity Compensation Plans
The Company has three equity compensation plans: the 1999 Equity Compensation Plan, with 9.0
million shares authorized for issuance; the 2001 Associates Equity Compensation Plan with 5.4
million shares authorized for issuance; and the 2004 Equity Compensation Plan, with 6.0 million
shares authorized for issuance. Employees and consultants are eligible for grants of stock
options, restricted stock awards, stock appreciation rights, stock units, performance units and
other stock-based awards under each of these plans; directors and executive officers are eligible
for grants only under the 1999 and 2004 Equity Compensation Plans. During 2005, 6.0 million options
also were awarded outside of existing plans as inducement awards in accordance with New York Stock
Exchange rules.
To the extent allowable, all grants are incentive stock options. Options granted under the
plans are at prices equal to the fair market value at the date of grant. Upon exercise of stock
options, the Company issues shares first from treasury stock, if available, then from authorized
but unissued shares. At December 31, 2006, the Company had reserved 23.4 million shares of common
stock for possible future issuance under its equity compensation plans. Several subsidiaries also
maintain separate equity compensation plans for their employees, directors and advisors.
93
Table of Contents
SAFEGUARD SCIENTIFICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)
Classification of Stock-Based Compensation Expense
Stock-based compensation expense was recognized in the Consolidated Statements of Operations
as follows:
| Year Ended | ||||
| December 31, | ||||
| 2006 | ||||
| (in thousands) | ||||
Cost of sales |
$ | 85 | ||
Selling, general and administrative |
6,640 | |||
Research and development |
117 | |||
| $ | 6,842 | |||
Prior to adopting SFAS No. 123(R), the Company accounted for stock-based compensation in
accordance with APB Opinion No. 25, “Accounting for Stock Issued to Employees.” Had compensation
cost been recognized consistent with SFAS No. 123, “Accounting for Stock-Based Compensation,” the
Company’s consolidated net loss from continuing operations and discontinued operations and loss per
share from continuing operations and from discontinued operations would have been as follows:
| Year Ended | Year Ended | |||||||||||
| December 31, | December 31, | |||||||||||
| 2005 | 2004 | |||||||||||
| (in thousands, except per share data) | ||||||||||||
Consolidated net loss from continuing operations |
As reported | $ | (38,108 | ) | $ | (25,341 | ) | |||||
Add: Stock-based compensation expense included in
net loss, net of minority interest |
As reported | 2,439 | 3,878 | |||||||||
Deduct: Total stock based employee
compensation expense from continuing
operations determined under fair value based
method for all awards, net of related tax effects |
(7,927 | ) | (8,418 | ) | ||||||||
Consolidated net loss from continuing operations |
Pro forma | (43,596 | ) | (29,881 | ) | |||||||
Net income (loss) from discontinued operations |
As reported | 6,038 | (29,479 | ) | ||||||||
Deduct: Total stock based employee
compensation expense from discontinued
operations determined under fair value based
method for all awards, net of related tax effects |
(379 | ) | (760 | ) | ||||||||
| Pro forma | $ | (37,937 | ) | $ | (60,120 | ) | ||||||
Basic and Diluted Income (Loss) Per Share: |
||||||||||||
Net loss from continuing operations |
As reported | $ | (0.32 | ) | $ | (0.21 | ) | |||||
Net income (loss) from discontinued operations |
As reported | 0.05 | (0.25 | ) | ||||||||
| $ | (0.27 | ) | $ | (0.46 | ) | |||||||
Net loss from continuing operations |
Pro forma | $ | (0.36 | ) | $ | (0.25 | ) | |||||
Net income (loss) from discontinued operations |
Pro forma | 0.04 | (0.25 | ) | ||||||||
| $ | (0.32 | ) | $ | (0.50 | ) | |||||||
94
Table of Contents
SAFEGUARD SCIENTIFICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS—(Continued)
The Company
The fair value of the Company’s stock-based awards to employees during the years ended
December 31, 2006, 2005 and 2004 was estimated at the date of grant using the Black-Scholes
option-pricing model. The risk-free rate is based on the U.S. Treasury yield curve in effect at
the end of the quarter in which the grant occurred. The expected life of stock options granted was
estimated using the historical exercise behavior of employees. Expected volatility was based on
historical volatility for a period equal to the stock option’s expected life.
| Year Ended December 31, | ||||||||||||
| 2006 | 2005 | 2004 | ||||||||||
Service-Based Awards |
||||||||||||
Dividend yield |
0 | % | 0 | % | 0 | % | ||||||
Expected volatility |
69 | % | 84 | % | 86 | % | ||||||
Average expected option life |
5 years | 5 years | 5 years | |||||||||
Risk-free interest rate |
4.7 | % | 4.4 | % | 3.6 | % | ||||||
| Year Ended December 31, | ||||||||
| 2006 | 2005 | |||||||
Market-Based Awards |
||||||||
Dividend yield |
0 | % | 0 | % | ||||
Expected volatility |
62 | % | 67 | % | ||||
Average expected option life |
5 — 7 years | 5 — 7 years | ||||||
Risk-free interest rate |
4.8 | % | 4.3 | % | ||||
The weighted-average grant date fair value of options issued by the Company during the years
ended December 31, 2006, 2005 and 2004 was $1.36, $0.95 and $1.45 per share, respectively.
The Company granted 1.6 million market-based stock option awards to employees during the year
ended December 31, 2006 and 8.6 million market-based stock option awards during the year ended
December 31, 2005. The awards entitle participants to vest in a number of options determined by
achievement of certain target market capitalization increases (measured by reference to stock price
increases on a specified number of outstanding shares) over an eight-year period. The requisite
service periods for the market-based awards are based on the Company’s estimate of the dates on
which the market conditions will be met as determined using a Monte Carlo simulation model.
Compensation expense is recognized over the requisite service periods using the straight-line
method, but is accelerated if market capitalization targets are achieved earlier than estimated.
Based on the achievement of market capitalization targets, 1.7 million shares vested during the
year ended December 31, 2006. During the year ended December 31, 2006, 0.8 million market-based
awards were forfeited. The Company recorded $1.9 million of compensation expense related to the
market-based awards in the year ended December 31, 2006. The maximum number of unvested shares at
December 31, 2006 attainable under these grants is 7.6 million shares.
All other outstanding options are service-based awards that generally vest over four years
after the date of grant and expire eight years after the date of grant. Compensation expense is
recognized over the requisite service period using the straight-line method. The requisite service
period for service-based awards is the period over which the award vests. The Company recorded
$2.0 million of compensation expense related to these awards during the year ended December 31,
2006.
During the
year ended December 31, 2006, the Company granted 21 thousand stock options
to members of its advisory boards, which comprise non-employees. Such awards vest over one year,
are equity classified and are marked-to-market each period.
95
Table of Contents
SAFEGUARD SCIENTIFICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)
Option activity of the Company is summarized below:
| Weighted | Weighted Average | Aggregate | ||||||||||||||
| Average | Remaining | Intrinsic | ||||||||||||||
| Shares | Exercise Price | Contractual Life | Value | |||||||||||||
| (In thousands) | (In years) | (In thousands) | ||||||||||||||
Outstanding at December 31, 2003 |
10,319 | $ | 8.10 | |||||||||||||
Options granted |
2,719 | 2.09 | ||||||||||||||
Options exercised |
(442 | ) | 3.15 | |||||||||||||
Options canceled/forfeited |
(3,380 | ) | 14.69 | |||||||||||||
Outstanding at December 31, 2004 |
9,216 | 4.15 | ||||||||||||||
Options granted |
10,924 | 1.44 | ||||||||||||||
Options exercised |
(44 | ) | 1.39 | |||||||||||||
Options canceled/forfeited |
(1,125 | ) | 10.82 | |||||||||||||
Outstanding at December 31, 2005 |
18,971 | 2.20 | ||||||||||||||
Options granted |
2,723 | 2.19 | ||||||||||||||
Options exercised |
(238 | ) | 1.58 | |||||||||||||
Options canceled/forfeited |
(2,728 | ) | 3.74 | |||||||||||||
Outstanding at December 31, 2006 |
18,728 | 1.98 | 6.0 | $ | 11,456 | |||||||||||
Options exercisable at December 31, 2006 |
8,063 | 2.42 | 4.9 | 3,848 | ||||||||||||
Options vested and expected to vest at
December 31, 2006 |
13,065 | 2.15 | 5.6 | 7,193 | ||||||||||||
Shares available for future grant |
3,359 | |||||||||||||||
The total intrinsic value of options exercised for the year ended December 31, 2006 was $0.2
million.
At December 31, 2006, total unrecognized compensation cost related to non-vested stock options
granted under the plans for service-based awards was $2.7 million. That cost is expected to be
recognized over a weighted-average period of 2.3 years.
At December 31, 2006, total unrecognized compensation cost related to non-vested stock options
granted under the plans for market-based awards was $3.9 million. That cost is expected to be
recognized over a weighted-average period of 4.5 years but would be accelerated if market
capitalization targets are achieved earlier than estimated.
Total compensation expense for restricted stock issuances was approximately $0.4 million and
$0.5 million for the years ended December 31, 2005 and 2004, respectively, including amounts
recorded by consolidated subsidiaries. Unrecognized compensation expense related to restricted
stock issuances was $0.1 million at December 31, 2006.
The Company has previously issued deferred stock units to certain employees. The Company
issued deferred stock units during the years ended December 31, 2006 and 2005, to directors who
elected to defer all or a portion of directors’ fees earned. Deferred stock units issued to
directors in lieu of directors fees are 100% vested at grant; matching deferred stock units equal
to 25% of directors’ fees deferred vest one year following grant. Deferred stock units are payable
in stock on a one-for-one basis. Payments in respect of the deferred stock units are generally
distributable following termination of employment or service, death, permanent disability or
retirement. Total compensation expense for deferred stock units was approximately $0.4 million,
$1.0 million and $2.2 million for the years ended December 31, 2006, 2005 and 2004, respectively,
including amounts recorded by consolidated subsidiaries. Unrecognized compensation expense related
to deferred stock units at December 31, 2006 is $0.1 million. The total fair value of deferred
stock units vested during the year ended December 31, 2006 was $0.4 million.
96
Table of Contents
SAFEGUARD SCIENTIFICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)
Deferred stock unit and restricted stock activity is summarized below:
| Weighted | ||||||||
| Average | ||||||||
| Shares | Grant Date Fair Value | |||||||
| (In thousands) | ||||||||
Unvested at December 31, 2005 |
204 | $ | 3.17 | |||||
Granted |
83 | 2.26 | ||||||
Vested |
(172 | ) | 2.56 | |||||
Forfeited |
(44 | ) | 4.41 | |||||
Unvested at December 31, 2006 |
71 | 2.82 | ||||||
Consolidated Subsidiaries
The fair value of the Company’s subsidiaries’ stock-based awards issued to employees during
the years ended December 31, 2006, 2005 and 2004 was estimated at the date of grant using the
Black-Scholes option-pricing model. The risk-free rate is based on the U.S. Treasury yield curve
in effect at the end of the quarter in which the grant occurred. The expected life of stock
options granted was estimated using the historical exercise behavior of employees. The expected
life of stock options granted for subsidiaries that do not have sufficient historical exercise
behavior of employees was calculated using the simplified method of determining expected term as
provided in Staff Accounting Bulletin No. 107, “Share-Based Payment” (“SAB 107”). Expected
volatility for publicly-held subsidiaries was based on historical volatility for a period equal to
the stock option’s expected life. Expected volatility for privately-held subsidiaries is based on
the average historical volatility of comparable companies for a period equal to the stock option’s
expected life. The fair value of the underlying stock of privately-held subsidiaries on the date
of grant was determined based on a number of valuation methods, including discounted cash flows and
revenue and acquisition multiples.
| Year Ended December 31, | ||||||||||||
| 2006 | 2005 | 2004 | ||||||||||
Dividend yield |
0 | % | 0 | % | 0 | % | ||||||
Expected volatility |
38% to 92 | % | 50% to 103 | % | 70% to 109 | % | ||||||
Average expected option life |
5 to 8 years | 4 to 5 years | 4 to 5 years | |||||||||
Risk-free interest rate |
4.5% to 5.3 | % | 3.9% to 4.5 | % | 2.5 to 3.9 | % | ||||||
Stock options granted by subsidiaries generally are service-based awards that vest four years
after the date of grant and expire 7 to 10 years after the date of grant. Compensation expense is
recognized over the requisite service period using the straight-line method. The requisite service
period is the period over which the award vests. The Company’s consolidated subsidiaries recorded
$2.8 million, $1.4 million and $2.0 million of stock-based compensation expense related to these
awards during the years ended December 31, 2006, 2005 and 2004, respectively.
At December 31, 2006, total unrecognized compensation cost related to non-vested stock options
granted under the consolidated subsidiaries’ plans was $4.3 million. That cost is expected to be
recognized over a weighted-average period of 2.8 years.
During the year ended December 31, 2006, certain subsidiaries granted stock options to
advisory boards, which comprise of non-employees. Such awards vest over four years, are equity
classified and are marked-to-market each period.
97
Table of Contents
SAFEGUARD SCIENTIFICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)
Certain employees of the Company’s subsidiaries have the right to require the respective
subsidiary to purchase shares of common stock of the subsidiary received by the employee pursuant
to the exercise of options or the conversion of deferred stock units. The employee must hold the
shares for at least six months prior to exercising this right. The required purchase price is 75%
to 100% of the fair market value at the time the right is exercised. These options and deferred
stock units qualify for equity-classification under SFAS No. 123(R). In accordance with EITF Issue
No. D-98, however, these instruments are classified outside of permanent equity on the Consolidated
Balance Sheet as Redeemable Stock-Based Compensation at their current redemption amount based on
the number of options and deferred stock units vested as of December 31, 2006.
13. Other Income
| Year Ended December 31, | ||||||||||||
| 2006 | 2005 | 2004 | ||||||||||
| (In thousands) | ||||||||||||
Gain on sale of companies and funds, net |
$ | 1,181 | $ | 7,292 | $ | 44,486 | ||||||
Gain (loss) on trading securities |
321 | (229 | ) | (396 | ) | |||||||
Impairment charges |
— | (1,425 | ) | (3,197 | ) | |||||||
Other |
4,071 | 1,700 | (2,090 | ) | ||||||||
| $ | 5,573 | $ | 7,338 | $ | 38,803 | |||||||
Gain on sale of companies and funds for the year ended December 31, 2006 of $1.2 million
primarily relates to the sale of a cost method investment whose carrying value was zero. Gain on
sale of companies and funds for the year ended December 31, 2005 of $7.3 million includes gains of
sales of partnership interests in private equity funds in the third and fourth quarters of 2005.
Total proceeds from the sales of certain interests in private equity funds during 2005 were $27.6
million. As a result of the sale, the Company was also relieved of $9.1 million of future fund
commitments. Gain on sale of companies and funds for the year ended December 31, 2004 of $44.5
million includes a gain of $31.7 million related to the sale of our interest in Sanchez and $8.5
million related to our sale of Tangram. Also included in gain on sale of companies and funds in
2004 is $2.7 million attributable to a distribution from a bankruptcy proceeding and $1.5 million
relating to the final payment of an installment sale of a company sold in 1997. Total net cash
proceeds for gains on sales of companies and funds was $37.5 million for the year ended December
31, 2004.
Gain on trading securities in 2006 primarily reflects a net gain of $0.4 million on the sale
of our holdings in Traffic.com. Loss on trading securities in 2005 reflects the loss on the sale
of our holdings in stock distributed from a private equity fund, which were sold in the third
quarter of 2005. Loss on trading securities in 2004 primarily reflect the adjustment to fair value
of our holdings in Opsware and subsequent loss on sale of Opsware stock of $0.1 million.
We have recorded impairment charges for certain holdings accounted for under the cost method
determined to have experienced an other than temporary decline in value in accordance with our
existing policy regarding impairment of ownership interests in and advances to companies.
For the year ended December 31, 2006, the Company recognized a net gain of $4.3 million on the
repurchase of $21 million of face value of the 2024 Debentures, which is included in Other above.
98
Table of Contents
SAFEGUARD SCIENTIFICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)
14. Income Taxes
The provision (benefit) for income taxes is was follows:
| Year Ended December 31, | ||||||||||||
| 2006 | 2005 | 2004 | ||||||||||
| (In thousands) | ||||||||||||
Current, primarily state |
$ | (1,039 | ) | $ | (83 | ) | $ | (182 | ) | |||
Deferred, primarily state |
16 | — | 62 | |||||||||
| $ | (1,023 | ) | $ | (83 | ) | $ | (120 | ) | ||||
Total income tax provision (benefit) differed from the amounts computed by applying the U.S.
Federal income tax rate of 35% to net loss from continuing operations before income taxes as a
result of the following:
| Year Ended December 31, | ||||||||||||
| 2006 | 2005 | 2004 | ||||||||||
Statutory tax benefit |
(35.0 | )% | (35.0 | )% | (35.0 | )% | ||||||
Increase (decrease) in taxes resulting from: |
||||||||||||
State taxes, net of federal tax benefit |
(2.3 | ) | (0.2 | ) | (0.5 | ) | ||||||
Non-deductible amortization |
— | 4.4 | 3.2 | |||||||||
Valuation allowance |
36.1 | 29.4 | 30.1 | |||||||||
Other adjustments |
(1.1 | ) | 1.2 | 1.7 | ||||||||
| (2.3 | )% | (0.2 | )% | (0.5 | )% | |||||||
The tax effects of temporary differences that gave rise to significant portions of the
deferred tax assets and deferred tax liabilities were as follows:
| As of December 31, | ||||||||
| 2006 | 2005 | |||||||
| (In thousands) | ||||||||
Deferred tax asset (liability): |
||||||||
Carrying values of subsidiaries / holdings |
$ | 41,468 | $ | 42,293 | ||||
Tax loss and credit carryforwards |
189,579 | 177,754 | ||||||
Accrued expenses |
4,519 | 3,806 | ||||||
Intangible assets |
(2,092 | ) | (1,420 | ) | ||||
Other |
4,090 | 8,577 | ||||||
| 237,564 | 231,010 | |||||||
Valuation allowance |
(238,475 | ) | (231,905 | ) | ||||
Net deferred tax liability |
$ | (911 | ) | $ | (895 | ) | ||
The Company has not recognized gross deferred tax assets for the difference between the book
and tax basis of its holdings in the stock of certain consolidated subsidiaries where we do not
believe we will dispose of the asset in the foreseeable future.
99
Table of Contents
SAFEGUARD SCIENTIFICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)
As of December 31, 2006, the Company had federal net operating loss carryforwards and federal
capital loss carryforwards of approximately $254 million and $140 million, respectively. These
carryforwards expire as follows:
| Total | ||||
| (In thousands) | ||||
2007 |
$ | 29,707 | ||
2008 |
102,564 | |||
2009 |
1,087 | |||
2010 |
14,656 | |||
2011 and thereafter |
246,102 | |||
| $ | 394,116 | |||
Limitations on utilization of both the net operating loss carryforward and capital loss
carryforward may apply.
In assessing the recoverability of deferred tax assets, management considers whether it is
more likely than not that some portion or all of the deferred tax assets will not be realized. The
Company has determined that it is more likely than not that certain future tax benefits may not be
realized as a result of current and future income. Accordingly, a valuation allowance has been
recorded against substantially all of the Company’s deferred tax assets. In the event of a
decrease in the valuation allowance in future years, a portion of the decrease will reduce the
Company’s recorded goodwill. This is due to deferred tax assets acquired as part of the purchase
of a subsidiary which currently requires a valuation allowance.
Clarient, the Company’s subsidiary which is not consolidated for tax return purposes, had
additional federal net operating loss carryforwards of $119 million, which expire in various
amounts from 2011 to 2026. Limitations on utilization of the net operating loss carryforwards may
apply. Accordingly, valuation allowances have been provided to account for the potential
limitations on utilization of these tax benefits.
100
Table of Contents
SAFEGUARD SCIENTIFICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)
15. Net Loss Per Share
The calculations of net income (loss) per share were:
| Year Ended December 31, | ||||||||||||
| 2006 | 2005 | 2004 | ||||||||||
| (In thousands except per share data) | ||||||||||||
Basic: |
||||||||||||
Net loss from continuing operations |
$ | (43,780 | ) | $ | (38,108 | ) | $ | (25,341 | ) | |||
Net income (loss) from discontinued operations |
89,810 | 6,038 | (29,479 | ) | ||||||||
Net income (loss) |
$ | 46,030 | $ | (32,070 | ) | $ | (54,820 | ) | ||||
Average common shares outstanding |
121,476 | 120,845 | 119,965 | |||||||||
Net loss per share from continuing operations |
$ | (0.36 | ) | $ | (0.32 | ) | $ | (0.21 | ) | |||
Net income (loss) per share from discontinued operations |
0.74 | 0.05 | (0.25 | ) | ||||||||
Net income (loss) per share |
$ | 0.38 | $ | (0.27 | ) | $ | (0.46 | ) | ||||
Diluted: |
||||||||||||
Net loss from continuing operations |
$ | (43,780 | ) | $ | (38,108 | ) | $ | (25,341 | ) | |||
Net income (loss) from discontinued operations |
89,810 | 6,038 | (29,479 | ) | ||||||||
| 46,030 | (32,070 | ) | (54,820 | ) | ||||||||
Effect of holdings |
(126 | ) | (106 | ) | — | |||||||
Adjusted net income (loss) |
$ | 45,904 | $ | (32,176 | ) | $ | (54,820 | ) | ||||
Average common shares outstanding |
121,476 | 120,845 | 119,965 | |||||||||
Net loss per share from continuing operations |
$ | (0.36 | ) | $ | (0.32 | ) | $ | (0.21 | ) | |||
Net income (loss) per share from discontinued operations |
0.74 | 0.05 | (0.25 | ) | ||||||||
Diluted income (loss) per share |
$ | 0.38 | $ | (0.27 | ) | $ | (0.46 | ) | ||||
Basic and diluted average common shares outstanding for purposes of computing net income
(loss) per share includes outstanding common shares and vested deferred stock units (DSUs).
If a consolidated or equity method partner company has dilutive stock options, unvested
restricted stock, DSUs, warrants or securities outstanding, diluted net loss per share is computed
by first deducting from net loss the income attributable to the potential exercise of the dilutive
securities of the partner company. This impact is shown as an adjustment to net loss for purposes
of calculating diluted net loss per share.
The following potential shares of common stock and their effects on income were excluded from
the diluted net loss per share calculation because their effect would be anti-dilutive:
101
Table of Contents
SAFEGUARD SCIENTIFICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)
| • | At December 31, 2006, 2005 and 2004, options to purchase 18.7 million, 19.0 million and 9.2 million shares of common stock, respectively, at prices ranging from $1.03 to $45.47 per share, were excluded from the calculation. | ||
| • | At December 31, 2006, 2005 and 2004, unvested restricted stock units and DSUs convertible into 0.1 million, 0.2 million and 0.8 million shares of stock, respectively, were excluded from the calculations. | ||
| • | At December 31, 2004, a total of 3.4 million shares related to the Company’s 2006 Notes (See Note 9) representing the weighted average effect of assumed conversion of the 2006 Notes were excluded from the calculation. | ||
| • | At December 31, 2006 and 2005, a total of 19.3 million and 20.8 million shares related to the Company’s 2024 Debentures (See Note 9) representing the weighted average effect of assumed conversion of the 2024 Debentures were excluded from the calculation. |
16. Related Party Transactions
In October 2000, the Company guaranteed certain margin loans advanced by a third party to Mr.
Musser, then the Chief Executive Officer of the Company. The securities subject to the margin
account included shares of the Company’s common stock. The Company entered into this guarantee
arrangement to maintain an orderly trading market for its equity securities, to maintain its
compliance posture with the Investment Company Act of 1940, and to avoid diversion of the attention
of a key executive from the performance of his responsibilities to the Company. In May 2001, the
Company entered into a $26.5 million loan agreement with Mr. Musser. The proceeds of the loan were
used to repay the margin loans guaranteed by the Company in October 2000. The purpose of the May
2001 loan agreement was to eliminate the guarantee obligations and to provide for direct and senior
access to Mr. Musser’s assets as collateral for the loan. The Company demanded repayment in
January 2003 and, when no payment was received, declared a default. Based on the information
available to us, the Company concluded that Mr. Musser may not have sufficient personal assets to
satisfy the outstanding balance due under the loan. Through September 30, 2006, the Company had
impaired the loan over time by an aggregate of $15.7 million to the estimated value of the
collateral.
In December 2006, the Company restructured the obligation to reduce the amount outstanding to
$14.8 million, bearing interest at a rate of 5% per annum, in order to obtain new collateral, which
is expected to be the primary source of repayment, along with additional collateral required to be
provided to the Company over time. Cash payments, when received, will reduce the carrying value of
the note, and thereafter, will be recognized as Recovery-related party in the Consolidated
Statements of Operations. Subsequent to the restructuring of the obligation and prior to December
31, 2006, the Company received cash of approximately $1.0 million from the sale of collateral, which exceeded its
then carrying value of the loan. The excess of $0.4 million is reflected as Recovery-related party
in the Consolidated Statements of Operations. The carrying value of the loan at December 31, 2006
is zero.
In the normal course of business, the Company’s directors, officers and employees hold board
positions of companies in which the Company has a direct or indirect ownership interest.
The Company’s Chairman is the President and CEO of TL Ventures. The Company had invested or
committed a total of $67 million in the seven TL Ventures and EnerTech Capital funds. The Company
owned less than 7% of the partnership interests of each of these funds prior to the sale of certain
interests the Company had in the funds.
102
Table of Contents
SAFEGUARD SCIENTIFICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)
As described in Note 13, the Company sold certain holdings in private equity funds in the fourth
quarter of 2005 to a third party.
17. Commitments and Contingencies
The Company, and its partner companies, are involved in various claims and legal actions
arising in the ordinary course of business, and which may from time to time arise from facility
lease terminations. While in the current opinion of management, the ultimate disposition of these
matters will not have a material adverse effect on the Company’s consolidated financial position or
results of operations, no assurance can be given as to the outcome of these lawsuits, and one or
more adverse rulings could have a material adverse effect on the Company’s consolidated financial
position and results of operations, or that of our partner companies.
The Company and its subsidiaries conduct a portion of their operations in leased facilities
and lease machinery and equipment under leases expiring at various dates to 2015. Total rental
expenses under operating leases was $5.8 million, $6.3 million and $5.4 million in 2006, 2005 and
2004, respectively. Future minimum lease payments under non-cancelable operating leases with
initial or remaining terms of one year or more at December 31, 2006, are (in millions): $6.2 —
2007; $5.7 — 2008; $4.1 — 2009; $2.0 — 2010; $1.6 — 2011; and $6.3 thereafter.
In connection with its ownership interests in certain affiliates, the Company had the
following outstanding guarantees at December 31, 2006:
| Debt Included on | ||||||||
| Consolidated | ||||||||
| Amount | Balance Sheet | |||||||
| (in millions) | (in millions) | |||||||
Consolidated companies guarantees — credit facilities |
$ | 28.0 | $ | 25.5 | ||||
Other consolidated company guarantees — operating leases |
4.7 | — | ||||||
Non-consolidated company guarantees |
3.8 | — | ||||||
Total |
$ | 36.5 | $ | 25.5 | ||||
103
Table of Contents
SAFEGUARD SCIENTIFICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)
The Company has committed capital of approximately $6.2 million, including a conditional
commitment to provide a partner company with additional funding and commitments made to various
private equity funds in prior years. These commitments will be funded over the next several years,
including approximately $4.9 million which is expected to be funded during the next twelve months.
Under certain circumstances, the Company may be required to return a portion or all the
distributions it received as a general partner of certain private equity funds (the “clawback”).
Assuming the private equity funds in which the Company was a general partner were liquidated or
dissolved on December 31, 2006 and assuming for these purposes the only distributions from the
funds were equal to the carrying value of the funds on the December 31, 2006 financial statements,
the maximum clawback the Company would be required to return for our general partner interest is
approximately $8 million. The Company estimates its liability to be approximately $6.7 million of
which $5.3 million was reflected in Accrued Expenses and Other Current Liabilities and $1.4 million
was reflected in Other Long-Term Liabilities on the Consolidated Balance Sheets.
The Company’s ownership in the funds which have potential clawback liabilities range from
19-30%. The clawback liability is joint and several, such that the Company may be required to fund
the clawback for other general partners should they default. The funds have taken several steps to
reduce the potential liabilities should other general partners default, including withholding all
general partner distributions in escrow and adding rights of set-off among certain funds. The
Company believes its liability due to the default of other general partners is remote.
In October 2001, the Company entered into an agreement with Mr. Musser, its former Chairman
and Chief Executive Officer, to provide for annual payments of $650,000 per year and certain health
care and other benefits for life. The related current liability of $0.8 million was included in
Accrued Expenses and the long-term portion of $2.5 million was included in Other Long-Term
Liabilities on the Consolidated Balance Sheet at December 31, 2006.
The Company has agreements with certain employees that provide for severance payments to the
employee in the event the employee is terminated without cause or an employee terminates his
employment for “good reason”. The maximum aggregate exposure under the agreements was
approximately $8 million at December 31, 2006.
104
Table of Contents
SAFEGUARD SCIENTIFICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)
18. Parent Company Financial Information
Parent company financial information is provided to present the financial position and results
of operations of the Company as if the consolidated companies (see Note 1) were accounted for under
the equity method of accounting for all periods presented during which the Company owned its
interest in these companies.
Parent Company Balance Sheets
| As of December 31, | ||||||||
| 2006 | 2005 | |||||||
| (In thousands) | ||||||||
Assets: |
||||||||
Cash and cash equivalents |
$ | 59,933 | $ | 108,300 | ||||
Restricted cash |
— | 1,098 | ||||||
Marketable securities |
94,155 | 31,770 | ||||||
Restricted marketable securities |
3,869 | 3,805 | ||||||
Other current assets |
1,978 | 1,704 | ||||||
Asset held-for-sale |
— | 24,242 | ||||||
Total current assets |
159,935 | 170,919 | ||||||
Ownership interests in and advances to companies |
178,409 | 150,891 | ||||||
Long-term marketable securities |
487 | 3,311 | ||||||
Long-term restricted marketable securities |
5,737 | 9,457 | ||||||
Cash held in escrow |
19,398 | — | ||||||
Other |
3,377 | 5,109 | ||||||
Total Assets |
$ | 367,343 | $ | 339,687 | ||||
Liabilities and Shareholders’ Equity: |
||||||||
Current convertible senior debentures |
— | 5,000 | ||||||
Current liabilities |
18,816 | 13,625 | ||||||
Total current liabilities |
18,816 | 18,625 | ||||||
Long-term liabilities |
5,625 | 11,087 | ||||||
Convertible senior debentures |
129,000 | 145,000 | ||||||
Shareholders’ equity |
213,902 | 164,975 | ||||||
Total Liabilities and Shareholders’ Equity |
$ | 367,343 | $ | 339,687 | ||||
Parent Company Statements of Operations
| Year Ended December 31, | ||||||||||||
| 2006 | 2005 | 2004 | ||||||||||
| (In thousands) | ||||||||||||
Operating expenses |
$ | (24,346 | ) | $ | (18,063 | ) | $ | (19,293 | ) | |||
Other income, net |
5,441 | 6,343 | 38,659 | |||||||||
Recovery (impairment) — related party |
360 | 28 | (3,400 | ) | ||||||||
Interest income |
6,703 | 4,871 | 2,409 | |||||||||
Interest expense |
(4,617 | ) | (4,914 | ) | (8,647 | ) | ||||||
Equity loss |
(28,605 | ) | (26,373 | ) | (35,069 | ) | ||||||
Net loss from continuing operations before income taxes |
(45,064 | ) | (38,108 | ) | (25,341 | ) | ||||||
Income tax benefit |
1,284 | — | — | |||||||||
Equity income (loss) attributable to discontinued operations |
89,810 | 6,038 | (29,479 | ) | ||||||||
Net income (loss) |
$ | 46,030 | $ | (32,070 | ) | $ | (54,820 | ) | ||||
105
Table of Contents
SAFEGUARD SCIENTIFICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)
Parent Company Statements of Cash Flows
| Year Ended December 31, | ||||||||||||
| 2006 | 2005 | 2004 | ||||||||||
| (In thousands) | ||||||||||||
Cash Flows from Operating Activities: |
||||||||||||
Net income (loss) |
$ | 46,030 | $ | (32,070 | ) | $ | (54,820 | ) | ||||
Adjustments to reconcile to net cash used in operating activities: |
||||||||||||
(Income) loss from discontinued operations |
(89,810 | ) | (5,094 | ) | 19,819 | |||||||
Depreciation |
197 | 183 | 203 | |||||||||
Equity loss |
28,605 | 25,404 | 44,729 | |||||||||
Non-cash compensation charges |
4,037 | 1,264 | 2,153 | |||||||||
Other income, net |
(5,441 | ) | (6,343 | ) | (38,659 | ) | ||||||
(Recovery) impairment — related party |
(360 | ) | (28 | ) | 3,400 | |||||||
Changes in assets and liabilities, net of effect of acquisitions
and dispositions: |
||||||||||||
Other current assets |
— | 1,111 | (320 | ) | ||||||||
Other current liabilities |
4,703 | 2,039 | (968 | ) | ||||||||
Net cash provided by (used in) operating activities |
(12,039 | ) | (13,534 | ) | (24,463 | ) | ||||||
Cash Flows from Investing Activities |
||||||||||||
Proceeds from sales of available-for-sale and trading securities |
3,551 | 241 | 14,784 | |||||||||
Proceeds from sales of and distributions from companies and funds |
1,530 | 29,467 | 39,085 | |||||||||
Advances to companies |
— | (3,898 | ) | (615 | ) | |||||||
Acquisitions of ownership interests in companies and funds, net
of cash acquired |
(52,596 | ) | (44,964 | ) | (58,263 | ) | ||||||
Repayment of note receivable-related party, net |
360 | 1,413 | 7,162 | |||||||||
Increase in restricted cash and short-term investments |
(208,514 | ) | (55,602 | ) | (42,160 | ) | ||||||
Decrease in restricted cash and short-term investments |
146,129 | 57,387 | 16,143 | |||||||||
Purchases of held-to-maturity securities |
— | — | (16,715 | ) | ||||||||
Capital expenditures |
(101 | ) | (44 | ) | (272 | ) | ||||||
Other, net |
72 | — | 1,068 | |||||||||
Proceeds from sale of discontinued operations |
93,410 | — | 125,853 | |||||||||
Net cash provided by (used in) investing activities |
(16,159 | ) | (16,000 | ) | 86,070 | |||||||
Cash Flows from Financing Activities: |
||||||||||||
Proceeds from convertible senior debentures |
— | — | 150,000 | |||||||||
Payment of offering costs on convertible senior debentures |
— | — | (4,887 | ) | ||||||||
Repurchase of convertible senior debentures |
(16,215 | ) | — | — | ||||||||
Repurchase of convertible subordinated notes |
— | — | (200,000 | ) | ||||||||
Payment of costs to repurchase convertible subordinated notes |
— | — | (1,368 | ) | ||||||||
Decrease in restricted cash |
1,098 | — | — | |||||||||
Advance (to) from subsidiary |
(5,500 | ) | 9,511 | — | ||||||||
Issuance of Company common stock, net |
448 | 61 | 1,392 | |||||||||
Net cash provided by (used in) financing activities |
(20,169 | ) | 9,572 | (54,863 | ) | |||||||
Net Increase (Decrease) in Cash and Cash Equivalents |
(48,367 | ) | (19,962 | ) | 6,744 | |||||||
Cash and Cash Equivalents at beginning of period |
108,300 | 128,262 | 121,518 | |||||||||
Cash and Cash Equivalents at end of period |
$ | 59,933 | $ | 108,300 | $ | 128,262 | ||||||
Parent Company cash and cash equivalents excludes marketable securities, which consists of
longer-term securities, including commercial paper and certificates of deposit.
106
Table of Contents
SAFEGUARD SCIENTIFICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)
19.
Supplemental Cash Flow Information
During the years ended December 31, 2006, 2005 and 2004, the Company converted $0.2 million,
$2.3 million and $1.2 million, respectively, of advances to companies into ownership interests in
companies.
Interest paid in 2006, 2005 and 2004 was $6.7 million, $6.5 million and $9.2 million,
respectively, of which $3.7 million in 2006, $3.9 million in 2005 and $7.6 million in 2004 was
related to the Company’s convertible subordinated notes and senior debentures.
Cash paid for taxes in the years ended December 31, 2006, 2005 and 2004 was $0.3 million, $0.2
million and $0.2 million, respectively.
During the years ended December 31, 2006 and 2005, the Company received distributions from a
private equity fund of 68,026, and 37,658 common shares of Arbinet-the-exchange (“Arbinet”), valued
at $0.5 million and $0.5 million on the date of distribution, respectively. The Arbinet shares
were sold during 2006 and 2005 for net cash proceeds of $0.3 million and $0.2 million,
respectively. During the year ended December 31, 2004, the Company sold its interest in Sanchez
for $32.1 million in cash and 226,435 shares of FNF common stock valued at $8.3 million on the date
of the merger. The FNF shares were sold during 2004 for net cash proceeds of $8.3 million. Also
during 2004, the Company sold its interest in Tangram Enterprise Solutions for shares of Opsware,
Inc. valued at $6.9 million. The Opsware shares were sold during 2004 for $6.5 million in net cash
proceeds.
20. Operating Segments
The Company presents its five consolidated partner companies as separate segments —
Acsis, Alliance Consulting, Clarient, Laureate Pharma and Pacific Title. The results of operations
of the Company’s non-consolidated partner companies and the Company’s ownership in private equity
funds are reported in the “Other Companies” segment. The Other Companies segment also includes the
gain or loss on the sale of companies and funds, except for gains and losses included in
discontinued operations.
Management evaluates segment performance based on segment revenue, operating income
(loss) and income (loss) before income taxes, which reflects the portion of income (loss) allocated
to minority shareholders.
Other items include certain expenses which are not identifiable to the operations of our
operating business segments. Other items primarily consists of general and administrative expenses
related to our corporate operations including employee compensation, insurance and professional
fees, including legal, finance and consulting. Other items also includes interest income, interest
expense and income taxes, which are reviewed by management independent of segment results.
The following tables reflect the Company’s consolidated operating data by reportable segment.
Segment results include the results of the consolidated partner companies, impairment charges,
gains or losses related to the disposition of the partner companies, the Company’s share of income
or losses for entities accounted for under the equity method and the mark to market of trading
securities. All significant intersegment activity has been eliminated in consolidation.
Accordingly, segment results reported by the Company exclude the effect of transactions between the
Company and its subsidiaries and among the Company’s subsidiaries.
Segment assets in Other Items included primarily cash, cash equivalents and marketable
securities of $154.1 million and $141.2 million at December 31, 2006 and 2005 respectively.
107
Table of Contents
SAFEGUARD SCIENTIFICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)
Revenue is attributed to geographic areas based on where the services are performed or the
customer’s shipped to location. A majority of the Company’s revenue is generated in the United
States.
As of December 31, 2006 and 2005, the Company’s assets were primarily located in the United
States.
The following represents the segment data from continuing operations:
| For the Year Ended December 31, 2006 | ||||||||||||||||||||||||||||||||||||
| (in thousands) | ||||||||||||||||||||||||||||||||||||
| Total | ||||||||||||||||||||||||||||||||||||
| Alliance | Laureate | Pacific | Other | Total | Other | Continuing | ||||||||||||||||||||||||||||||
| Acsis | Consulting | Clarient | Pharma | Title | Companies | Segments | Items | Operations | ||||||||||||||||||||||||||||
Revenue |
$ | 18,634 | $ | 104,571 | $ | 33,605 | $ | 11,714 | $ | 29,536 | $ | — | $ | 198,060 | $ | — | $ | 198,060 | ||||||||||||||||||
Operating income (loss) |
(8,776 | ) | 808 | (15,607 | ) | (9,129 | ) | 2,368 | — | (30,336 | ) | (24,346 | ) | (54,682 | ) | |||||||||||||||||||||
Net income (loss) from
continuing operations |
(8,264 | ) | 127 | (9,587 | ) | (9,737 | ) | 2,384 | (2,455 | ) | (27,532 | ) | (16,248 | ) | (43,780 | ) | ||||||||||||||||||||
Segment Assets: |
||||||||||||||||||||||||||||||||||||
December 31, 2006 |
$ | 27,266 | $ | 83,766 | $ | 42,652 | $ | 25,626 | $ | 20,589 | $ | 55,035 | $ | 254,934 | $ | 188,447 | $ | 443,381 | ||||||||||||||||||
December 31, 2005 |
30,993 | 80,959 | 40,599 | 21,479 | 18,864 | 21,208 | 214,102 | 161,242 | 375,344 | |||||||||||||||||||||||||||
| For the Year Ended December 31, 2005 | ||||||||||||||||||||||||||||||||||||
| (in thousands) | ||||||||||||||||||||||||||||||||||||
| Total | ||||||||||||||||||||||||||||||||||||
| Alliance | Laureate | Pacific | Other | Total | Other | Continuing | ||||||||||||||||||||||||||||||
| Acsis | Consulting | Clarient | Pharma | Title | Companies | Segments | Items | Operations | ||||||||||||||||||||||||||||
Revenue |
$ | 2,022 | $ | 82,604 | $ | 20,150 | $ | 7,709 | $ | 31,346 | $ | — | $ | 143,831 | $ | — | $ | 143,831 | ||||||||||||||||||
Operating income (loss) |
(2,579 | ) | (422 | ) | (15,981 | ) | (10,471 | ) | 3,644 | — | (25,809 | ) | (18,063 | ) | (43,872 | ) | ||||||||||||||||||||
Net income (loss) from
continuing operations |
(2,556 | ) | (1,194 | ) | (9,717 | ) | (10,870 | ) | 3,748 | (791 | ) | (21,380 | ) | (16,728 | ) | (38,108 | ) | |||||||||||||||||||
| For the Year Ended December 31, 2004 | ||||||||||||||||||||||||||||||||
| (in thousands) | ||||||||||||||||||||||||||||||||
| Total | ||||||||||||||||||||||||||||||||
| Alliance | Laureate | Pacific | Other | Total | Other | Continuing | ||||||||||||||||||||||||||
| Consulting | Clarient | Pharma | Title | Companies | Segments | Items | Operations | |||||||||||||||||||||||||
Revenue |
$ | 71,814 | $ | 9,769 | $ | 884 | $ | 25,609 | $ | 1,278 | $ | 109,354 | $ | — | $ | 109,354 | ||||||||||||||||
Operating income (loss) |
(7,439 | ) | (20,974 | ) | (251 | ) | 1,226 | (1,396 | ) | (28,834 | ) | (19,259 | ) | (48,093 | ) | |||||||||||||||||
Net income (loss) from
continuing
operations |
(7,736 | ) | (12,829 | ) | (270 | ) | 1,157 | 26,157 | 6,479 | (31,820 | ) | (25,341 | ) | |||||||||||||||||||
Other Items
| Year Ended December 31, | ||||||||||||
| 2006 | 2005 | 2004 | ||||||||||
| (In thousands) | ||||||||||||
Corporate operations |
$ | (17,271 | ) | $ | (16,811 | ) | $ | (31,940 | ) | |||
Income tax benefit (expense) |
1,023 | 83 | 120 | |||||||||
| $ | (16,248 | ) | $ | (16,728 | ) | $ | (31,820 | ) | ||||
108
Table of Contents
SAFEGUARD SCIENTIFICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)
21. Selected Quarterly Financial Information (Unaudited)
| Three Months Ended | ||||||||||||||||
| March 31 | June 30 | September 30 | December 31 | |||||||||||||
| (In thousands except per share data) | ||||||||||||||||
2006: |
||||||||||||||||
Revenue |
$ | 46,100 | $ | 48,010 | $ | 50,608 | $ | 53,342 | ||||||||
Cost of sales |
34,025 | 34,643 | 35,829 | 37,893 | ||||||||||||
Selling, general and administrative |
24,006 | 24,819 | 24,599 | 26,538 | ||||||||||||
Research and development |
1,750 | 1,622 | 1,660 | 1,945 | ||||||||||||
Amortization of intangibles |
973 | 972 | 700 | 768 | ||||||||||||
Total operating expenses |
60,754 | 62,056 | 62,788 | 67,144 | ||||||||||||
Operating loss |
(14,654 | ) | (14,046 | ) | (12,180 | ) | (13,802 | ) | ||||||||
Other income (loss), net |
3,137 | (1,243 | ) | 3,077 | 602 | |||||||||||
Recovery (impairment) — related party |
— | — | — | 360 | ||||||||||||
Interest income |
1,543 | 1,576 | 1,399 | 2,396 | ||||||||||||
Interest expense |
(1,618 | ) | (1,659 | ) | (1,777 | ) | (1,767 | ) | ||||||||
Equity income (loss) |
(605 | ) | 335 | (1,910 | ) | (1,087 | ) | |||||||||
Minority interest |
1,997 | 1,895 | 1,789 | 1,439 | ||||||||||||
Net loss from continuing operations before income taxes |
(10,200 | ) | (13,142 | ) | (9,602 | ) | (11,859 | ) | ||||||||
Income tax (expense) benefit |
(12 | ) | 1,235 | (83 | ) | (117 | ) | |||||||||
Net loss from continuing operations |
(10,212 | ) | (11,907 | ) | (9,685 | ) | (11,976 | ) | ||||||||
Income from discontinued operations, net of tax |
3,760 | 2,672 | 78 | 83,300 | ||||||||||||
| $ | (6,452 | ) | $ | (9,235 | ) | $ | (9,607 | ) | $ | 71,324 | ||||||
Basic income (loss) per share (a) |
||||||||||||||||
Net loss from continuing operations |
$ | (0.08 | ) | $ | (0.10 | ) | $ | (0.08 | ) | $ | (0.10 | ) | ||||
Net income from discontinued operations |
0.03 | 0.02 | — | 0.69 | ||||||||||||
| $ | (0.05 | ) | $ | (0.08 | ) | $ | (0.08 | ) | $ | 0.59 | ||||||
Diluted income (loss) per share (a) |
||||||||||||||||
Net loss from continuing operations |
$ | (0.08 | ) | $ | (0.10 | ) | $ | (0.08 | ) | $ | (0.10 | ) | ||||
Net income from discontinued operations |
0.03 | 0.02 | — | 0.69 | ||||||||||||
| $ | (0.05 | ) | $ | (0.08 | ) | $ | (0.08 | ) | $ | 0.59 | ||||||
2005: |
||||||||||||||||
Revenue |
$ | 31,965 | $ | 37,145 | $ | 34,033 | $ | 40,688 | ||||||||
Cost of sales |
23,784 | 25,756 | 25,624 | 30,017 | ||||||||||||
Selling, general and administrative |
17,846 | 16,638 | 18,834 | 20,860 | ||||||||||||
Research and development |
887 | 759 | 921 | 1,227 | ||||||||||||
Purchased in-process research and development |
— | — | — | 2,183 | ||||||||||||
Amortization of intangibles |
632 | 589 | 611 | 535 | ||||||||||||
Total operating expenses |
43,149 | 43,742 | 45,990 | 54,822 | ||||||||||||
Operating loss |
(11,184 | ) | (6,597 | ) | (11,957 | ) | (14,134 | ) | ||||||||
Other income (loss), net |
(9 | ) | 1,259 | 966 | 5,122 | |||||||||||
Recovery (impairment) — related party |
(158 | ) | (102 | ) | — | 288 | ||||||||||
Interest income |
1,119 | 1,132 | 1,363 | 1,370 | ||||||||||||
Interest expense |
(1,491 | ) | (1,549 | ) | (1,659 | ) | (1,729 | ) | ||||||||
Equity loss |
(4,031 | ) | (1,376 | ) | (599 | ) | (591 | ) | ||||||||
Minority interest |
1,636 | 1,215 | 1,849 | 1,656 | ||||||||||||
Net loss from continuing operations before income taxes |
(14,118 | ) | (6,018 | ) | (10,037 | ) | (8,018 | ) | ||||||||
Income tax (expense) benefit |
176 | (136 | ) | (38 | ) | 81 | ||||||||||
Net loss from continuing operations |
(13,942 | ) | (6,154 | ) | (10,075 | ) | (7,937 | ) | ||||||||
Income (loss) from discontinued operations, net of tax |
(2,151 | ) | (1,525 | ) | (565 | ) | 10,279 | |||||||||
| $ | (16,093 | ) | $ | (7,679 | ) | $ | (10,640 | ) | $ | 2,342 | ||||||
Basic income (loss) per share (a) |
||||||||||||||||
Net loss from continuing operations |
$ | (0.12 | ) | $ | (0.05 | ) | $ | (0.08 | ) | $ | (0.07 | ) | ||||
Net income (loss) from discontinued operations |
(0.01 | ) | (0.01 | ) | (0.01 | ) | 0.09 | |||||||||
| $ | (0.13 | ) | $ | (0.06 | ) | $ | (0.09 | ) | $ | 0.02 | ||||||
Diluted income (loss) per share (a) |
||||||||||||||||
Net loss from continuing operations |
$ | (0.12 | ) | $ | (0.05 | ) | (0.08 | ) | $ | (0.07 | ) | |||||
Net income (loss) from discontinued operations |
(0.01 | ) | (0.01 | ) | (0.01 | ) | 0.09 | |||||||||
| $ | (0.13 | ) | $ | (0.06 | ) | $ | (0.09 | ) | $ | 0.02 | ||||||
109
Table of Contents
SAFEGUARD SCIENTIFICS, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS — (Continued)
| (a) | Per share amounts for the quarters have each been calculated separately. Accordingly, quarterly amounts may not add to the annual amounts because of differences in the average common shares outstanding during each period. Additionally, in regard to diluted per share amounts only, quarterly amounts may not add to the annual amounts because of the inclusion of the effect of potentially dilutive securities only in the periods in which such effect would have been dilutive, and because of the adjustments to net income (loss) for the dilutive effect of partner company common stock equivalents and convertible securities. |
22. Trade Accounts Receivable
The following table summarizes the activity in the allowance for doubtful accounts:
| (In thousands) | ||||
Balance, December 31, 2003 |
$ | 1,016 | ||
Charged to costs and expenses |
643 | |||
Charge-offs |
(309 | ) | ||
Other |
(272 | ) | ||
Balance, December 31, 2004 |
1,078 | |||
Charged to costs and expenses |
1,612 | |||
Charge-offs |
(1,220 | ) | ||
Other |
250 | |||
Balance, December 31, 2005 |
1,720 | |||
Charged to costs and expenses |
942 | |||
Charge-offs |
(869 | ) | ||
Balance, December 31, 2006 |
$ | 1,793 | ||
23. Subsequent Events
On March 8, 2007, Clarient sold its technology group business (which developed, manufactured
and marketed the ACIS Automated Image Analysis System) and related intellectual property to Zeiss
MicroImaging, Inc. (the “ACIS Sale”) for an aggregate purchase price of $12.5 million (including $1.5 million in contingent purchase price). As part of the ACIS Sale, Clarient entered into a
license agreement with Zeiss pursuant to which Zeiss granted Clairent a non-exclusive, perpetual
and royalty-free license to certain of the intellectual property for use in connection with imaging
applications and Clarient’s laboratory services business. Clarient and Zeiss also committed to
pursue strategic joint development arrangements to develop novel markers and new menu applications
for the ACIS product line.
On March 7, 2007, the Company provided a subordinated revolving credit line (the “Mezzanine
Facility”) to Clarient. Under the Mezzanine Facility, which
expires December 8, 2008, the Company
committed to provide Clarient access to up to $6 million in working capital funding. Amounts
funded under the Mezzanine Facility will earn interest at an annual rate of 12%. The Mezzanine
Facility was originally $12 million, but was reduced by $6 million as a result of the ACIS Sale.
In connection with the Mezzanine Facility, Clarient issued to the Company warrants to purchase
Clarient common stock and will issue additional warrants depending on amounts borrowed under the
Mezzanine Facility.
110
Table of Contents
Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure
None.
Item 9A. Controls and Procedures
(a) Evaluation of Disclosure Controls and Procedures
Our management, with the participation of our Chief Executive Officer and Acting Chief
Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of the
end of the period covered by this report. Based on that evaluation, the Chief Executive Officer
and Acting Chief Financial Officer concluded that our disclosure controls and procedures as of the
end of the period covered by this report are functioning effectively to provide reasonable
assurance that the information required to be disclosed by us in reports filed under the Securities
Exchange Act of 1934 is (i) recorded, processed, summarized and reported within the time periods
specified in the SEC’s rules and forms and (ii) accumulated and communicated to our management,
including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely
decisions regarding disclosure. A controls system cannot provide absolute assurance, however, that
the objectives of the controls system are met, and no evaluation of controls can provide absolute
assurance that all control issues and instances of fraud, if any, within a company have been
detected.
No change in our internal control over financial reporting occurred during our most recent
fiscal quarter that has materially affected, or is reasonably likely to materially affect, our
internal control over financial reporting. Our business strategy involves the acquisition of new
businesses on an on-going basis, most of which are young, growing companies. Typically, these
companies have not historically had all of the controls and procedures they would need to comply
with the requirements of the Securities Exchange Act of 1934 and the rules promulgated thereunder.
These companies also frequently develop new products and services. Following an acquisition, or
the launch of a new product or service, we work with the company’s management to implement all
necessary controls and procedures.
(b) Management’s Report on Internal Control Over Financial Reporting
Our management’s report on internal control over financial reporting is set forth in Item 8 of
this annual report on Form 10-K and is incorporated by reference herein.
(c) Change in Internal Control over Financial Reporting
No change in our internal control over financial reporting occurred during our most recent
fiscal quarter that has materially affected, or is reasonably likely to materially affect, our
internal control over financial reporting.
Item 9B. Other Information
None
111
Table of Contents
PART III
Item 10. Directors, Executive Officers and Corporate Governance
Incorporated by reference to the portions of the Definitive Proxy Statement entitled “Election
of Directors,” “Corporate Governance Principles and Board Matters” and “Section 16(a) Beneficial
Ownership Reporting Compliance.” Information about our executive officers is included as an Annex
to Part I above.
Item 11. Executive Compensation
Incorporated by reference to the portions of the Definitive Proxy Statement entitled
“Compensation Discussion and Analysis,” “Compensation Committee Report,” “Compensation Committee
Interlocks and Insider Participation,” and “Executive Compensation.”
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder
Matters
Incorporated by reference to the portion of the Definitive Proxy Statement entitled “Stock
Ownership of Directors and Officers.”
Securities Authorized for Issuance under Equity Compensation Plans
Our equity compensation plans provide a broad-based program designed to attract and retain
talent while creating alignment with the long-term interests of our shareholders. Employees at all
levels participate in our equity compensation plans. In addition, members of our Board of
Directors (“Board”) and members of our Technology and Life Sciences Advisory Boards (“Advisory
Boards”) receive stock options for their service on our Board and Advisory Boards, respectively.
Members of our Board also are eligible to defer directors’ fees and receive deferred stock units
with a value equal to the directors’ fees deferred and matching deferred stock units equal to 25%
of the directors’ fees deferred.
Our Board is authorized to administer our equity compensation plans, adopt, amend and repeal
the administrative rules relating to the plans, and interpret the provisions of the plans. Our
Board has delegated to the Compensation Committee of the Board (the “Compensation Committee”)
authority to administer our equity compensation plans.
Our Compensation Committee has the authority to select the recipients of grants under our
equity compensation plans and determine the terms and conditions of the grants, including but not
limited to (i) the number of shares of common stock covered by such grants, (ii) the type of grant,
(iii) the dates upon which such grants vest (which for time-based vesting options is typically 25%
on the first anniversary of the grant date and in 36 equal monthly installments thereafter) and for
market-based vesting options is based upon the achievement of improvement in Safeguard’s market
capitalization above the base market capitalization established at the time of grant), (iv)
the exercise price of options (which is equal to the average of the high and low prices of a
share of our common stock as reported on the New York Stock Exchange consolidated tape on
the grant date) or the consideration to be paid in connection with restricted stock, stock units or
other stock-based grants (which may be no consideration), and (iv) the term of the grant. Deferred
stock units issued to directors are payable, on a one-for-one basis, in shares of Safeguard common
stock following a director’s termination of service on the Safeguard Board.
The 2001 Plan provides for the grant of nonqualified stock options, stock appreciation rights,
restricted stock, performance units, and other stock-based awards to employees, consultants or
advisors of Safeguard and its subsidiaries, provided that no grants can be made under this plan to
executive officers and directors of Safeguard. Under the NYSE rules that were in effect at the
time this plan was adopted in 2001, shareholder approval of the plan was not required. This plan
is administered by the Compensation Committee which, as described above, has the authority to issue
equity grants under the 2001 Plan and to establish the terms and conditions of such grants. Except
for the persons eligible to participate in the 2001 Plan and the inability to grant incentive stock
options under the 2001 Plan, the terms of the 2001 plan are substantially the same as the other
equity compensation plans approved by our shareholders (which have been described in previous
filings).
112
Table of Contents
A total of 5,400,000 shares of our common stock are authorized for issuance under the 2001
Plan. At December 31, 2006, 3,764,031 shares were subject to outstanding options, 99,389 shares
were available for future issuance, and 1,536,580 shares had been issued under the 2001 Plan. If
any option granted under the 2001 Plan expires or is terminated, surrendered, canceled or
forfeited, or if any shares of restricted stock, performance units or other stock-based grants are
forfeited, the unused shares of common stock covered by such grants will again be available for
grant under the 2001 Plan.
Our Board is authorized to make appropriate adjustments in connection with the 2001 Plan to
reflect any stock split, stock dividend, recapitalization, liquidation, spin-off or other similar
event. The 2001 Plan also contains provisions addressing the consequences of any Reorganization
Event or Change in Control (as such terms are defined in the 2001 Plan). If a Reorganization or
Change of Control Event occurs, unless the Compensation Committee determines otherwise, all
outstanding options and stock appreciation rights (SARs) that are not exercised will be assumed by,
or replaced with comparable options or rights by, the surviving corporation (or a parent of the
surviving corporation), and other outstanding grants will be converted to similar grants of the
surviving corporation or a parent of the surviving corporation). Notwithstanding that provision,
the Compensation Committee has the authority to take one or both of the following actions: (i)
require that grantees surrender their outstanding options and SARs in exchange for a payment by
Safeguard in cash or company stock, as determined by the Compensation Committee, in an amount equal
to the amount by which the then fair market value of the shares of stock subject to the unexercised
options and SARs exceeds the exercise price of the options or the base amount of the SARs, as
applicable, or (ii) after giving grantees an opportunity to exercise their outstanding options and
SARs or otherwise realize the value of all of their other grants, terminate any or all unexercised
options, SARs and grants at such time as the Compensation Committee deems appropriate.
During 2005, the Safeguard Board’s Compensation Committee granted “employee inducement” awards
to two newly hired executive officers. The awards were granted outside of Safeguard’s existing
equity compensation plans under NYSE rules and consisted of options to purchase up to an aggregate
of 6,000,000 shares of Safeguard common stock. The awards have an eight-year term and a per share
exercise price equal to the average of the high and low prices of Safeguard common stock on the
respective executive’s employment commencement date. Of the shares underlying the options, an
aggregate of 375,000 shares vested on the first anniversary of the grant date, 1,125,000 shares
vest in 36 equal monthly installments thereafter and the remaining 4,500,000 shares vest
incrementally based upon the achievement of certain specified levels of improvement in Safeguard’s
market capitalization. With the exception of the market-based vesting provisions, the terms and
provisions of the employee inducement awards are substantially the same as options previously
awarded to other executives under Safeguard’s equity compensation plans.
113
Table of Contents
The following table provides information as of December 31, 2006 about the securities
authorized for issuance under our equity compensation plans.
Equity Compensation Plan Information
| Number of securities | ||||||||||||
| Number of | remaining available | |||||||||||
| securities to be | Weighted-average | for future issuance | ||||||||||
| issued upon | exercise price of | under equity | ||||||||||
| exercise of | outstanding | compensation plans | ||||||||||
| outstanding | options, warrants | (excluding securities | ||||||||||
| options, warrants | and rights | reflected in column | ||||||||||
| Plan Category | and rights | (1) | (a)) | |||||||||
| (a) | (b) | (c) | ||||||||||
Equity compensation
plans approved by
security holders
(2) |
10,235,012 | $ | 2.2238 | 3,259,786 | ||||||||
Equity compensation
plans not approved
by security holders
(3) |
9,764,031 | $ | 1.7562 | 99,389 | ||||||||
Total |
19,999,043 | $ | 1.9800 | 3,359,175 | ||||||||
| (1) | The weighted average exercise price calculation excludes 1,271,127 shares underlying outstanding deferred stock units awarded to executive officers and directors included in column (a) which are payable in stock, on a one-for-one basis. | |
| (2) | Represents awards granted, and shares available for issuance, under the 1999 Equity Compensation Plan and the 2004 Equity Compensation Plan. Includes 1,135,145 shares underlying deferred stock units awarded to executive officers and directors for no consideration and 135,982 shares underlying deferred stock units awarded to directors in lieu of all or a portion of directors’ fees. Payments in respect of deferred stock units are generally distributable following termination of employment or service, death, permanent disability or retirement. The value of the deferred stock units was approximately $3.8 million based on the fair value of the stock on the various grant dates. The deferred stock units generally vest over a period of four years, with the exception of deferred stock units issued to directors in lieu of compensation, which are fully vested, and matching deferred stock units awarded to directors, which vest on the first anniversary of the grant. | |
| (3) | Includes awards granted and shares available for issuance under the 2001 Plan and 6,000,000 “employee inducement” awards. |
Item 13. Certain Relationships and Related Transactions, and Director Independence
Incorporated by reference to the portions of the Definitive Proxy Statement entitled
“Corporate Governance Principles and Board Matters —
‘Board Independence’ and ‘Review and Approval of Transactions with
Related Persons’” and “Relationships and Transactions with Management and Others.”
Item 14. Principal Accountant Fees and Services
Incorporated by reference to the portion of the Definitive Proxy Statement entitled
“Independent Public Accountant — Audit Fees.”
114
Table of Contents
PART IV
Item 15. Exhibits and Financial Statement Schedules
(a) Consolidated Financial Statements and Schedules
Incorporated by reference to Item 8 of this Report on Form 10-K.
(b) Exhibits
The exhibits required to be filed as part of this Report are listed in the exhibit index
below.
Exhibits
The following is a list of exhibits required by Item 601 of Regulation S-K filed as part of
this Report. For exhibits that previously have been filed, the Registrant incorporates those
exhibits herein by reference. The exhibit table below includes the Form Type and Filing Date of
the previous filing and the location of the exhibit in the previous filing which is being
incorporated by reference herein. Documents which are incorporated by reference to filings by
parties other than the Registrant are identified in footnotes to this table.
| Incorporated Filing Reference | ||||||||||
| Original | ||||||||||
| Exhibit | Form Type & | Exhibit | ||||||||
| Number | Description | Filing Date | Number | |||||||
2.1
|
Agreement and Plan of Merger dated as of November 9, 2005 by and among Safeguard Delaware, Inc., Safeguard Scientifics, Inc., AI Acquisition Corporation, Acsis, Inc., certain stockholders of Acsis, Inc., and Wand Equity Portfolio II LP | Form 8-K 11/10/05 |
99.1 | |||||||
2.2
|
Agreement and Plan of Merger, dated as of August 14, 2006, among Safeguard Scientifics, Inc., Safeguard Delaware, Inc., Safeguard 2001 Capital, L.P., SRA Ventures, LLC, SRA International, Inc., Systems Research and Application Corporation, Mantas, Inc., i-flex solutions, ltd., i-flex America, inc. and Mandarin Acquisition Corp. | Form 8-K 8/15/06 |
99.2 | |||||||
3.1
|
Amended and Restated Articles of Incorporation of Safeguard | Form 10-K 3/15/04 |
3.1 | |||||||
3.2
|
By-laws of Safeguard, as amended | Form 10-Q 5/15/01 |
3.1 | |||||||
4.1
|
Rights Agreement dated as of March 1, 2000 between Safeguard Scientifics, Inc. and ChaseMellon Shareholder Services LLC, as Rights Agent | Form 8-K 2/29/00 |
4 | |||||||
4.2
|
Designation of Series A Junior Participating Preferred Shares | Form 10-K 3/22/00 |
4.11 | |||||||
4.3
|
Indenture, dated as of February 18, 2004 between Safeguard Scientifics, Inc. and Wachovia Bank, National Association, as trustee, including the form of 2.625% Convertible Senior Debentures due 2024 | Form 10-K 3/15/04 |
4.10 | |||||||
10.1.1 *
|
Safeguard Scientifics, Inc. 1999 Equity Compensation Plan, as amended | Form 10-K 4/2/01 |
4.3 | |||||||
10.1.2 *
|
Amendment No. 1 to the Safeguard Scientifics, Inc. 1999 Equity Compensation Plan | Form 10-Q 8/6/04 |
10.2 | |||||||
10.2.1
|
Safeguard Scientifics, Inc. 2001 Associates Equity Compensation Plan | Form S-8 11/14/01 |
4.1 | |||||||
115
Table of Contents
| Incorporated Filing Reference | ||||||||||
| Original | ||||||||||
| Exhibit | Form Type & | Exhibit | ||||||||
| Number | Description | Filing Date | Number | |||||||
10.2.2
|
Amendment No. 1 to the Safeguard Scientifics, Inc. 2001 Associates Equity Compensation Plan | Form 10-K 3/21/03 |
4.4.1 | |||||||
10.2.3
|
Amendment No. 2 to the Safeguard Scientifics, Inc. 2001 Associates Equity Compensation Plan | Form 10-Q 8/6/04 |
10.3 | |||||||
10.3 *
|
Safeguard Scientifics, Inc. 2004 Equity Compensation Plan | Form 10-Q 8/6/04 |
10.1 | |||||||
10.4 *
|
Stock Option Grant Certificate issued to Peter J. Boni dated August 16, 2005 | Form 10-Q 11/9/05 |
10.2 | |||||||
10.5 *
|
Stock Option Grant Certificate issued to James A. Datin dated September 7, 2005 | Form 10-Q 11/9/05 |
10.4 | |||||||
10.6 *
|
Stock Option Grant Certificate issued to John A. Loftus dated September 13, 2005 | Form 8-K 9/19/05 |
99.1 | |||||||
10.7.1*
|
Stock Option Grant Certificate issued to Christopher J. Davis dated October 25, 2005 | Form 8-K 10/31/05 |
99.1 | |||||||
10.7.2 *
|
Stock Option Grant Certificate issued to Christopher J. Davis dated December 16, 2005 | Form 8-K 12/21/05 |
99.1 | |||||||
10.8 *
|
Stock Option Grant Certificate issued to Steven J. Feder dated October 25, 2005 | Form 8-K 10/31/05 |
99.2 | |||||||
10.9 *†
|
Stock Option Grant Certificate issued to Stephen Zarrilli dated December 15, 2006 | — | — | |||||||
10.10 *†
|
Restricted Stock Grant Agreement issued to John A. Loftus dated December 15, 2006 | — | — | |||||||
10.11.1 *
|
Form of directors’ stock option grant certificate (prior to February 21, 2007) | Form 10-Q 11/9/04 |
10.3 | |||||||
10.11.2 *†
|
Form of directors’ stock option grant certificate as of February 21, 2007 | — | — | |||||||
10.12 *
|
Form of officers’ stock option grant certificate | Form 10-Q 11/9/04 |
10.4 | |||||||
10.13 *
|
Safeguard Scientifics, Inc. Group Stock Unit Award Program—form of grant document | Form 10-Q 11/9/04 |
10.5 | |||||||
10.14 *
|
Safeguard Scientifics, Inc. Group Stock Unit Program for Directors—form of grant document | Form 10-Q 11/9/04 |
10.6 | |||||||
10.15 *
|
Form of Restricted Stock Grant Agreement | Form 10-Q 11/9/04 |
10.7 | |||||||
10.16 *
|
Safeguard Scientifics, Inc. Long Term Incentive Plan, as amended and restated effective June 15, 1994 | Form 10-K 3/30/95 |
10.6 | |||||||
10.17 *
|
Safeguard Scientifics, Inc. Executive Deferred Compensation Plan (amended and restated as of October 25, 2005) | Form 10-K 3/13/06 |
10.16 | |||||||
10.18 *
|
2006 Management Incentive Plan | Form 8-K 2/27/06 |
99.1 | |||||||
10.19 *†
|
Compensation Summary — Non-employee Directors | — | — | |||||||
10.20 *
|
Employment Transition and Retirement Agreement between Safeguard Scientifics, Inc. and Anthony L. Craig dated April 13, 2005 | Form 8-K 4/15/05 |
99.1 | |||||||
10.21.1 *
|
Employment Agreement dated August 17, 2004 between Safeguard Scientifics, Inc. and Christopher J. Davis | Form 10-Q 11/9/04 |
10.2 | |||||||
10.21.2 *†
|
Agreement dated December 14, 2006 between Safeguard Scientifics, Inc. and Christopher J. Davis | — | — | |||||||
116
Table of Contents
| Incorporated Filing Reference | ||||||||||
| Original | ||||||||||
| Exhibit | Form Type & | Exhibit | ||||||||
| Number | Description | Filing Date | Number | |||||||
10.22 *
|
Employment Letter, effective November 17, 2004, and Letter Agreement, dated November 17, 2004, by and between Safeguard Scientifics, Inc. and Steven J. Feder | Form 8-K 11/19/04 |
99.1 | |||||||
10.23 *
|
Letter Agreement dated February 25, 2005 by and between Safeguard Scientifics, Inc. and John A. Loftus | Form 8-K 2/25/05 |
99.1 | |||||||
10.24 *
|
Agreement by and between Safeguard Scientifics, Inc. and Peter J. Boni dated August 1, 2005 | Form 8-K 8/4/05 |
99.1 | |||||||
10.25 *
|
Agreement by and between Safeguard Scientifics, Inc. and James A. Datin dated September 7, 2005 | Form 8-K 9/13/05 |
99.1 | |||||||
10.26 *†
|
Agreement by and between Safeguard Scientifics, Inc. and Stephen Zarrilli dated as of December 15, 2006 | — | — | |||||||
10.27.1
|
Loan Agreement dated May 10, 2002 by and among Comerica Bank — California, Safeguard Delaware, Inc. and Safeguard Scientifics (Delaware), Inc. | Form 10-Q 8/14/02 |
10.1 | |||||||
10.27.2
|
First Amendment dated May 9, 2003 to Loan Agreement dated May 10, 2002, by and among Comerica Bank — California, Safeguard Delaware, Inc. and Safeguard Scientifics (Delaware), Inc. | Form 10-Q 5/13/03 |
10.1 | |||||||
10.27.3
|
Second Amendment dated February 12, 2004 to Loan Agreement dated May 10, 2002 by and among Comerica Bank — California, Safeguard Delaware, Inc. and Safeguard Scientifics (Delaware), Inc. | Form 10-K 3/15/04 |
10.19 | |||||||
10.27.4
|
Third Amendment dated May 5, 2004 to Loan Agreement dated May 10, 2002 by and among Comerica Bank — California, Safeguard Delaware, Inc. and Safeguard Scientifics (Delaware), Inc. | Form 10-Q 5/10/04 |
10.29 | |||||||
10.27.5
|
Fourth Amendment dated September 30, 2004 to Loan Agreement dated May 10, 2002 by and among Comerica Bank, successor by merger to Comerica Bank — California, Safeguard Delaware, Inc. and Safeguard Scientifics (Delaware), Inc. | Form 8-K 10/5/04 |
10.1 | |||||||
10.27.6
|
Fifth Amendment dated as of May 2, 2005, to Loan Agreement dated as of May 10, 2002, as amended, by and among Comerica Bank, successor by merger to Comerica Bank — California, Safeguard Delaware, Inc. and Safeguard Scientifics (Delaware), Inc. | Form 8-K 5/6/05 |
99.1 | |||||||
10.27.7
|
Sixth Amendment dated as of August 1, 2005, to Loan Agreement dated as of May 10, 2002, as amended, by and among Comerica Bank, successor by merger to Comerica Bank — California, Safeguard Delaware, Inc. and Safeguard Scientifics (Delaware), Inc. | Form 8-K 8/4/05 |
99.4 | |||||||
10.27.8
|
Guaranty dated May 10, 2002 by Safeguard Scientifics, Inc. to Comerica Bank, successor by merger to Comerica Bank—California | Form 10-K 3/15/05 |
10.18.6 | |||||||
10.27.9
|
Affirmation and Amendment of Guaranty dated September 30, 2004, by Safeguard Scientifics, Inc. to Comerica Bank, successor by merger to Comerica Bank—California | Form 8-K 10/5/04 |
10.2 | |||||||
117
Table of Contents
| Incorporated Filing Reference | ||||||||||
| Original | ||||||||||
| Exhibit | Form Type & | Exhibit | ||||||||
| Number | Description | Filing Date | Number | |||||||
10.27.10
|
Seventh Amendment dated as of May 4, 2006 to Loan Agreement dated as of May 10, 2002, as amended, by and between Comerica Bank, Safeguard Delaware, Inc. and Safeguard Scientifics (Delaware), Inc. | Form 10-Q 8/4/06 |
10.1 | |||||||
10.27.11 †
|
Eighth Amendment dated as of February 28, 2007 to Loan Agreement dated as of May 10, 2002, as amended, by and between Comerica Bank, Safeguard Delaware, Inc. and Safeguard Scientifics (Delaware), Inc. | — | — | |||||||
10.28.1
|
Loan Agreement dated as of November 17, 2006 by and among Commerce Bank, N.A., Safeguard Delaware, Inc. and Safeguard Scientifics (Delaware), Inc. | Form 8-K 11/20/06 |
99.1 | |||||||
10.28.2
|
Guaranty dated as of November 17, 2006 by Safeguard Scientifics, Inc. to Commerce Bank, N.A. | Form 8-K 11/20/06 |
99.2 | |||||||
10.29.1
|
Guaranty dated September 30, 2004 by Safeguard Delaware, Inc. and Safeguard Scientifics (Delaware), Inc. (on behalf of Alliance Consulting) | Form 8-K 10/5/04 |
10.4 | |||||||
10.29.2
|
Affirmation of Guaranty dated September 30, 2004 by Safeguard Scientifics, Inc. | Form 8-K 10/5/04 |
10.5 | |||||||
10.29.3
|
Amendment and Affirmation of Guaranty dated as of February 28, 2006 by Safeguard Delaware, Inc. and Safeguard Scientifics (Delaware), Inc. (on behalf of Alliance) | Form 8-K 3/6/06 |
99.7 | |||||||
10.29.4
|
Amendment and Affirmation of Guaranty dated as of February 28, 2006 by Safeguard Scientifics, Inc. (on behalf of Alliance) | Form 8-K 3/6/06 |
99.6 | |||||||
10.29.5 †
|
Amended and Restated Loan Agreement dated February 28, 2007 for $15 million by and among Comerica Bank, Alliance Consulting Group Associates, Inc. and Alliance Holdings, Inc. | — | — | |||||||
10.29.6 †
|
Amended and Restated Loan Agreement dated February 28, 2007 for $5 million by and among Comerica Bank, Alliance Consulting Group Associates, Inc. and Alliance Holdings, Inc. | — | — | |||||||
10.29.7 †
|
Affirmation of Guaranty dated February 28, 2007 by Safeguard Delaware, Inc. and Safeguard Scientifics (Delaware), Inc. (on behalf of Alliance Consulting) | — | — | |||||||
10.30.1
|
Loan Agreement dated March 11, 2005, by and between Comerica Bank—California and ChromaVision Medical Systems, Inc. | (1 | ) | 10.10 | ||||||
10.30.2
|
First Amendment dated October 21, 2003 to Loan and Security Agreement dated February 13, 2003 between ChromaVision Medical Systems, Inc. and Comerica Bank | (2 | ) | 10.4 | ||||||
10.30.3
|
Second Amendment dated January 22, 2004 to Loan and Security Agreement dated February 13, 2003 between ChromaVision Medical Systems, Inc. and Comerica Bank | (3 | ) | 10.6 | ||||||
10.30.4
|
Third Amendment dated as of January 31, 2005 to Loan Agreement dated February 13, 2003 by and between Comerica Bank and ChromaVision Medical Systems, Inc. | Form 8-K 2/3/05 |
99.2 | |||||||
10.30.5
|
Fourth Amendment dated as of March 11, 2005 to Loan Agreement dated February 13, 2003 by and between Comerica Bank and ChromaVision Medical Systems, Inc. | (3 | ) | 10.8 | ||||||
118
Table of Contents
| Incorporated Filing Reference | ||||||||||
| Original | ||||||||||
| Exhibit | Form Type & | Exhibit | ||||||||
| Number | Description | Filing Date | Number | |||||||
10.30.6
|
Amended and Restated Unconditional Guaranty dated March 11, 2005 to Comerica Bank provided by Safeguard Delaware, Inc. and Safeguard Scientifics (Delaware), Inc. (on behalf of ChromaVision) | (3 | ) | 10.9 | ||||||
10.30.7
|
Reimbursement and Indemnity Agreement dated as of March 11, 2005 by ChromaVision Medical Systems, Inc. in favor of Safeguard Delaware, Inc. and Safeguard Scientifics (Delaware), Inc. | (3 | ) | 10.10 | ||||||
10.30.8
|
Waiver and Fifth Amendment dated as of August 1, 2005 to Loan Agreement dated February 13, 2003 by and between Comerica Bank and Clarient, Inc. | (4 | ) | 99.1 | ||||||
10.30.9
|
Second Amended and Restated Unconditional Guaranty dated August 1, 2005 to Comerica Bank provided by Safeguard Delaware, Inc. and Safeguard Scientifics (Delaware), Inc. (on behalf of Clarient, Inc.) | (4 | ) | 99.2 | ||||||
10.30.10
|
Reimbursement and Indemnity Agreement dated as of August 1, 2005 by Clarient, Inc. in favor of Safeguard Delaware, Inc. and Safeguard Scientifics (Delaware), Inc. | (4 | ) | 99.3 | ||||||
10.30.11
|
Sixth Amendment dated as of February 28, 2006, to Loan Agreement dated as of February 13, 2003, as amended, by and between Comerica Bank and Clarient, Inc., formerly known as ChromaVision Medical Systems, Inc. | Form 8-K 3/6/06 |
99.3 | |||||||
10.31.1
|
Loan and Security Agreement dated as of December 1, 2004 by and between Comerica Bank and Laureate Pharma, Inc. | Form 8-K 12/7/04 |
99.1 | |||||||
10.31.2
|
Guaranty dated December 1, 2004 to Comerica Bank provided by Safeguard Delaware, Inc. and Safeguard Scientifics (Delaware), Inc. (on behalf of Laureate Pharma) | Form 8-K 12/7/04 |
99.2 | |||||||
10.31.3
|
First Amendment dated as of January 31, 2005 to Loan and Security Agreement dated as of December 1, 2004 by and between Comerica Bank and Laureate Pharma, Inc. | Form 8-K 2/3/05 |
99.3 | |||||||
10.31.4
|
Second Amendment dated as of May 5, 2005 to Loan and Security Agreement dated as of December 1, 2004 by and between Comerica Bank and Laureate Pharma, Inc. | Form 10-Q 8/8/05 |
10.4 | |||||||
10.31.5
|
Third Amendment dated as of June 20, 2005 to Loan and Security Agreement dated as of December 1, 2004 by and between Comerica Bank and Laureate Pharma, Inc. | Form 10-Q 8/8/05 |
10.5 | |||||||
10.31.6
|
Affirmation and Amendment of Guaranty dated June 20, 2005 to Comerica Bank provided by Safeguard Delaware, Inc. and Safeguard Scientifics (Delaware), Inc. (on behalf of Laureate Pharma) | Form 10-Q 8/8/05 |
10.6 | |||||||
10.31.7
|
Fourth Amendment dated as of February 28, 2006 to Loan and Security Agreement dated as of December 1, 2004, by and between Comerica Bank and Laureate Pharma, Inc. | Form 8-K 3/6/06 |
99.4 | |||||||
10.31.8
|
Fifth Amendment dated as of August 2, 2006 to Loan and Security Agreement dated as of December 1, 2004, by and between Comerica Bank and Laureate Pharma, Inc. | Form 10-Q 11/3/06 |
10.2 | |||||||
10.31.9 †
|
Sixth Amendment dated as of February 28, 2007 to Loan and Security Agreement dated as of December 1, 2004, by and between Comerica Bank and Laureate Pharma, Inc. | — | — | |||||||
119
Table of Contents
| Incorporated Filing Reference | ||||||||||
| Original | ||||||||||
| Exhibit | Form Type & | Exhibit | ||||||||
| Number | Description | Filing Date | Number | |||||||
10.31.10 †
|
Amendment and Affirmation of Guaranty dated February 28, 2007 to Comerica Bank provided by Safeguard Delaware, Inc. and Safeguard Scientifics (Delaware), Inc. (on behalf of Laureate Pharma) | — | — | |||||||
10.31.11 †
|
Deficiency Guaranty dated February 28, 2007 to Comerica Bank provided by Safeguard Delaware, Inc. and Safeguard Scientifics (Delaware), Inc. (on behalf of Laureate Pharma) | — | — | |||||||
10.32.1
|
Securities Purchase Agreement dated November 8, 2005 by and among Clarient, Inc. and the investors named therein | (5 | ) | 99.1 | ||||||
10.32.2
|
Registration Rights Agreement dated November 8, 2005 by and among Clarient, Inc. and the investors named therein | (5 | ) | 99.2 | ||||||
10.32.3
|
Form of Common Stock Purchase Warrant issued by Clarient, Inc. pursuant to the Securities Purchase Agreement dated November 8, 2005 | (5 | ) | 99.3 | ||||||
10.33
|
Letter of Credit issued to W.P. Carey | Form 8-K 10/5/04 |
10.1 | |||||||
10.34
|
Purchase and Sale Agreement dated as of December 9, 2005 by and among HarbourVest VII Venture Ltd., Dover Street VI L.P. and several subsidiaries and affiliated limited partnerships of Safeguard Scientifics, Inc. | Form 10-K 3/13/06 |
10.36 | |||||||
14 †
|
Code of Business Conduct and Ethics | — | — | |||||||
21 †
|
List of Subsidiaries | — | — | |||||||
23.1 †
|
Consent of Independent Registered Public Accounting Firm — KPMG LLP | — | — | |||||||
31.1 †
|
Certification of Peter J. Boni pursuant to Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934 | — | — | |||||||
31.2 †
|
Certification of Stephen T. Zarrilli pursuant to Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934 | — | — | |||||||
32.1 †
|
Certification of Peter J. Boni pursuant to 18 U.S.C. Section 1350, as Adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | — | — | |||||||
32.2 †
|
Certification of Stephen T. Zarrilli pursuant to 18 U.S.C. Section 1350, as Adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | — | — | |||||||
| † | Filed herewith | |
| * | These exhibits relate to management contracts or compensatory plans, contracts or arrangements in which directors and/or executive officers of the Registrant may participate. | |
| (1) | Incorporated by reference to the Annual Report on Form 10-K filed March 31, 2003 by Clarient, Inc. (SEC File No. 000-22677) | |
| (2) | Incorporated by reference to the Quarterly Report on Form 10-Q filed on November 14, 2003 by Clarient, Inc. (SEC File No. 000-22677) | |
| (3) | Incorporated by reference to the Annual Report on Form 10-K filed March 14, 2005 by Clarient, Inc. (SEC File No. 000-22677) |
120
Table of Contents
| (4) | Incorporated by reference to the Current Report on Form 8-K filed on August 4, 2005 by Clarient, Inc. (SEC File No. 000-22677) | |
| (5) | Incorporated by reference to the Current Report on Form 8-K filed on November 9, 2005 by Clarient, Inc. (SEC File No. 000-22677) |
121
Table of Contents
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
| Safeguard Scientifics, Inc. |
||||
| By: | PETER J. BONI | |||
| Peter j. boni | ||||
| President and Chief Executive Officer | ||||
Dated:
March 27, 2007
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been
signed below by the following persons on behalf of the Registrant and in the capacities and on the
dates indicated.
| Signature | Title | Date | ||
Peter j. Boni
|
President and Chief Executive Officer and Director (Principal Executive Officer) | Dated: March 27, 2007 | ||
Stephen T. Zarrilli
|
Acting Senior Vice President, Acting Chief Administrative Officer and Acting Chief Financial Officer (Principal Financial and Accounting Officer) | Dated: March 27, 2007 | ||
Michael J. Cody
|
Director | Dated: March 27, 2007 | ||
Julie A. Dobson
|
Director | Dated: March 27, 2007 | ||
Robert E. Keith, JR.
|
Chairman of the Board of Directors | Dated: March 27, 2007 | ||
Andrew E. Lietz
|
Director | Dated: March 27, 2007 | ||
George Mackenzie
|
Director | Dated: March 27, 2007 | ||
George McClelland
|
Director | Dated: March 27, 2007 | ||
Jack L. Messman
|
Director | Dated: March 27, 2007 | ||
John W. Poduska, SR.
|
Director | Dated: March 27, 2007 | ||
John J. Roberts
|
Director | Dated: March 27, 2007 |
122